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Abstract 
 
Background: Severe symptomatic aortic stenosis (AS) heralds a poor prognostic outlook and 
significant co-morbidity, with valve replacement the only definitive cure. Transcatheter aortic valve 
implantation (TAVI) has developed as an alternative to the standard treatment of surgical aortic valve 
replacement (SAVR) in high-risk or inoperable AS patients. The clinical and cost effectiveness of 
TAVI compared to SAVR requires further investigation.  
Methods: A prospective study of sixty seven TAVI and twenty seven SAVR patients, recruited from 
September 2009 to September 2011. Baseline assessments included a cerebral and cardiovascular 
magnetic resonance scan (1.5 Tesla MRI system) and the completion of two health surveys (EQ 5D 
and SF 12). Follow-up MRI was performed at 5±2 days (cerebral MRI) and 6 months (cardiovascular 
MRI) post AVR. Health status was assessed at 30 days, 6 months and one year. A cost-effectiveness 
analysis was performed using a 10 year Markov model with deterministic and probabilistic sensitivity 
analyses.  
Results: TAVI and SAVR resulted in similar levels of ventricular reverse remodelling. TAVI had a 
greater reduction in valvular impedance (21±8mmHg vs. 35±13mmHg, p=0.017) and myocardial 
fibrosis (10.9±6 % vs. 8.5±5%, p=0.03). Cerebral emboli occurred in 77% of TAVI patients.  Age 
(r=0.37, p=0.042), severity of atheroma (r=0.91, p<0.001) and catheterisation time (r=0.45, p=0.02) 
were predictors of cerebral infarcts. HRQOL significantly improved over 12 months (PCS, p=0.02; 
EQ-5D, p=0.02; VAS, p=0.01 and SF6D p=0.03). Male gender (SF6D, p=0.01) and increased 
operator experience (PCS, EQ5D and VAS, p<0.05) predicted an improvement in HRQOL. Despite 
greater procedural costs, TAVI was cost-effective compared to SAVR over the 10 year model horizon 
(costs £52,593 vs. £53,943 and QALYs 2.81 vs. 2.75) indicating that TAVI dominated SAVR. 
Conclusions: TAVI has comparable cardiac and health benefits to SAVR, but greater cerebral 
complications. TAVI is likely to represent a clinical and cost effective alternative to SAVR. 
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1 Introduction 
 
1.1 Aortic Stenosis 
 
1.1.1 Background 
Aortic Stenosis (AS) is the most common form of valvular heart disease in Europe and America, 
constituting approximately 40% of all valvular lesions (Nkomo et al., 2006). AS has profound effects 
upon patient morbidity and mortality and represents a significant clinical problem within medicine. 
Symptomatic patients have poor survival, and individuals often present late with pronounced co-
morbidities. Asymptomatic patients have a greater event free survival but are still likely to require 
treatment within 5 years (Nkomo et al., 2006, Rosenhek et al., 2000). The disease remains 
predominantly one of age.  Calcific aortic valve disease is present in approximately 25% of adults 
aged >65 years, with up to 15% of these individuals progressing to clinically significant AS in the 
next 2 to 7 years (Owens et al., 2010). The disease prevalence of AS increases from 2.5% at 75 years 
to 8.1% at 85 years (Lindroos et al., 1993). The incidence of AS is increasing in the United Kingdom 
(Berry et al., 2013). Given future demographic predictions, AS is set to become a significant public 
health problem  as a greater number of people are diagnosed and require treatment in an ageing 
population (Iung et al., 2003b).  
1.1.2 Aetiology and Pathophysiology 
AS is the progressive narrowing of the aortic valve. It is believed to be a degenerative process as a 
result of several interacting factors. The dominant hypothesis remains changes secondary to ‘wear and 
tear’. The older age of presentation and declining incidence of rheumatic fever (<0.5 per 1000) have 
contributed to the development of this theory. Mechanical stress from blood flow through the aortic 
valve creates an inflammatory process at the cellular level resulting in lipid accumulation, 
calcification and eventual valvular obstruction. Initial sub-endothelial damage from reactive oxygen 
species results in the accumulation of low-density lipoprotein (LDL), macrophages and T-
lymphocytes. These cells stimulate the inflammatory response involving several cytokines: Tumour 
Necrosis Factor , Tumour Growth Factor , C-Reactive Protein and Interleukin 1-. The renin-
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angiotensin system is also involved in disease progression, as Angiotensin Converting Enzyme (ACE) 
and its product Angiotensin ΙΙ are found to be present in the lesions of advanced aortic valve disease. 
Macrophages produce Angiotensin ΙΙ which contributes to the regulation of the inflammatory process, 
increasing LDL uptake, smooth muscle adhesion and producing plasminogen activator inhibitor-1 
(O'Brien et al., 2002). These signalling pathways are integral in the differentiation of interstitial cells 
to an osteoblast like phenotype and the subsequent process of valvular calcification (Miller et al., 
2011). Fibroblasts become phenotypic osteoblasts that produce matrix proteins including osteopontin 
and osteocalcin. These stimulate bony differentiation mediated by the Lrp5/Wnt3 signalling pathways, 
with eventual calcium deposition in the extracellular matrix (O'Brien et al., 2002, Otto, 2006, 
Rajamannan et al., 2007, Cawley and Otto, 2009).  
This cellular response within the aortic valve has histological and pathological features common to 
the process of atherosclerosis in the arterial vasculature. Risk factors for the development of both 
diseases are therefore similar; increased age, male sex, hypertension, diabetes mellitus, elevated LDL 
and smoking (Rajamannan et al., 2007, Otto, 2006, Stewart et al., 1997). Individuals with abnormal 
valve morphology (bicuspid, unicuspid and quadricuspid) appear to be at a greater risk of this 
inflammatory process, possibly due to the greater mechanical stress upon the valve.  Bicuspid Aortic 
Valve (BAV) is a congential condition that is present in 0.5% of the population and accounts for 
approximately 50% of cases presenting for Surgical Aortic Valve Replacement (SAVR). Genetic 
factors are also believed to play a role but are less clearly defined. The expression of micro-RNA is 
down regulated and is believed to contribute towards fibrosis. Abnormalities in DNA methylation 
occur with increased age and are involved in the differentiation of fibroblasts to osteoblasts. A defect 
in the NOTCH signalling pathway (NOTCH 1 gene) also plays a role in the phenotypic change of 
fibroblasts by failing to suppress the bone morphogenic protein (BMP2/4) signalling. This gene 
abnormality has been found in families with both calcified aortic valve disease and bicuspid aortic 
valves (Miller et al., 2011, Garg et al., 2005).       
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1.1.3 Haemodynamic severity 
The progressive narrowing of the aortic valve can be assessed, quantified and graded according to the 
degree of left ventricular outflow obstruction. The severity of AS is traditionally assessed by 
transthoracic echocardiography (TTE). AS is differentiated from ‘sclerosis’ or valve thickening by the 
restriction of valve leaflet opening, a raised peak velocity measurement (Vmax) across the valve and 
increased transaortic mean pressure gradient (∆Pmean) calculated by the Bernoulli equation (Equation 
1). The Doppler waveforms are then combined with the cross sectional area (CSA) of the left 
ventricular outflow track (LVOT) in the continuity equation to determine the valves aortic valve area 
(AVA) (Equation 2), (Chambers, 2009).  
 
Equation 1 Bernoulli equation  
∆Ppeak (mmHg) = 4(V2
2
- V1
2
) 
∆Ppeak = peak pressure gradient; V1= Subaortic peak velocity; V2= Transaortic peak velocity 
 
Equation 2 Continuity equation 
 AVA (cm
2
) = (LVOT CSA  VTI1)/VTI2 
CSA = LVOT cross sectional area (cm); VTI = Velocity Time Integral; VTI1= velocity time integral 
at the LVOT; VTI2= velocity time integral at the aorta. 
 
In small individuals AVA may be more accurate if indexed to the body surface area (BSA). However, 
this can underestimate the true functional area in obese patients.  In these circumstances the ratio of 
LVOT to aortic velocity is used, with a ratio of 1 normal and 0.25 significantly abnormal.  
 
AS is graded for severity and classified according to the American Heart Association (AHA) and 
European Society of Cardiology (ESC) working groups’ definitions (Table 1-1). 
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Table 1-1 Aortic Stenosis classification 
Aortic stenosis Velocity (m/s) Mean gradient (mmHg) AVA (cm2) Other 
Mild 2.5-3 10-20 1.5-3 
 
Moderate 3-4 20-40 1-1.5 
 
Severe  > 4 >40 <1 AVAi 
<0.6cm
2
/m
2 
Critical 
>5 >60 <0.6  
Low output, low gradient 3-4 20-40 <1 SVi <35ml/ 
m
2
 
 
AVAi = aortic valve area indexed to BSA; SVi = stroke volume indexed to BSA 
 
Severe AS is defined as an aortic orifice area of less than 1cm
2 
(or < 0.6cm
2
 indexed to BSA), 
(Chambers, 2009). As the orifice of the aortic valve narrows, a pressure gradient develops from the 
left ventricular cavity across the aortic valve to the aorta. This abnormal chronic pressure overload has 
several consequences primarily on the structure and function of the left ventricular wall, causing it to 
remodel. 
 
1.1.4 Left ventricular remodelling 
1.1.4.1 Normal ventricular structure and mechanics 
The normal left ventricle (LV) wall is composed of myofibres that are arranged in a helical formation. 
The orientation of these fibres change from a leftward direction at the sub-epicardium to a rightward 
direction in the sub-endocardium. Myofibre contraction causes a circumferential rotation or twist that 
follows 4 defined phases over time:  
Phase 1: Isovolumetric contraction 
Phase 2: Systolic ejection 
Phase 3: Isovolumetric relaxation 
Phase 4: Early diastolic filling 
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Systolic rotation differs across the myocardial layers. The sub-epicardial fibres rotate in a counter-
clockwise direction at the apex and clockwise direction at the base, where as the sub-endocardial 
fibres rotate clockwise apically and counter-clockwise basally. The global direction of myocardial 
contraction is controlled by the sub-epicardial layer (apical counter-clockwise and basal clockwise 
rotation), as its higher mass and longer radius contribute the greatest torque. Electrical activation of 
this process occurs in a sub-endocardial to sub-epicardial direction from the mid-apical septal wall. 
Thus in normal systolic contraction the apex initially rotates in a clockwise direction prior to the 
dominant counter-clockwise motion. The sub-endocardial layer is responsible for the radial thickening 
and contraction into the LV cavity as well as the longitudinal shortening of the LV (Taber et al., 1996, 
Sengupta et al., 2008a). In normal individuals most systolic rotation occurs during phase 1 
(isovolumetric contraction) with little rotation occurring at systolic ejection (Nagel et al., 2000). 
Diastolic untwisting or relaxation is the rotation of the cardiac fibres in the opposite direction to 
systolic movement (counter-clockwise at base and clockwise at the apex). Potential energy built up 
and stored in the sub-endocardial fibres during systolic twisting is released. Early in diastole 
isovolumetric relaxation (IVR) occurs, where the twisted fibres lengthen secondary to elastic recoil 
without altering the LV volume. Diastolic rotation predominantly occurs during the IVR time (IVRT) 
with diastolic filling of the LV following this as a separate process (Stuber et al., 1999).   
The difference between apical and basal twist is known as ‘Torsion’. Torsion is important in 
distributing the uneven shortening of sub-endocardial and sub-epicardial fibres equally over the LV 
(optimisation of strain). If absent during systolic contraction this would result increased endocardial 
shortening, decreased epicardial shortening, greater wall stress and as a result a higher workload for 
the ventricle, increased oxygen demand and reduced efficiency (Rüssel et al., 2009) (Sengupta et al., 
2008b). Normal torsion is thus essential for a normally functioning LV. Small but significant 
variations of torsion occur in the normal ventricle, as the inferior and septal walls demonstrate lower 
levels of torsion compared to the anterior and lateral walls. This is likely an effect of the right 
ventricular mass displacing the axis of rotation and influencing left ventricular torsion. The clinical 
implications of this observation are predominantly in the analysis and interpretation of regional rather 
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than global torsion. Russel et al suggest that circumferential segmental (AHA-16-segment model) 
analysis is less reliable than transmural (whole wall base, mid and apex) analysis (Russel et al., 2008).  
1.1.4.2 Twist and Torsion in AS 
Systolic twist (rotation) is affected by the loading conditions of the ventricle; an increase in preload 
exaggerates twist whereas increased afterload attenuates it.  Ageing results in reduced sub-endocardial 
function, increased apical twist and torsion but reduced velocity of untwisting. Physiological 
hypertrophy (athletes) increases LV wall thickness but maintains the ratio to cavity size, thus 
developing the same level of twist and torsion (Stuber et al., 1999). In the pressure-overloaded 
ventricle of AS the increased wall thickness to cavity size ratio produces higher levels of ventricular 
strain. Basal systolic twist is reduced and apical twist is increased and delayed. Torsion is therefore 
significantly higher increased compared to normal. This process is believed to be a consequence of 
sub-endocardial fibre dysfunction that is in part due to reduced endocardial blood flow in AS 
(Rajappan, 2002). 
Diastolic untwisting is also affected in AS. Untwisting is delayed with a reduced peak rotation 
velocity. The prolonged untwisting results in an overlap of relaxation and filling times and delayed 
diastolic filling which now occurs in late diastole (Nagel, 2000). The increase in torsion and 
prolonged untwisting of the LV in AS is related to the severity of the AS (van Dalen et al., 2011) and 
has been shown to precede any gross remodelling changes of the ventricle. Sandstede et al also 
demonstrated that abnormal twist and torsion have the potential to normalise following AVR 
(Sandstede et al., 2002).  
1.1.4.3 Low-flow AS 
Myocardial function may therefore be significantly impaired in the presence of a normal ejection 
fraction (Pibarot and Dumesnil, 2009). Ejection fraction is a measurement of myocardial fractional 
shortening (radial movement) and change in cavity size rather than an assessment of the workload and 
function of the LV wall. Therefore, in a ventricle with altered geometric shape (structural 
remodelling) a normal ejection fraction does not guarantee normal myocardial function. One third of 
asymptomatic AS patients with concentric remodelling were found to have impaired mid-wall 
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shortening, despite a normal ejection fraction (Cramariuc et al., 2009, Dumesnil et al., 2010). This 
finding is consistent with other observations that approximately one third of AS patients have a 
reduced stroke volume/body surface area (<35ml/m
2
) and low cardiac output (Hachicha et al., 2007, 
Pibarot and Dumesnil, 2012). These low flow situations may result in a paradoxically low pressure 
gradient across the valve, leading to an underestimation of the true severity of the stenosis (Pibarot 
and Dumesnil, 2010). Low flow-low gradient AS is a well recognised clinical scenario which poses 
difficulties surrounding the appropriateness and timing of treatment.   
1.1.4.4 LV structural remodelling 
Several physiological and pathological conditions result in the left ventricle altering its geometric 
shape, size and function (Linzbach, 1960). This structural remodelling has been described and 
classified according to the pattern of geometric changes in wall thickness, wall mass and cavity 
volume as recommended by the American Society of Echocardiography (Lang et al., 2005), Table 1-2 
(Gaasch and Zile, 2011). These measurements have been validated predominantly in hypertensive 
populations using angiography (Gaasch et al., 1972), echocardiography (Ganau et al., 1992) and 
cardiac MRI (Heckbert et al., 2006) with excellent correlation between the techniques.  
Table 1-2 Classification of structural remodelling 
  
RWT 
 
LVMI* LV EDV* M/V ratio 
Normal 0.32-0.42 70-90g/m
2 
<100ml/m
2 
1.1-1.3 
Concentric remodelling >0.42 70-90g/m
2 
<100ml/m
2
 >1.3 
Concentric hypertrophy >0.42 >90g/m
2
 <100ml/m
2
 >1.3 
Physiological hypertrophy 0.32-0.42 >90g/m
2
 <100ml/m
2
 1.1-1.3 
Eccentric remodelling <0.32 70-90g/m
2
 ≥100ml/m2 ≤1 
Eccentric hypertrophy <0.32 >90g/m
2
 ≥100ml/m2 ≤1 
   
RWT = relative wall thickness; M/V = mass to volume ratio; LVMI = left ventricular mass index 
* indexed to Body Surface Area (BSA) 
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1.1.4.4.1 Concentric hypertrophy 
In a pressure overloaded state such as AS the LV compensates for the increased pressure gradient by 
ventricular hypertrophy in order to maintain a constant after-load, but with no increase in the cavity 
radius. The increase in absolute and relative wall thickness (RWT) is known as concentric 
hypertrophy. This compensatory action maintains normal levels of wall stress but results in a late 
systolic peak compared to the early systolic peak in normal individuals. The rise in LV filling 
pressures alters the diastolic pressure-volume relationship reduces compliance and decreases 
ventricular preload capacity and is known as ‘diastolic dysfunction’ (Hess et al., 1993). Over time the 
LV starts to decompensate; it becomes scarred as collagen is deposited, cardiac output falls ‘systolic 
dysfunction’ and the cavity dilates.   
1.1.4.4.2 Eccentric hypertrophy 
Eccentric hypertrophy is the structural remodelling process where the geometric changes include: An 
increase in myocardial mass, peak wall stress and cavity size, with a small increase in absolute wall 
thickness but normal or reduced RWT. This pattern of remodelling has been classically described in 
volume overloaded conditions (mitral and aortic regurgitation) but can occur as the LV 
decompensates at the end stage of a pressure overloaded process (Dweck et al., 2012). Figure 1 
represents two different patterns of remodelling as demonstrated by cardiac MRI. 
Figure 1-1 Geometric patterns of remodelling 
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A = eccentric remodelling (increased mass and EDV with reduced RWT). B = concentric remodelling 
(increased mass and RWT with a lower EDV) 
1.1.4.4.3 Mass to volume ratio 
The mass to volume ratio (M/V) is easily assessed by cardiovascular magnetic resonance (CMR) 
imaging and correlates with the RWT of the ventricle. A measurement <1.1 is consistent with 
eccentric remodelling and >1.3 concentric remodelling. The pattern of ventricular remodelling has 
been established as important as an independent adverse prognostic marker for cardiovascular events, 
with concentric hypertrophy the strongest predictor of poor outcomes (Bluemke et al., 2008, Koren et 
al., 1991).  Differences in the geometric structure and remodelling process exist between races 
(Rodriguez et al., 2010), gender (Piro et al., 2010) and also in response to concomitant factors such as 
blood pressure (Wang et al., 2011). 
1.1.4.5 Valvuloarterial impedance 
The left ventricular workload is not solely dependent upon the pressure gradient across the aortic 
valve but the total pressure generated by vascular and valvular resistance. Given that a large 
proportion of AS patients (>50%) will have coexisting hypertension and reduced arterial compliance 
(Nemes et al., 2004), the assessment of global workload is important. Global workload can be 
estimated by calculating the valvuloarterial impedance (Zva), Equation 3. 
Equation 3, Valvuloarterial impedance: 
Zva (mm Hg∙ml
-1∙m2) = (SAP + MPG) / SVI
 
SAP = systolic arterial pressure; MPG = mean tranvalvular pressure gradient; SVI = stroke volume index  
 
Zva can be categorised as low (≤3.5 mm Hg∙ml
-1∙m2), intermediate (3.6-4.4 mm Hg∙ml-1∙m2) and high 
(≥4.4 mm Hg∙ml-1∙m2). Increased levels of Zva (>3.5 mm Hg∙ml
-1∙m2) can predict systolic dysfunction 
independent of and superior to the standard measures of AS severity (Briand et al., 2005).  It has also 
been shown to be an independent prognostic marker for mortality in asymptomatic moderate- severe 
AS patients (Cramariuc et al., 2009) and symptomatic severe AS patients regardless of their therapy 
(surgical or percutaneous valve replacement and medical therapy) (Hachicha et al., 2007, Katsanos et 
al., 2013).  
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1.1.5 Asymptomatic aortic stenosis 
Left ventricular remodelling occurs gradually, progressing with the disease severity. In mild and 
moderate AS patients may remain asymptomatic but as the stenosis becomes severe the high 
valvuloarterial impedance and increased ventricular workload frequently result in symptoms. The 
outlook for an asymptomatic patient with severe AS is reasonable at a 20-50% 5-year symptom free 
survival (Rosenhek et al., 2000).  Despite having a better outlook compared to symptomatic patients, 
the early identification and treatment of asymptomatic individuals may help prevent systolic 
dysfunction, heart failure and death (Lund, 1990). Several adverse prognostic indicators have 
therefore been identified to help risk stratify these asymptomatic individuals at an increased risk of 
symptoms, surgery and cardiovascular death.  
Patient characteristics and demographics that represent increased risk include, increased age 
(especially >80), the presence of coronary artery disease, renal dysfunction, hypertension, 
dyslipidaemia and diabetes mellitus (Pellikka, 2005, Berry et al., 2013).  Echocardiography has been 
used to identify several high-risk features. The severity of valve calcification (Rosenhek et al., 2009), 
a very high pressure-gradient (>5m/s) (Otto et al., 1997, Pellikka et al., 2005, Rosenhek et al.) and 
LV systolic dysfunction (Pellikka et al., 1990) are all independent predictors of increased risk. Newer 
imaging techniques are being implemented to help identify predictors of adverse outcomes in these 
asymptomatic individuals. CMR has been used to help identify reduced ejection fraction (Caruthers 
et al., 2003), increased twist and torsion (Nagel et al., 2000, Stuber et al., 1999) and reduced 
myocardial perfusion reserve (Steadman et al., 2012). The non-invasive detection and quantification 
of myocardial fibrosis has also been identified as an independent predictor of mortality in mild-
severe AS patients (Dweck et al., 2011). Exercise stress testing is used to risk stratify asymptomatic 
severe AS patients, with an early positive test predicting the onset of symptoms, aortic valve 
replacement (AVR) and cardiovascular death (Das et al., 2005, Amato, 2001 ).  
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1.1.6 Symptomatic aortic stenosis 
Once symptoms develop the prognosis of the patient becomes extremely poor with a mean survival 
of 23 months (Otto, 2006, Ambler et al., 2005, Horstkotte and Loogen, 1988). Presenting symptoms 
are frequently a consequence of the LV adaptations, the most common of which are angina, syncope 
and dyspnoea. Angina tends to be the earliest symptom and heralds an expected life expectancy of 
4.5 years. Its mechanism is secondary to the increased myocardial oxygen demand of the left 
ventricle. Concomitant coronary artery disease, which is present in 30% of AS patients, may 
contribute to or exacerbate the symptom. When syncope occurs an average survival of 2.6 years is 
observed. Syncope is usually exertional and is secondary to the LV baroreceptor response to elevated 
LV pressure causing arterial hypotension and bradycardia. Exertional dyspnoea presents last, 
indicating a predicted survival < 1 year. This may be due to diastolic dysfunction with high LV end 
diastolic pressures or systolic dysfunction with the signs of heart failure. The severity of 
breathlessness is traditionally measured by the New York Heart Association (NYHA) classification, 
Table 1-3. 
Table 1-3 NYHA classification 
Class 
 
Description 
 
Ι No limitation of physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, or dyspnoea (shortness of breath) 
 
ΙΙ Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity 
causes fatigue, palpitations, or dyspnoea 
 
ΙΙΙ Marked limitation of physical activity. Comfortable at rest, but less than ordinary 
activity causes fatigue, palpitations, or dyspnoea. 
 
ΙV Unable to carry out any physical activity without discomfort. Symptoms of dyspnoea at 
rest. If any physical activity is undertaken, discomfort is increased. 
 
 
1.2 Medical Therapy 
 
Attempts to delay the chronic progressive nature of AS through medical therapies have largely been 
unsuccessful (Moura et al., 2007, Rossebo, 2008). Trials have concentrated on medications that might 
influence the pathological process of degenerative valvular calcification. Statins (Rossebo, 2008, 
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Chan et al., 2010), ACE inhibitors (O'Brien, 2002, O'Brien et al., 2005) and angiotensin receptor 
blockers (ARB) (Nadir et al., 2011) have all been shown to have no impact upon delaying the 
progressive calcific degeneration of the valve or altering clinical outcomes.   
Medical interventions have therefore concentrated upon reducing the impact of AS and and 
consequences of pressure overload. ACE inhibitors and ARB have been used to delay the remodelling 
process and treat any concomitant hypertension (thus reducing the valvuloarterial impedance) with 
some success, reducing the incidence of heart failure and cardiovascular death (Litwin et al., 1995, 
Chockalingam et al., 2004). Coronary artery disease (CAD) and atrial fibrillation (AF) are commonly 
associated co-morbidities, which may require aspirin, beta-blockade or even warfarin anti-
coagulation.     
1.3 Surgical Aortic Valve Replacement 
 
Aortic valve replacement is the definitive treatment strategy in symptomatic AS, as the evidence 
supports an improvement in patient survival and quality of life (Vahanian et al., 2006, Kvidal et al., 
2000, Bakaeen et al., 2010). Traditionally this has required open cardiac surgery (Surgical Aortic 
Valve Replacement, SAVR) with either a mid-line sternotomy (if requiring coronary artery bypass 
grafts (CABG)) or a lateral mini-thoractomy. Mechanical or bioprosthetic valves may be implanted.  
Mechanical valves were frequently favoured in younger patients due to their better durability. 
However, there is an increasing trend to greater usage of bioprosthetic valves, even in individuals <65 
years (Lee et al., 2011, Brown et al., 2009). This changing pattern likely reflects the improved 
durability of new valves, patient choice (no anticoagulation) and the availability of a future 
percutaneous option. Different bioprosthetic valve types are available; bovine pericardial and porcine 
heterograft or a homograft. The Ross procedure (aortic replacement with pulmonary autograft and 
pulmonary homograft replacement) is still used in expert centres as another option. No outcome data 
exists to support the preference of one particular valve type over another; therefore the decision 
remains that of patient and surgical choice.  
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1.3.1 Clinical outcomes 
Recent data from the Society of Thoracic Surgeons (STS) in North America have shown an increase 
in the number of SAVRs being performed and a trend towards patients being older with greater co-
morbidities. Diabetes, hypertension, obesity and cerebrovascular disease were particularly prevalent 
conditions amongst the AS population. Cardiothoracic valve surgery is therefore becoming 
increasingly complicated, and this is reflected by a pattern of higher predicted surgical risk scores 
(STS surgical risk estimate). However, outcomes following SAVR remain good with 30 day survival 
between 2.6% (isolated SAVR) and 5.6% (SAVR+ Coronary Artery Bypass Grafting (CABG)), and a 
risk of stroke of 1.3%. (Brown et al., 2009, Kvidal et al., 2000).  
Surgical and patient factors influence patient survival. Observed mortality actually appears to be 
declining over time, possibly due to improved techniques and better post-operative care. High-volume 
surgical centres appear to have lower mortality rates, possibly due to surgical competence and overall 
quality of care (Brown et al., 2009). Patient factors are varied but include; advanced age, NYHA 
class, presence of atrial fibrillation, concomitant CABG and poor LV function. Frailty and impaired 
cognition are increasingly recognised as markers of worse outcome but as of yet remain poorly 
quantified. 
1.3.1.1 Surgical risk calculators 
In an attempt to estimate surgical risk the surgical societies of America and Europe have devised two 
risk calculators to approximate an individuals 30-day mortality:  
1. STS score (Brown et al., 2009) 
2. European System for Cardiac Operative Risk Evaluation (EuroSCORE) (Michel et al., 
2003b).  
 
These calculators use patient clinical variables to estimate the 30 day operative risk at the time of 
surgery from 0-100%, with a higher score indicating a greater risk. They also provide some indication 
of long-term outcome. The estimation of surgical risk is important to better inform clinicians and 
patients. It can help guide clinical practice and act as a benchmark allowing comparison between 
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national and local services. Due to the poor predictive capacity of the previously used Parsonnet 
score, EuroSCORE was created from the results of data acquired in eight European countries (Nashef 
et al., 1999). Initially an additive then logistic model (Michel et al., 2003a), EuroSCORE has been 
extensively validated as a useful predictive model for cardiac surgery (Roques et al., 2003). However, 
some limitations do exist particularly in reference to the estimation of risk in females, individuals 
undergoing multiple cardiac operations and those higher risk individuals (Ranucci et al., 2009, 
Choong et al., 2009). EuroSCORE ΙΙ was developed in order to address these issues by using more 
specific data such as poor and very poor ejection fraction and entry of the specific creatinine clearance 
(Nashef et al., 2012). Validation of EuroSCORE ΙΙ is ongoing but early results suggest its improved 
precision for higher-risk individuals and those undergoing combined CABG and AVR (Nashef et al., 
2013). Whilst providing some incremental benefit over the original logistic EuroSCORE, questions 
still remain concerning its accuracy in isolated AVR and CABG (Grant et al., 2012, Chalmers et al., 
2013). Additionally, there are no data to establish its role in the estimation of risk for the large number 
of patient being considered for TAVI.       
 
1.3.2 Decision to operate 
A decision to operate remains difficult in severe asymptomatic AS but is mandated when a patient 
becomes symptomatic. However, in elderly symptomatic patients with multiple co-morbidities, high 
cardiovascular and operative risk, a ‘simple’ decision process becomes an increasingly complicated 
one of balancing patient risks and benefits (Grossi et al., 2008, Schueler et al., Schueler et al., 2012).  
The European Heart Survey on valvular heart disease investigated this decision-making process. It 
discovered that up to one third of patients with severe AS and symptoms were not referred for 
definitive surgical treatment (Iung et al., 2003a). Age and LV dysfunction were two of the main 
factors stated as the reason for a judgment not to operate. This study highlighted a significant problem 
in the management of a heterogenous group of elderly complicated patients. Whilst these patients may 
have the highest absolute risk they equally have the greatest risk-benefit ratio and thus survival, 
relative to an age matched general population. (Kvidal et al., 2000) 
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1.4 Transcatheter Aortic Valve Implantation 
 
1.4.1 History of transcatheter valves 
The requirement for a less invasive therapy to treat severe AS resulted in the development of a 
transcatheter based valve system. In the 1980’s Cribier et al used balloon aortic vavuloplasty (BAV) 
to treat severe AS (Cribier et al., 1986).  This proved successful in initial symptomatic improvement 
but did not to alter the end outcomes of the disease process (Lieberman et al., 1995). Supra-coronary 
transcatheter valve devices had been trialled successfully in canine models through the 1960’s to the 
1980’s (Phillips et al., 1976). The first sub-coronary aortic device implantation was demonstrated in 
pigs by the Aarhus group in Denmark (Andersen et al., 1992). This device was a porcine aortic valve 
with a balloon expandable surrounding stainless steel stent.  A further balloon expandable stent-valve 
was subsequently developed by Alain Cribier  et al who went on to perform the first in human 
implantation in 2002 (Cribier et al., 2002). This equine pericardial and stainless steel, stent-valve was 
inserted using a balloon expandable technique via an antegrade route.  Subsequently the retrograde 
transfemoral (Webb et al., 2006) and transaxillary approaches have been developed, using both 
balloon and self-expandable devices (Grube et al., 2005).  
 
1.4.2 Transcatheter aortic valve implantation 
The evolution of Transcatheter aortic valve implantation (TAVI) in clinical practice was initially 
driven by a population requirement rather than good evidence. The first patients were therefore 
individuals who were deemed very high-surgical risk (calculated logistic EuroSCORE >20) or had 
inoperable factors such as a porcelain aorta, chronic obstructive pulmonary disease or chronic kidney 
disease. This approach is in comparison to the normal method for trialling new treatment devices 
which would commence in the low risk groups and following good results continue in a higher-risk 
group. (Buellesfeld and Windecker, 2011). On the basis of substantial registry data and one 
randomised controlled trial (Placement of Aortic Transcatheter Valves (PARTNER) trial) two types 
of transcatheter valve were given European CE marked approval in 2007:  
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1.4.2.1 Edwards SAPIEN valve 
Edwards Transcatheter Heart Valve (THV), (Edwards Lifesiences Inc, Irvine, California, USA) 
(Figure 1-2) is a bovine pericardial valve leaflet within a cobalt chromium frame.  It is suitable for 
aortic and pulmonary positions and can be deployed via either a femoral or transapical route. The 
Novaflex (Edwards Lifesiences Inc) delivery system requires a 16-19F sheath and an ileofemoral 
minimum diameter of 6mm. The valve is available in 20, 23, 26 and 29 mm sizes and is recommended 
for an annulus diameter of 18-25mm. Once in position the valve is deployed by a balloon expandable 
system.   
1.4.2.2 Medtronic CoreValve 
CoreValve™ ReValving system (Medtronic Inc., Minneapolis, MN, USA), (Figure 1-2) is a porcine 
pericardial leaflet within a nitinol self-expanding frame. It is suitable for both transfemoral and 
subclavian access but not transapical route. Percutaneous vascular access is required for the 18F 
delivery sheath which is based on an over the wire catheter system. The device is of either 26, 29 or 
31 mm sizes and is recommended for aortic annulus diameters of 20-27mm. The valve is removed 
from its sheath in the anatomically suitable position using fluoroscopic and transoesophageal 
echocardiogrphic (TOE) guidance. The frame self-expands and is anchored within the annulus 
extending superiorly, supracoronary and into the ascending aorta. It can be post-dilated if required and 
has the potential for retrieval if not fully deployed. Vascular closure is via the Prostar™ suture 
system. 
Patients require several pre-operative assessments to identify whether the patient is technically 
appropriate for TAVI. Investigations include transoesophageal echocardiography, computed 
tomography (CT) scanning and coronary angiography to assess coronary anatomy, aortic root and 
peripheral vascular suitablilty for TAVI. The clinical case is subsequently discussed in a multi-
disciplinary forum involving cardiac surgeons, interventional and imaging cardiologists, cardiac 
anaesthetists and geriatricians. This ‘heart team’ decide upon the appropriateness of any treatments, as 
to whether a patient is suitable for SAVR, TAVI or if all interventions would be futile. Once a 
consensus is achieved the potential risks and benefits are conveyed to the patient for a final decision.  
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Figure 1-2: Transcatheter valves 
 
A = The Medtronic CoreValve; B = The Edwards SAPIEN THV 
 
1.4.3 Evidence for TAVI  
The evidence for TAVI will be summarised from two main data sources; registry data and that of the 
randomised controlled trail, PARTNER.  
1.4.3.1 Registry data 
Registry data remains the main source of information regarding procedural success, complications and 
clinical outcomes following TAVI.  In Europe early CE approval (2007) resulted in a rapid uptake of 
the procedure, particularly in Germany where 40% of TAVI’s were performed (Binder and Webb, 
2012). Thus far over 50,000 patients have been treated worldwide with six national registries 
published (Piazza et al., 2008, Eltchaninoff et al., 2010, Zahn et al., 2010, Tamburino et al., 2011, 
Khawaja et al., 2011, Moat et al., 2011). These registries report the short term outcomes of TAVI 
using both available valve types (THV and MCV) and all of the potential access routes (transapical, 
transfemoral and subclavian).  
1.4.3.2 PARTNER study 
One randomised controlled trial has been published comparing TAVI against the current standard 
clinical care pathway, either SAVR or standard medical therapy. The Placement of Aortic 
Transcatheter Valves (PARTNER) trial (Clinical trials.gov number, NCT00530894) is a multi-centre 
RCT recruiting in the USA, Canada and Germany from 2007-2009. There are 4 arms to this study and 
A B 
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2 separate cohorts: In PARTNER cohort A  patients were required to have severe AS with clinical 
symptoms (NYHA class ≥2) and were classified as high-risk (STS ≥10%) but still suitable for surgical 
intervention. Cohort B patients had similar entry criteria but were not deemed suitable for surgical 
intervention, due to a calculated 30 day risk of death ≥50% or a serious irreversible illness. Patient 
suitability was decided by at least two cardiothoracic surgeons. Exclusion criteria included a bicuspid 
or non-calcified aortic valve, prior acute myocardial infarct, coronary artery disease requiring 
revascularisation, a left ventricular ejection fraction <20%, an aortic annulus <18mm or >25mm, 
severe mitral or aortic regurgitation, severe renal insufficiency and a stroke or transient ischaemic 
attack in the previous 6 months.  
The primary outcomes measure for both cohorts was freedom from death at one year (cohort A) and 
for the length of the study (cohort B) which is estimated to complete in 2014 (5 year follow-up). 
Secondary endpoints were measured at 30 days, 6 months and 1 year. They included freedom from 
major adverse cardiovascular and cerebrovascular events (MACCE), improved valve function or 
evidence of valve dysfunction, length of hospital stay and functional improvement in NYHA class and 
quality of life. An important note is that the PARTNER trial used only the Edwards-Sapien THV and 
the manufacturer Edwards Lifesciences were involved in the funding and design of the study.  
Transcatheter aortic valve implantation for aortic stenosis in patients who cannot undergo surgery 
(PARTNER cohort B) recruited 358 patients with severe AS, randomised to either TAVI (n=179) or 
standard medical therapy (n=179) and has to date published its one (Leon et al., 2010) and 2 year 
outcomes (Makkar et al., 2012b).  
Transcatheter versus surgical aortic valve replacement in high risk patients (PARTNER cohort A) 
recruited 699 patients randomised to either TAVI (n=348) or SAVR (n=351), and has also reported its 
one (Smith et al., 2011) and 2 year results (Kodali et al., 2012b). 
A European (Danish) RCT (NCT01057173) using both the THV and MCV devices is presently 
recruiting (an estimated 280 individuals) and should complete in 2018 with provisional results 
predicted to be reported in 2014.  
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1.4.3.3 Patient population 
Baseline characteristics of the registry and PARTNER study populations were similar with a mean 
age of ≥81 years and approximately 50% female gender. All patients had severe symptomatic AS as 
defined by the AHA guidelines using TTE Doppler measurements. There were high levels of co-
morbid conditions observed in the study populations. These included; prior MI (21%-22%), coronary 
artery disease (41%-60%), hypertension (60%-75%), previous stroke (7%-10%), Diabetes mellitus 
(22%-37%) and chronic kidney disease (21%-25%). A significant number of the patients had 
undergone previous coronary revascularisation by either PCI (28%-34%), CABG (16% -30%). The 
symptomatic burden was also high with > 75% of patients in either NYHA class ΙΙΙ or ΙV heart 
failure. The majority of patients had normal or mildly impaired LV function with only 9-14% of the 
populations having an EF < 30%. 
1.4.3.4 Procedural success and complications 
The registry and PARTNER procedural success rates were excellent (92.6%-98.7%) with a low rate 
of conversion to surgery (0.5%-0.8%) (Piazza et al., 2008, Smith et al., 2011). Early complications 
were principally related to procedural difficulties. Valve embolization (0.6%-1%) and valve-in valve 
re-implantation (0.5%-2.6%) were uncommon complications of device implantation. A significant 
proportion of individuals were noted to have some degree of aortic regurgitation (AR) post valve 
implantation (21-72%). Vascular complications experienced included cardiac tamponade (1.2%-2%) 
and arterial access dissection or haematoma (1.9%-3.2%). The main risk factor for a vascular 
complication was the size of the device and arterial access sheath. The Edwards THV and its larger 
(22-24F) sheath therefore had a greater frequency of vascular problems.  
Permanent Pacemaker (PPM) implantation was required in 12%-39% of patients within 30 days of 
their TAVI procedure, considerably higher than the SAVR complication rate of <10% (Limongelli et 
al., 2003, Smith et al., 2011). The rate of PPM implantation post-CoreValve is approximately double 
that following Edwards THV (Zahn et al., 2010, Eltchaninoff et al., 2010). Male sex, greater septal 
hypertrophy, left axis deviation, right bundle branch block, longer QRS duration and peri-procedural 
AV block have all been identified as risk factors for the need for permanent pacing. Procedural factors 
identified were: peri-procedural block, balloon pre-dilatation and the use of the larger Medtronic 
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CoreValve (29mm) (Khawaja et al., 2011). The likely aetiology of this complication arises secondary 
to damage to the conduction system of the left ventricle during either valvuloplasty or valve 
implantation. The left bundle branch sits in the membraneous septum in close proximity to the right 
and non-coronary leaflets of the aortic valve. In AS leaflet calcification and fusion brings them even 
closer to the conduction system. Thus during valvuloplasty or valve expansion the thickened valve is 
compressed against the left bundle branch and the conduction system may become damaged, resulting 
in an atrio-ventricular block. The higher percentage of PPM post-MCV compared to Edwards THV 
can be explained by the deployment of its nitinol frame which sits into the left ventricular outflow 
tract (11.2±4mm), leaving it in direct contact with the inter-ventricular septum and LBB. Thus the 
potential for peri and post-procedural damage is increased (Khawaja et al., 2011).   
Stroke and sub-clinical cerebral infarction are important complications of the TAVI procedure. The 
UK high-risk TAVI registry reported a stroke risk of 4% at 30 days (Moat et al., 2011). Patients who 
were randomised to TAVI in the PARTNER B study had an increased likelihood of stroke compared 
to medical therapy (5% vs. 1.1%), but the composite of death or stroke was still significantly lower in 
the TAVI group. The PARTNER A study revealed an early increased risk of all neurological events 
post TAVI compared to SAVR (5.5% vs. 2.4%), but no significant difference in the rate of major 
stroke. Longer-term follow up has now revealed no difference between the incidence of stroke 
between TAVI and SAVR at 2 years (Kodali et al., 2012b). The majority of cerebral events diagnosed 
were ischaemic in origin and are believed to be secondary to emboli from aortic atheroma dislodged 
during the passage of the bulky delivery apparatus, or degenerative valvular material released during 
the valvuloplasty and valve deployment. Predictors of cerebral infarcts included previous stroke, 
increased atherosclerotic burden and the transapical approach (Smith et al., 2011). 
1.4.3.5 Patient survival 
Early survival is reported as 30 day mortality post TAVI, with late survival data available up to 5 
years for registry studies and 2 years from PARTNER (cohort A and B). Early (30 day) mortality 
rates of approximately 10% (5.4% and 12.7%) are reported from the registry data. The latest survival 
figures suggest a trend towards a reduction in this mortality to 5%. This improvement is believed to 
be a consequence of greater procedural experience (the ‘learning curve’), improvements in patient 
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selection and developments in device technology (Gurvitch et al., 2011, Nuis et al., 2011). Late 
survival (1 year) ranges from 69% to 85% in the registry data (Thomas et al., 2011, Moat et al., 2011, 
Tamburino et al., 2011, Kodali et al., 2011). The PARTNER B study found all cause mortality to be 
similar between TAVI and standard therapy at 30 days (5% vs. 2.8% respectively) but by one-year 
TAVI was superior (30.7% vs. 50.7%) and was maintained to 2 years (43% vs. 68%). PARTNER A’s 
clinical outcome data (on an intention to treat basis) found no significant difference in all cause 
mortality between TAVI and SAVR at 30 days (3.4% vs. 6.5%), 1 year (24.2% vs. 26.8%) and 2 years 
(33.9% vs. 35%).  Cardiovascular mortality at the 3 time points was also similar between the groups. 
TAVI was therefore non-inferior to SAVR on the basis of the studies primary outcome. Longer-term 
survival data are limited but suggest an expected increase in mortality over time to 50% at 3 years, 
58% at 4 years and 65% at 5 years (Kodali et al., 2012b, Toggweiler et al., 2013, Buellesfeld et al., 
2011). These survival rates are comparable to the contemporary SAVR data for operations on 
octogenarians (Vasques et al., 2012, Leontyev et al., 2009, Ashikhmina et al., 2011) and from the 
randomised PARTNER A cohort (Kodali et al., 2012b). Given the age and co-morbidities of the 
subject population the mortality observed is not outside of the expected mortality rates of an age 
matched normal population. Studies suggest that once patients have survived the early-mortality risk 
that patient death is more frequently non-cardiac or TAVI associated (Buellesfeld et al., 2011, 
Tamburino et al., 2011).  
Predictors of early mortality post TAVI have been identified as predominantly procedural factors; 
conversion to open heart surgery, cardiac tamponade and vascular access complications (Tamburino 
et al., 2011). Predictors of late mortality are primarily the pre-procedural patient characteristics or co-
morbid risk factors. NYHA functional class, prior stroke,  chronic kidney disease and increased mean 
pressure gradient are all significant independent predictors of mortality (Kodali et al., 2011, Kodali et 
al., 2012b, Makkar et al., 2012b, Tamburino et al., 2011, Ussia et al., 2012, Moat et al., 2011). Female 
gender appears to confer a greater cardiovascular risk of death but not all cause mortality (Gotzmann 
et al., 2012a).  
Post-procedural aortic regurgitation (AR) of any kind occurs in up to 58% of cases (Buellesfeld et al., 
2011, Unbehaun et al., 2012). Moderate to severe AR (≥ Grade 2) is an important predictor of early 
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and late mortality (Abdel-Wahab et al., 2011, Gotzmann et al., 2012b, Gotzmann et al., 2012a, Kodali 
et al., 2012b). The mechanism of AR is believed to be mostly paravalvular, as a consequence of 
malapposition of the valve to the aortic root due to underestimation of the aortic annulus, extensive 
valve calcification or poor device placement.  
1.4.3.6 Functional change 
In an elderly population the functional benefit of TAVI may be more important than greater survival. 
An improvement in quality of life, functional capacity (NYHA class and 6 minute walk test) have 
been described post TAVI (Gotzmann et al., 2010, Ussia et al., 2009). In addition, PARTNER 
demonstrated reduced hospitalisation compared to medical therapy and a shorter hospital stay with 
greater functional improvement compared to surgery (Smith et al., 2011, Leon et al., 2010).  
 
1.5 Cardiovascular Magnetic Resonance for valvular heart disease 
The diagnosis and assessment of valvular heart disease has traditionally been performed using 
invasive cardiac catheterization and non-invasive echocardiography. Echocardiography in particular 
remains the dominant force in valvular heart disease management due to its excellent temporal 
resolution, ready availability and the wealth of historical data. However, the technique is not without 
its problems. The quality of images is highly dependent upon the acoustic windows available, an issue 
increasing in size given the obesity epidemic. Difficulties and inaccuracies in quantifying the severity 
of valve stenosis and in particular absolute regurgitation do occur. Determining the consequences of 
valvular heart disease also remains problematic. The accurate assessment of left and right ventricular 
volumes and function are imperative, yet variations in intra and inter-observer variability with 
echocardiography may limit its sensitivity to small but significant variations.        
The technique of CMR imaging has developed extensively over the last 20 years and is now used as 
standard practice in the assessment of ischaemic heart disease (Bingham and Hachamovitch, 2011, 
Nagel, 2003, Bekkers et al., 2010, Friedrich et al., 2008), congenital heart disease (Hundley et al., 
2010), myocardial disease (Sechtem et al., 2006, Marcus et al., 2010) and imaging of the great 
vessels. CMR allows non-invasive, non-ionizing imaging of the heart at high levels of temporal and 
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spatial resolution with an unlimited field of view. Unique information relating to cardiac (myocardial 
or valvular) anatomy and function can be used to determine the severity and impact of valvular heart 
disease, thus assisting in the management of these patients.     
 
1.5.1 Principles of magnetic resonance 
1.5.1.1 Magnetic fields 
The principles of nuclear magnetic resonance underlie magnetic resonance imaging (MRI). Three 
magnetic fields are generated from three different electromagnetic components: The main ‘magnetic 
coil’ produces a strong constant magnetic field (Bo) in a horizontal direction to the centre of the coil (z 
axis). The strength of this magnetic field is measured in units of Tesla (T = 20,000 times the earths’ 
magnetic field). Three ‘gradient coils’  (inside the main magnet) produce a magnetic field gradient 
in the same direction as the main magnetic field (Bo). These gradient magnetic fields are measured in 
units of milliTesla per meter (mT/m). Each gradient coil can be switched on or off altering the 
strength and direction of the net magnetic field (Bo) in three orthogonal planes depending upon which 
coil is used. This ability to rapidly change the direction of the electromagnetic field (dB/dt) allows 
images to be acquired in several orthogonal planes or axes. The third ‘radiofrequency (rf) coil’ is 
integrated inside the main coil and generates a rf magnetic field (B1). This magnetic field is of low 
amplitude but oscillates at a resonant (Larmor) frequency measured in megahertz (MHz) at right 
angles to the Bo (X and Y axes). The rf magnetic field is used to deliver a short rf pulse sequence into 
the patients tissues.  
1.5.1.2 Radiofrequency pulses 
Hydrogen is an element which exhibits nuclear magnetic resonance properties and in the form of 
water is contained in all human tissues. It is made up of a single proton which ‘spins’ to produce a 
small magnetic field known as magnetic moments. These magnetic fields are normally randomly 
orientated, but by applying a magnetic gradient they all align in one direction (that of the magnetic 
field, Bo). The excess magnetic moments combine to produce a net magnetic field known as net 
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magnetization (M0). The strength of the net magnetization is proportional to the strength of the 
underlying magnetic gradient and is in the direction of this field (B0 or z axis).  
The rf coil transmits energy in the form of a rf pulse into the tissue hydrogen atoms at the Lamor 
frequency (ωo). 
Equation 4 Lamor equation 
ωo = γ x B0 
γ = gyromagnetic ratio (42.6 MHz/T) 
 
The rf pulse realigns all the magnetic moments (in a process known as coherence), away from its 
equilibrium at the z axis to a newly directed field in the direction of the x and y axis. As M0 moves 
away from its alignment with the B0 and B1 fields it starts to rotate around the z axis at the Larmor 
frequency (precession). Magnetization is now split in to two parts; the z or longitudinal component 
(Mz) and the xy or transverse component (Mxy).  The new angle of net magnetization (flip angle) is 
dependent upon the energy of the rf pulse applied which in turn is dependent upon the length and 
amplitude of the rf pulse. These pulses are known as excitation pulses. An excitation pulse with a flip 
angle of 90° (degrees) applies sufficient energy to move net magnetization 90° from the z-axis to the 
x and y plane (Mxy). Net magnetization is now wholly in the in the direction of the transverse 
component. This is known as a saturation pulse or spin-echo pulse sequence. A smaller flip angle 
(denoted as α) does not transfer all the net magnetization away from the z axis. Repeated pulse 
sequences of this type can therefore be used in quick succession and are used in fast imaging 
sequences known as gradient echo sequences. 180° pulses can also be applied to move the 
magnetization around 180° from either the xy plane (refocusing pulse) or z plane (inversion pulse). 
An inversion pulse is frequently used in black blood imaging.     
1.5.1.3 T1, T2 and T2* relaxation 
Following a rf pulse, net magnetization immediately attempts to return to its equilibrium. This process 
is known as relaxation and occurs by two separate actions according to the different components of 
magnetization, longitudinal (z axis) and transverse (xy) relaxation.  
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Longitudinal relaxation back toward the z-equilibrium is known as T1 relaxation. This is an 
exponential recovery with a time constant. The T1 relaxation time constant of a tissue is associated to 
the rate of energy release from its hydrogen protons. Protons that rotate close to the Larmor frequency 
(such as fat) have a rapid exchange of energy and the shortest T1 relaxation times. Larger molecules 
release energy at a slower rate and therefore have longer T1 relaxation times. Additionally, smaller 
molecules such as water have high levels of molecular motion which is unfavourable for energy 
transfer and thus have the longest T1 times.  
Transverse relaxation is the decay of net transverse magnetization (Mxy).  This process is known as 
free induction decay (FID), where protons uniformly aligned following an rf pulse lose coherence and 
become ‘out of phase’. T2 relaxation is the loss of coherence due to the individual protons magnetic 
field interacting with another proton to change its spin angle resulting in a change in phase direction 
(dephasing). T2 relaxation is also known as spin-spin relaxation, as small molecules with little spin-
spin interaction have long T2 relaxation times (water) compared to the short times of larger static 
molecules with greater interaction (muscle). Loss of coherence can also occur due to inhomogeneities 
in the magnetic field (B0). Variations in the magnetic field result in variations in the protons Larmor 
frequency and subsequent dephasing. When this is combined with the T2 relaxation the actual FID 
rate is higher and is known as T2* relaxation.  
1.5.1.4 Echoes 
The MR signal from FID is generated and detected in the form of an MR echo. Two main types of 
MR echo exist: Gradient and spin echoes.  
1.5.1.4.1 Gradient echoes 
Following a 90° rf pulse a magnetic field gradient is applied to dephase the protons in a set direction 
and reduces the FID to zero. A second magnetic field gradient of equal amplitude but opposite 
direction results in a re-phasing of the protons and a return of the FID. The MR signal generated from 
the re-phasing is known as the gradient echo. The echo time (TE) is the time taken from initial rf 
pulse transverse magnetization to the maximal amplitude of the gradient echo. Altering the echo time 
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(by applying a more rapid or slower second gradient) can be used to influence the effect of T2* 
relaxation on the image.  
1.5.1.4.2 Spin echoes 
Spin echoes use the application of a secondary 180° rf pulse following the initial transverse 
magnetization 90° rf pulse. This causes the spins dephasing due to field inhomogeneities to refocus 
(rephase) increasing the amplitude of the FID. The signal generated from the 180° rf pulse is known 
as the spin echo. As the amplitude of the signal is greater compared to gradient echo, spin echoes 
produce greater signal quality and are less susceptible to metallic field inhomogeneities 
 
1.5.2 Image acquisition 
MR echoes cannot be used in isolation to produce an image. Sequential gradient fields are applied to 
determine the slice direction, phase encoding direction and frequency encoding direction. Once the 
slice had been selected the phase encoding gradient shifts the protons in a pre-specified direction. A 
frequency encoding gradient is then produced at a right angle to the phase encoding direction. Three 
dimensional imaging becomes possible by using the three gradients in different combinations along 
the z, x and y axis to produce a transaxial, coronal or sagittal image.  
This process is repeated several times to form a pulse sequence. The slice and frequency encoding 
direction are maintained, but the phase encoding direction is changed in order to alter the phase over 
time. The MR echoes generated by the frequency encoded gradient therefore vary in amplitude and 
frequency. The individual frequency and amplitude of each wave is measured to indicate the signal 
from its original location in a pre-specified field of view. The signal analysis, known as Fourier 
transformation is dependent upon Nyquist’s rule that the sampling frequency should be twice that of 
the maximum signal frequency. 
The time between each repetition of signal echoes is called the repetition time (TR). The spatial 
resolution of an image (number of pixels) is dependent upon the number of phase encoding steps 
which in turn relies upon the TR and image acquisition time. Each MR echo signal has its own space 
or location, known as the k space. The spatial location of the k space is inversely related to its 
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frequency, so that higher spatial frequency waves are further away from the centre of k space. 
Gradients of differing length and strength are applied to alter the spatial frequency of a wave and thus 
sample all areas of the k space from edge to edge (linear order) or from the centre out (centric order). 
The number of data points acquired are dependent upon the number of phase encoding gradients (x 
axis) and the number of MR echo signals sampled (y axis). Once all the spatial frequencies have been 
acquired 2D Fourier transformation converts this into an image space.  
1.5.3 Image quality 
The quality of a MR image is dependent upon balancing the amount of signal generated to that of the 
background noise. This relationship is known as the signal to noise ratio (SNR). Several factors 
influence the SNR: The strength of magnetic field, the receiver coil, the image acquisition parameters 
and the pulse sequence. Each aspect can be varied in an attempt to improve the SNR. However, 
improving one factor is almost invariably at the detriment of another.    
1.5.3.1 Surface coil 
SNR can be improved by the use of a surface coil. This is a small dedicated coil with multiple 
(normally 5) receiver coils designed to maximize the signal by being closer to the patient and 
reducing the noise from outside the area of interest. The differently positioned phase array coils also 
provide spatial distribution information which permits the undersampling of the k space to reduce 
imaging time, in a process known as parallel imaging.  
1.5.3.2 Image acquisition parameters 
The number of pixels (phase encoding steps) determines the spatial resolution of the image in a set 
field of view. Increasing the spatial resolution is dependent upon increasing the number of phase 
encoding repetitions and therefore the image acquisition time. Slice thickness determines the volume 
of the image (voxel) and therefore the number of protons contributing signal. As spatial resolution 
increases, voxel volume decreases with a corresponding reduction in protons and signal yet an 
increase in background noise (decreased SNR).  
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1.5.3.3 Pulse sequence 
The strength of the MR signal from a tissue is influenced by its specific MR characteristics (proton 
density and relaxation times) and the applied pulse sequence. The recovery of equilibrium 
(longitudinal magnetization, Mz) depends upon the time given for recovery between pulses (TR), the 
rate of T1 relaxation and the amount of energy transferred to the transverse component (flip angle). 
The decay of the transverse magnetization is affected by the rate of T2 and T2* relaxation and the 
time of signal sampling (TE).  For gradient echo a variable flip TR, TE and flip angle can be used to 
alter the image signal. Spin echo sequences due the 180° refocusing rf pulse are not affected by T2* 
relaxation nor a variable flip angle. These factors can be changed within a pulse sequence in order to 
provide different contrast weighting of tissues. 
1.5.3.3.1 Long TR Short TE  
The long TR allows a full return to equilibrium, where a short TE allows little T2 decay. Therefore all 
tissues have high signal with little contrast between them. This is useful for anatomical imaging.  
1.5.3.3.2 Short TR Short TE 
Due to the short TR only tissues with short T1 times recover equilibrium. The effect of T2 relaxation 
is limited due to the short TE. Therefore images are influenced by the T1 time. This is known as T1 
weighted imaging. Signal from fat is high and low from fluid. This produces good signal contrast 
between tissues.  
1.5.3.3.3 Long TR Long TE 
The long TR means that most tissues will have recovered equilibrium. The long TE allows greater T2 
relaxation, so that the image is dependent upon the T2 and T2* relaxation rates. Fluid has a long T2 
relaxation time and therefore appears bright. These sequences are useful for the characterisation of 
myocardial oedema or haemorrhage (iron loading).  
1.5.3.3.4 Short TR Long TE 
T1 relaxation has little influence due to the short TR. The long TE also reduces signal secondary to T2 
relaxation. This has the effect of reducing the total MR signal and contrast between tissues.   
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1.5.4 Spin echo and gradient echo imaging 
1.5.4.1 Spin echo  
As discussed, spin echo pulse sequences use a 90° rf pulse to transfer all magnetization toward the 
transverse axis and a 180° refocusing pulse to reverse field inhomogeneities. These factors combine to 
produce high quality images with low susceptibility to magnetic field inhomogeneities. This sequence 
is known as a black blood sequence, as the blood that was initially magnetized by the excitation pulse 
has moved out of slice by the time of the 180° refocusing pulse and thus does not contribute towards 
the MR signal. Black-blood imaging is therefore suited to detailed anatomical assessments. 
Occasionally a second 180° pulse is used to re-invert magnetization within the slice but leave tissue 
outside inverted (nulled). The time from inversion pulse to excitation pulse is known as the time from 
inversion (TI).  
1.5.4.2 Gradient echo 
The single excitation pulse, low flip angles and short TR of gradient echo pulse sequences make them 
ideal for rapid imaging. The fast moving blood is therefore visible and this form of imaging is referred 
to as ‘bright blood’ imaging. Tissues are frequently saturated (low signal) due to the repeated pulse 
sequences reducing the time to return to equilibrium. The blood-tissue contrast is therefore good, and 
combined with the short TR makes this pulse sequence ideal for functional imaging. 
1.5.5 Cardiac imaging  
The problems and pitfalls of MR imaging are only enhanced in the attempt to image a beating heart. 
To reduce any motion artefact the imaging time (TR) is kept as short as possible and repeated at 
identical time points over several cardiac cycles. The ECG R wave is used in order to ensure the 
timing of the pulse sequence is identical between cardiac cycles. The time from the R wave to the first 
image acquisition is known as the Trigger delay. This technique can be used to produce both still and 
moving images.  
1.5.5.1 Still imaging 
A single line of k space data is acquired during each cardiac cycle at the exact same time point as 
specified by the operator (the trigger delay). This form of imaging is used in:  
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 Black blood T1 or T2 weighted, spin echo sequences for anatomical assessments.  
 Black blood STIR, triple inversion T2w, spin echo sequences to characterise tissues and 
myocardial oedema.  
 Late enhancement, inversion recovery gradient echo sequences for assessment of myocardial 
scar.       
1.5.5.2 Cine imaging 
Multiple lines of k space data are acquired during each cardiac cycle at different time points (phases). 
Each phase represents a different image which when reconstructed can be viewed as a movie or cine, 
permitting functional assessment of the heart. The timing of data acquisition can either be triggered 
(triggering) after each R wave or be continuous (gating). Data acquired from gating can be used 
prospectively, where data is given a set time point after each R wave, or retrospectively once all the 
data has been collected. Retrospective gating is particularly favourable if end-diastolic data is required 
or if the R-R interval is irregular (arrhythmias).  
1.5.5.2.1 Cine gradient echo 
Cardiac function is assessed using a bright blood cine gradient echo sequence with retrospective 
gating.  Two different pulse sequences can used:  
1. Spoiled Gradient echo (FLASH, T1 FFE): This pulse sequence uses an additional gradient to 
de-phase any residual transverse magnetization ensuring it does not interfere with the next 
pulse sequences signal. The imaging is therefore predominantly T1 weighted and relies upon 
blood movement for contrast between tissues. The greater sensitivity to flow means that this 
sequence is frequently used in valvular assessments to look for regurgitant or stenotic jets. 
2. Steady state free precession (true FISP, bFFE): Three additional gradients are applied to re-
phase all the transverse magnetization during each pulse sequence. The transverse 
magnetization signal following several sequence is increased producing higher signal and 
providing high quality images with excellent SNR. 
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1.5.5.2.2 Velocity encoded gradient echo 
Spoiled gradient echo can also be utilised to quantify the velocity of blood flow. Unlike static tissues 
moving blood is not re-phased by the bipolar gradient of the pulse sequence. The blood and tissue 
therefore have a difference in phase which correlates to the flow velocity of blood in the direction of 
the applied gradient. As phase changes may be influenced by magnetic field inhomogeneities and 
flow in more than one direction, two acquisitions are made with separate flow sensitivities to generate 
a phase map. These phase maps are subtracted to produce a map of phase shifts solely due to velocity 
changes, a velocity map. The flow sensitivity range or VENC must be set to prevent aliasing where 
positive velocities are interpreted as negative and vice versa.      
 
1.5.6 Imaging and assessment of the Aortic valve 
 
CMR can be utilised to determine the severity of valvular lesions. The severity of AS is assessed and 
graded using the same classification as TTE. However, CMR does not use the principals of Doppler 
but makes the use of two distinct techniques; cine functional assessment and phase-contrast imaging. 
1.5.6.1 Functional assessment 
Direct visualisation of the aortic valve allows the calculation of the AVA by planimetry, Figure 1-3. 
This technique is useful as it is independent of variations due to flow, which can lead to an under-
estimation of valve severity in instances of ‘low flow-low gradient AS’. Multi-planar CMR imaging 
enables the valve and its apparatus to be shown in several orthogonal planes with an unlimited field of 
view. Two different cine pulse sequences can be used to visualise the valve anatomy: Steady State 
Free Precession (SSFP) uses multiple phases throughout the cardiac cycle gated from the ECG with a 
typical repetition time (TR) of 3ms, echo time (TE) of 1.5ms and Temporal Resolution of 25-50ms. 
This produces a high signal to noise (SNR) ratio with good blood to myocardium contrast. Gradient 
fast low angle shot (FLASH) sequences differ by using a single shot sequence with a typical TR of 
8ms, TE 3.3ms, and Temporal Resolution of 30ms. There are relative advantages and disadvantages 
to using each sequence. FLASH with its longer TE is subject to spin dephasing artefacts which create 
a signal void from the stenotic jet, making analysis of the valve margins difficult. SSFP with its 
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shorter TE is less subject to these dephasing artefacts but is more susceptible to magnetic field 
inhomogeneities such as valve calcification (Schlosser et al., 2006, Friedrich et al., 2002). CMR 
planimetry has been compared to TOE (John et al., 2003), TTE (Reant et al., 2006) and cardiac 
catheterization (Friedrich et al., 2002) with an excellent correlation (r > 0.8). CMR is also highly 
reproducible with estimated intraclass coefficients (ICC) of greater than 0.9 for both intraobserver and 
interobserver variability (Pouleur et al., 2007, Reant et al., 2006). Whilst CMR planimetry provides 
better imaging quality compared to echocardiography, it slightly overestimates AVA compared to the 
Gorlin technique of cardiac catheterisation (Reant et al., 2006). Therefore, recent techniques have 
concentrated on the estimation of AVA and AS severity by using the technique of phase-contrast 
MRI.     
 
Figure 1-3 Aortic valve planimetry 
  
Gradient TFE pulse sequence (4mm slice thickness, 0mm gap, 10 phases. FOV 340, RFOV 60). 
  
1.5.6.2 Phase contrast MRI  
Phase contrast pulse sequences (velocity-encoded cine, VENC) can estimate the average flow-
velocity of blood in the aorta and use this information to determine the flow-volume of blood. A pulse 
sequence can detect the phase shift of moving protons by applying a biphasic gradient to them. 
Stationary protons have no phase shift in a magnetic field, where moving protons have a phase shift 
that is dependent upon their velocity and distance travelled. The measurement of blood flow velocity 
can thus be determined by analysing the appropriate region of interest (Lotz et al., 2002). Two images 
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are produced; a phase contrast and magnitude image, Figure 1-4. The phase contrast image displays 
the velocity map of individual pixels as a greyscale image, with flow towards the phase encoding 
direction being bright, flow away from the phase encoding direction dark and stationary pixels are 
grey. The magnitude image is an anatomical bright blood image that allows the delineation of the 
aortic wall as a region of interest, (ROI),. A contour can then drawn around the vessel in each of its 
phases, the velocity of each voxel is then measured and averaged over the whole of systole to produce 
a mean velocity (Cawley et al., 2009). Phase contrast mean velocity measurements correlate well with 
invasive methods of flow assessment (Evans et al., 1993) and are superior to the non-invasive Doppler 
ultrasound which tends to overestimate mean flow (Sadek et al., 1996).   
 
Figure 1-4 Phase velocity and modulus maps    
 
 
Images can be acquired in either a breath-hold or free breathing technique. Each method uses the 
cardiac cycle ECG (R wave) to trigger data collection. The breath-holding technique uses prospective 
gating, in that each R-wave triggers data collection of the subsequent cardiac cycle. Data is used over 
several cycles to determine the velocity. It does not however acquire data at the end of each cycle (late 
diastole), as it must wait for the next trigger. The length of acquisition is thus constant, which can be 
useful if an individual suffers from an irregular heartbeat (arrhythmia) due to this ‘arrhythmia 
rejection window’. A disadvantage of breath-hold images is that any data from late diastole is not 
acquired. This is a particular problem in valve disease with a regurgitant fraction, as regurgitation 
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occurs during diastole. Non-breath hold images are attained using retrospective gating of the ECG’s R 
wave. Information is acquired throughout the cardiac cycle and averaged over several cycles for the 
mean velocity. Any variations in the cardiac cycle are therefore not taken account of and can result in 
inaccuracies of the final data collected. It does however include diastolic data and is thus useful for 
any regurgitant blood flow. This technique has been validated for the estimation of AS severity using 
both VTI measurements and the continuity equation (Pouleur et al., 2007). 
Velocity measurements (cm/s) acquired by phase contrast imaging can be multiplied by the aortic area 
(ROI) to give a flow-volume (ml) measurement, Figure 1-5. Forward and backward flow volumes 
(ml/heart beat) can be determined by relating the velocity to the timing of the cardiac cycle 
(systole/diastole). This method of assessment has been used to assess the severity of aortic valve 
stenosis by Hakki’s formula (Puymirat et al., 2010) and regurgitation (regurgitant fraction) (Didier et 
al., 2000).   
Figure 1-5 Flow volume curve 
 
Phase contrast imaging does have several pitfalls and complications which should be accounted for. 
The encoding velocity (VENC limit) should not be set too high, as this can increase the noise in the 
velocity image which may affect the accuracy of the peak velocity measurement. Equally it is 
important not to set the VENC limit below the peak velocity (too low), as this can result in aliasing 
and an inaccurate velocity estimate. Aliasing occurs when the phase shift is greater than 180°. It can 
be corrected for in post-processing, but it is simpler to repeat the imaging at a higher VENC (Lotz et 
al., 2002).   
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Partial volume averaging may occur, where the peak velocity is underestimated due to an averaging of 
the vena contracta velocity as its surrounding voxels are included. This is a particular problem if the 
spatial resolution is too low or the slice thickness to high. Slice thickness should therefore be 
approximately 4mm (from 8-10mm) in order to reduce the effect of partial volume averaging. A low 
temporal resolution may also result in the underestimation of flow velocities as a short peak velocity 
may be missed. Further, the slice position should be perpendicular to the flow (jet) of blood to 
minimise any inaccuracies (Cawley et al., 2009). 
Phase offset errors are background stationary or moving spins, secondary to eddy currents and 
concomitant (Maxwell) gradients applied from the magnetic field. Small velocity offset errors can 
result in large flow quantification errors. Post-processing software correction ‘background correction’, 
can worsen the phase error as it relies upon uniformity of the gradients (Kilner et al., 2007). In 
addition each scanner will have its own particular background error (Gatehouse et al., 2010, Rolf et 
al., 2011). Chernobelsky et al suggested that the technique of ‘phantom correction’ is the most reliable 
and effective method of correcting background phase errors (Chernobelsky et al., 2007). Kilner et al 
have further recommended an acceptable level of error to be less than 0.5% of the velocity encoding 
limit (Kilner et al., 2007).    
 
1.5.7 Ventricular Function and Volumes 
 
Echocardiography remains the most common non-invasive imaging investigation used to estimate 
ventricular size and function. It does however depend upon good acoustic windows, clear myocardial 
definition and certain geometric assumptions. Analysis by M-mode and Simpsons method of discs 
may result in significant errors estimating cavity size and systolic function. These errors are 
exaggerated in an abnormally shaped ventricle which is remodelling (Bottini et al., 1995, Semelka et 
al., 1990a, Teichholz et al., 1976). CMR is a non-invasive, non-ionizing investigation that provides an 
unlimited field of view combined with high spatial and temporal resolution. It and has thus become 
the reference standard for the measurement of ventricular volumes, mass, morphology and function.  
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Cine (bright blood) SSFP imaging with its high signal to noise ratio provides good blood pool to 
myocardium contrast and excellent image quality. A reproducible LV stack of 10-12 (10mm) short 
axis cines is acquired, where each image is taken in a single breath hold (Barkhausen et al., 2001). 
Data acceleration techniques such as parallel imaging can be utilised to improve acquisition time by 
the theory of spatial undersampling. However, this method may reduce the signal to noise ratio and 
image quality. Cine images are ECG gated so that each image is the data averaged over several 
cardiac cycles. Retrospective gating occurs in most instances to ensure full diastolic coverage but 
prospective gating can be utilised should the ECG R-R interval (rhythm) be irregular.  
Several studies have validated the accuracy and reproducibility of left and right ventricular volumes 
as assessed by MRI. Ex vivo volumetric casts (Longmore et al., 1985) and in vivo stroke volumes 
(SV) (Kondo et al., 1991) have shown excellent correlation to MR estimates of volumes. 
Measurements of LV and RV mass have been compared to human and animal autopsy models with 
high levels of accuracy (Katz et al., 1993). The inter-observer and intra-observer reproducibility of 
volume and mass measurements using MR is the highest of any imaging modality (Semelka et al., 
1990b, Grothues et al., 2004). Furthermore, the high inter-study reproducibility results in small 
standard deviations (SD) meaning that smaller sample sizes are required for the adequate power 
design of a study compared to echocardiography (Grothues et al., 2002, Bellenger et al., 2000).  CMR 
is therefore ideally suited to study the serial assessment of a TAVI population, where ventricles are 
geometrically abnormal and sample sizes are small.  
Ventricular function can be described globally or separated into a regional assessment in accordance 
with the AHA 16 segment model (Duncan et al., 2011). The excellent endocardial and epicardial 
definition afforded by CMR further permits the assessment of wall thickness and the quantitation of 
wall dynamics (thickening), (Sheehan et al., 1986). Myocardial tagging is the application of a pre-
pulse saturation line (‘tag’) that moves and rotates with the contraction and relaxation of the 
myocardium. This technique allows the quantitative analysis of endocardial, epicardial and transmural 
motion, strain and torsion (Reichek, 1999).  
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1.5.8 Myocardial Fibrosis 
 
Myocardial fibrosis (MF) is recognised in several clinical conditions that are characterised by a 
dysfunctional ventricle. Myocardial infarction, dilated cardiomyopathy, hypertrophic cardiomyopathy 
and pressure overloaded ventricles represent different pathological processes that are associated with 
fibrosis of the failing ventricle. Fibrosis is the deposition of collagen in the myocardial tissue and can 
take the form of reactive interstitial fibrosis or replacement fibrosis. Replacement fibrosis is the 
deposition of Type 1 collagen in the place of necrotic myocytes secondary to ischaemic (infarct) or 
inflammatory (myocarditis) damage. This tends to be focal and irreversible. Reactive fibrosis however 
involves myofibroblasts depositing collagen in the interstitium (extra-cellular volume, ECV) and is 
potentially reversible (Mewton et al., 2011). The collagen deposition that occurs with each of these 
processes results in an increase in the ECV to cardiac myocyte ratio. MF is prevalent in patients with 
AS, and is believed to be in part a result of activation of the rennin-angiotensin-aldosterone system 
(Weidemann et al., 2009a, Weber and Brilla, 1991). Focal and diffuse MF alter the T1 relaxation 
properties of myocardial tissue. CMR can assess the T1 relaxation times and thus MF by two different 
techniques:  
1.5.8.1  Late Gadolinium Enhancement 
Late Gadolinium Enhancement (LGE) is an established technique based on the principal that 
gadolinium accumulates in the increased ECV space of a diseased collagenous myocardium. 
Gadolinium shortens the T1 relaxation time resulting in late-enhancement of focal fibrotic tissue on a 
background of normal ‘nulled’ myocardium. This technique has been validated against the 
histopathological findings of collagen deposition in animal and human hearts (Weidemann et al., 
2009a, Lima et al., 1995, Kim et al., 2000). There is excellent correlation of hyper-enhancement on 
CMR to the quantity of fibrosis with a high level of sensitivity (Wu et al., 2001). The first studies 
used a signal intensity threshold of 2 SD above normal myocardium to identify and quantify late 
gadolinium enhancement (focal fibrosis). This threshold was used predominantly due to the 
experience in post-myocardial infarction patients.  Due to the diffuse nature of fibrosis in non-
ischaemic cardiomyopathies accurate quantification of fibrosis poses a greater challenge, particularly 
in identifying ‘normal’ nulled myocardium. Several different signal intensity thresholds have been 
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trialled using 3SD, 5SD and 6SD above the normal myocardium and a full width half maximum 
(FWHM) technique using visually identifiable focal fibrosis to determine the threshold. Flett et al. 
compared 7 different quantification techniques in a myocardial infarct and hypertrophic 
cardiomyopathy cohort and found the FWHM technique to be the most reproducible and accurate 
(Flett et al., 2011).  
1.5.8.2 T1 Mapping 
In non-ischaemic cardiomyopathies such as hypertrophic cardiomyopathy (HCM), dilated 
cardiomyopathy (DCM) and AS, the type of MF is reactive or diffuse. Whilst LGE-CMR is excellent 
at defining focal fibrosis it is unable to quantify diffuse fibrosis. In diffuse MF the increased ECV is 
composed of greater collagen and water content, lengthening the longitudinal relaxation time (T1) of 
the myocardium. ‘T1 mapping’ is a developing technique that uses a modified Look-Locker inversion 
recovery (MOLLI) sequence to detect changes in T1 of the myocardium pre-contrast and following 
the administration of a gadolinium contrast agent (Iles et al., 2008). This has been compared to a 
standard Look-Locker sequence with excellent agreement (Nacif et al., 2011). The accuracy and 
precision of T1 measurements are however dependent upon the number of measurements along the 
T1-recovery curve, the SNR, the tissue T1 and the method of fitting. Phantom studies have 
demonstrated small but potentially significant variations may occur with different heart rates, field 
strengths and MR vendors (Kellman et al., 2013a, Kellman et al., 2013b, Messroghli et al., 2004). 
Early experience found the MOLLI sequence in practice was further limited by the long breath holds 
required. A shortened MOLLI (ShMOLLI) sequence was developed to address this issue, reducing the 
heart rate dependency and breath hold time with good agreement to MOLLI (Piechnik et al., 2010, 
Messroghli et al., 2006).  
T1 mapping has now been used to identify and quantify diffuse MF in several disease groups 
including post myocardial infarction (Dall'Armellina et al., 2012, Ferreira et al., 2012), AS (Flett et 
al., 2012), HCM (Flett et al., 2011), DCM (Dass et al., 2012) and amyloid heart disease (Karamitsos 
et al., 2013). The technique has been validated against histological samples from AS patients (Flett et 
al., 2012, Bull et al., 2013) and a transplant group (Miller et al., 2013). Normal values and ranges are 
however yet to be established, and several different methods are currently employed. The T1 
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calculation is also prone to frequency dependent errors, as the Look Locker correction is based on a 
spoiled gradient echo sequence despite the fact that T1 mapping uses an SSFP sequence (Kellman et 
al., 2013b).  
1.5.8.2.1   Native T1 mapping 
Native T1 mapping measures the T1 values of the myocardium at the level of an individual pixel, 
prior to the administration of a contrast agent. This removes the need for a defined ‘normal’ ROI 
making it more objective, reproducible and thus accurate. Native T1 values have been used in the 
assessment of myocardial infarction (Ugander et al., 2012a) and diffuse fibrosis with evidence of 
increased values in normal females and with age (Ugander et al., 2012b, Liu et al., 2013).    
1.5.8.2.2 Post contrast T1 mapping 
Similar to the principles of LGE, a gadolinium contrast agent is used which small enough to move 
freely between the vascular (blood) and extracellular compartments but does not enter the cells. 
Therefore gadolinium accumulates in the expanded ECV and proportionally shortens the T1 
relaxation time, which can be detected at a set time point following the administration of contrast 
agent. Variations in post-contrast T1 can result from differences in drug kinetics, a patients’ body 
composition, renal clearance and haematocrit. The pre and post contrast T1 values can be used to 
calculate a tissue to blood partition co-efficient, Equation 5 (Flacke et al., 2001). When corrected for 
the volume of blood contrast distribution (1-haematocrit) this provides a more accurate estimate of 
ECV (White et al., 2012). The clinical significance of ECV quantification is becoming apparent, as an 
independent predictor of left ventricular dysfunction (Ugander et al., 2012b), cardiac mortality (Wong 
et al., 2012) and heart failure (Wong et al., 2013).  
Equation 5 tissue to blood partition co-efficient 
λ = ΔR1m / ΔR1a = (1/T1post m - 1/T1post m) / (1/T1post b - 1/T1post b) 
Pre = pre contrast; Post = post contrast; m = myocardial; b = blood 
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1.6 Aims of the thesis 
 
The trial and registry data have shown TAVI clinical outcomes to be superior to medical therapy and 
non-inferior to SAVR at two years. TAVI however remains an interventional treatment in its infancy 
as studies have highlighted several aspects of TAVI that needed greater evidence and further 
investigation. The Valve Academic Research Consortium (VARC) therefore proposed definitions for 
clinical endpoints in TAVI in order to aid and improve the quality of research in this area (Leon et al., 
2011, Kappetein et al., 2012a). The aim of this thesis was to establish the safety and benefit of the 
TAVI procedure concentrating on 4 areas of research related to the advancement in knowledge of 
TAVI as recommended by VARC:  
1. Prosthetic valve performance 
2. Stroke 
3. Quality of life 
4. Cost-effectiveness 
The following chapters will concentrate on each individual subject of interest with an appropriate 
introduction, methods, results and discussion sections.  
Chapter 2, Prosthetic valve performance: Assessment of valve haemodynamics, reverse ventricular 
remodelling and myocardial fibrosis following Transcatheter Aortic Valve Implantation compared to 
Surgical Aortic Valve Replacement. 
Chapter 3, Stroke: Diffusion-weighted magnetic resonance imaging determined cerebral embolic 
infarction following Transcatheter Aortic Valve Implantation: Assessment of predictive risk factors 
and the relationship to subsequent health status. 
Chapter 4, Quality of Life: Serial change in health related quality of life over one year following 
Transcatheter Aortic Valve Implantation: Predictors of health outcomes. 
Chapter 5, Cost-effectiveness: The Cost-Effectiveness of Transcatheter Aortic Valve Implantation 
versus Surgical Aortic Valve Replacement in patients with severe aortic stenosis at high operative 
risk.  
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2 Assessment of Valve Haemodynamics, Reverse Ventricular 
Remodeling and Myocardial Fibrosis following Transcatheter 
Aortic Valve Implantation compared to Surgical Aortic Valve 
Replacement: A Cardiovascular Magnetic Resonance Study. 
 
2.1 Abstract 
 
Background: To compare the effects of TAVI and SAVR on aortic valve haemodynamics, 
ventricular reverse remodeling and MF by CMR imaging. 
Methods: Prospective study of 77 high-risk severe AS patients (age 77±8 years).  A 1.5T CMR scan 
was performed pre-operatively and 6 months post-operatively.  Fifty patients (25 TAVI, 25 SAVR) 
completed both pre and post-operative scans.    
Results: Patients were matched for gender and AS severity but not for age (80±6 vs. 73±7yrs, 
p=0.001) or EuroSCORE (22±14 vs. 7±3, p<0.001). Aortic valve mean pressure gradient decreased to 
a greater degree post-TAVI compared to SAVR (21±8mmHg vs. 35±13mmHg, p=0.017). Aortic 
regurgitation (AR) reduced by 8% in both groups, only reaching statistical significance for TAVI 
(p=0.003). TAVI and SAVR improved (p<0.05) left ventricular (LV) end-systolic volumes 
(46±18ml/m
2
 vs. 41±17ml/m
2
; 44±22ml/m
2
 vs.32±6ml/m
2
) and mass (83±20g/m
2
 vs. 65±15g/m
2
; 
74±11g/m
2
 vs. 59±8g/m
2
). SAVR reduced end-diastolic volumes (92±19ml/m
2
 vs. 74±12ml/m
2
, 
p<0.001) and TAVI increased EF (52±12% vs. 56±10%, p=0.01). MF reduced post-TAVI (10.9±6 % 
vs. 8.5±5%, p=0.03) but not post-SAVR (4.2±2% vs. 4.1±2%, p=0.98). Myocardial scar (p=0.01) and 
baseline ventricular volumes (p<0.001) were the major predictors of reverse remodeling.  
Conclusions: TAVI was comparable to SAVR at LV reverse remodeling and superior at reducing the 
valvular pressure gradient and MF. Future work should assess the prognostic importance of reverse 
remodeling and fibrosis post-TAVI to aid patient selection.  
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2.2 Introduction 
 
AS is the most common valve disease in the western world (Nkomo et al., 2006), and the onset of 
symptoms predicts a substantially reduced life expectancy (Otto, 2006).  Restricted aortic valve 
leaflets cause a pressure overloaded LV to compensate by altering its wall geometry in order to 
maintain wall stress. This hypertrophic remodeling process is pathological, with myocyte 
degeneration and replacement MF, leading to ventricular dysfunction.  Aortic valve replacement 
removes this aorto-valvular impedance resulting in geometric changes (mass regression, volume 
reduction and improved function) known as ‘reverse remodeling’. This process has been shown to be 
the essential factor in improving symptoms and prognosis following SAVR (Sandstede et al., 2000, 
Sandstede et al., 2002, Gaudino, 2004, Lund et al., 1997). 
TAVI has emerged as an alternative treatment option for severe AS patients who are unsuitable or too 
high-risk for SAVR. Randomized trials have shown the two-year mortality following TAVI to be 
superior to standard medical therapy and non-inferior to SAVR (Makkar et al., 2012a, Smith et al., 
2011, Leon et al., 2010, Kodali et al., 2012a), with good registry outcomes at 5 years. TAVI studies 
have used transthoracic echocardiography (TTE) to demonstrate an improvement in aortic valve 
haemodynamics and left ventricular function (Clavel et al., 2009). However, TTE has limited 
reproducibility and relies on mathematical assumptions of left ventricular geometry and cavity size, 
which may not apply in the remodeled ventricle. In addition, paravalvular aortic regurgitation (AR) is 
difficult to quantify using TTE yet is common post-TAVI (Smith et al., 2011). Finally, MF has been 
shown to adversely affect prognosis and functional outcomes following SAVR (Azevedo et al., 2010) 
but as of yet has not been assessed in a TAVI population. 
CMR is the reference standard for the assessment of right and left ventricular mass, volumes and 
ejection fraction (EF). Aortic stenosis severity can be determined comparably to echocardiography 
and regurgitant volume assessed with greater precision and reproducibility (Caruthers et al., 2003, 
Cawley et al., 2013). CMR can also determine the presence, distribution and quantity of MF (Kwong 
and Farzaneh-Far, 2011).  
The primary aim of this study was to use CMR to accurately assess and compare the post-operative 
changes in aortic valve haemodynamics, reverse ventricular remodeling and MF at 6 months 
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following TAVI and SAVR. Secondary aims were to identify clinical predictors of impaired ‘reverse 
ventricular remodeling’ and to establish the importance of pre-operative myocardial fibrosis on 
clinical outcomes.  
 
2.3 Methods 
 
2.3.1 Study Population 
 
This study prospectively recruited 77 patients with severe AS who were referred for either TAVI 
(n=50) or SAVR (n=27) at the University Hospitals of Leeds and Leicester, United Kingdom, 
between July 2008 and December 2010. Severe AS was classified by TTE as an aortic valve area of 
≤0.8cm2 or peak velocity >4m/s. Decision for TAVI was taken by a multidisciplinary heart team in 
accordance with international guidance (Logistic EuroSCORE >20 or inoperable co-morbidities). 
Higher-risk (higher EuroSCORE) SAVR patients were recruited so that their baseline demographics 
were more comparable to the TAVI group. Exclusion criteria included any contraindication to CMR. 
The study was approved by the institutional ethics committee, complied with the Declaration of 
Helsinki and all patients provided written informed consent.  
2.3.2 Transcatheter Aortic Valve Implantation 
 
Patients were screened using echocardiography, CT angiography, invasive coronary angiography and 
aortography. TAVI was performed using an 18F CoreValve
TM
 Revalving system (CVR, Medtronic, 
Minneapolis, Minnesota, US). A standard technique was employed for implantation of the 
CoreValveTM prosthesis. All procedures were performed under general anaesthesia with TEE guidance 
and aortic balloon valvuloplasty prior to valve deployment.Valve selection (26 or 29mm) depended 
upon the aortic annulus measurements. Where vascular access was suitable (common femoral artery 
≥6mm) a percutaneous femoral route with Prostar® XL (Abbott, Illinois) closure was used. In the 
presence of significant peripheral vascular disease (PVD) a surgical subclavian artery approach was 
performed. Following implantation the valve was post-dilated if deemed necessary by the primary 
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operator. Percutaneous coronary intervention (PCI) of a single vessel was performed in one individual 
one month preceding TAVI.  
2.3.3 Surgical Aortic Valve Replacement 
 
SAVR was performed by standard midline sternotomy with cardiopulmonary bypass and mild 
hypothermia. Biological or mechanical prostheses of varying sizes were used according to surgical 
preference. 
 
2.3.4 CMR Protocol 
 
Identical baseline pre-operative and 6 month post-operative scans were performed on the same 1.5T 
MRI system (Intera, Phillips Healthcare, Best, Netherlands or Avanto, Siemens Medical Systems, 
Erlangen, Germany). An illustration of the full cardiac MR protocol is presented as Figure 2-1. Multi-
slice, multi-phase cine imaging was performed using a standard SSFP pulse sequence in the short axis 
(repetition time [TR] 3 msec, echo time [TE] 1.7 msec, flip angle 60°, reduction factor 2, 10mm slice 
thickness, 0mm interslice gap, 30 phases, typical FOV 340mm, RFOV 100) to cover the entire left 
and right ventricles.  
Two left ventricular outflow tract SSFP acquisitions in coronal and sagittal-oblique views (5 slices, 
6mm slice thickness, 0mm interslice gap, 30 phases, FOV 380mm, RFOV 100mm) were obtained to 
allow the planning of an aortic valve cine and the aortic valve phase encoded velocity. Aortic valve 
cines were performed using a spoiled gradient echo pulse sequence (repetition time [TR] 8.5 msec, 
echo time [TE] 5.1 msec, flip angle 35°, 8 slices, 4mm slice thickness, 0mm interslice gap, FOV 
340mm, RFOV 60mm) with retrospective ECG gating over multiple breath holds. Through-plane 
velocity encoded (VENC) phase contrast imaging was then performed perpendicular to the aortic 
valve jet at the aortic sinotubular junction (repetition time [TR] 4.3 msec, echo time [TE] 2.6 msec, 
flip angle 15°, slice thickness 6mm, 40 phases, FOV 340mm), with VENC limit of between 250-
500cm/s and retrospective ECG gating. A sagittal-oblique aortic ‘candycane’ image was acquired 
(SSFP sequence; repetition time [TR] 3 msec, echo time [TE] 1.7 msec, flip angle 60°, reduction 
factor 2, 5 slices, 6mm slice thickness, 0 mm interslice gap) to enable the planning of an axial SSFP 
  
64 
 
slice, perpendicular to the ascending and descending aorta at the level of the pulmonary artery 
bifurcation.  Aortic distensibility was calculated using a high temporal resolution single SSFP slice 
(repetition time [TR] 3 msec, echo time [TE] 1.6 msec, flip angle 60°, 1 slice, 8mm slice thickness, 50 
phases, FOV 320mm, RFOV 100mm). Through-plane velocity encoded phase contrast imaging 
(repetition time [TR] 16.8 msec, echo time [TE] 2.7 msec, flip angle 40°, slice thickness 6mm, 50 
phases, FOV 340mm, RFOV 70mm, VENC limit 250cm/s) was then performed in an identical image 
position in order to acquire the ascending and descending thoracic aortic blood flow velocity for 
calculation of aortic arch pulse wave velocity. 
Myocardial tagging was conducted on three separate slices (apical, mid and base) planned from a ‘3 
of 5’. Five slices are planned in systole where the first and last slices are at the base and apical tip 
respectively. These are then reduced to 3 slices with an equal distance factor (Messroghli et al., 2005). 
The tagging sequence used was CSPAMM (repetition time [TR] 30 msec, echo time [TE] 6 msec, flip 
angle 25°, slice thickness 10mm, FOV 300mm, RFOV 75mm).  
LGE imaging (10-12 short axis slices, 10mm thickness, matrix 240x240, typical FOV 340mm, RFOV 
100mm) was performed following a Look-Locker sequence (inversion time scout, single mid-
ventricular slice, 11mm thickness, FOV 390mm, RFOV 95mm), 10 minutes after the administration 
of 0.2mmol/kg of Gadoteric acid (Dotarem, Guerbet, SA, Villepinte) or Gadolinium-DTPA 
(Magnevist, Schering, Germany). An identical contrast agent was used at both study time-points.  
 
Figure 2-1 Cardiac MR protocol 
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Figure 2-2 Aortic flow planning 
 
 
2.3.5 CMR Analysis 
 
Endocardial and epicardial borders were manually contoured at end-diastole and end-systole to allow 
the calculation of ventricular volumes (summation of discs methodology) and mass (epicardial 
volume - endocardial volume multiplied by myocardial density (1.05g/cm
3
)); values were indexed to 
BSA. Structural remodeling was defined by LV mass/end diastolic volume ratio as previously 
described (Gaasch and Zile, 2011). A reference point was placed at the inferior right ventricular 
insertion for automatic segmentation of the LV, enabling regional geometric analysis according to the 
AHA 16 segment model, Figure 2-3. End-diastolic (EDWT) and end-systolic (ESWT) wall thickness 
were used to calculate systolic wall thickening (SWT% = (ESWT-EDWT)/EDWT * 100). Wall 
motion (mm) was calculated as the radial displacement of the mid-ventricular marker. Aortic valve 
area (AVA) was measured from a cine image (gradient TFE pulse sequence, 4mm thickness, FOV 
340mm) by manual planimetry of the smallest orifice at the time of maximal opening in early systole. 
Aortic flow was quantified using cross-sectional phase contrast images with contouring of the aortic 
lumen (Figure 2-4) to provide a peak forward flow velocity (m/s), forward flow volume (ml), 
backward flow volume (ml) for the calculation of trans-valvular pressure gradient (Bernoulli 
equation) and regurgitant fraction (%). Mitral regurgitant fraction (%) was calculated as (LV stroke 
volume–aortic stroke volume)/LV stroke volume * 100.  
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Focal MF and scarring (secondary to infarction) were differentiated then reported qualitatively as 
either present or absent. Quantitative assessment was performed by semi-automated signal intensity 
analysis according to the FWHM technique.  All analyses were performed using QMass or QFlow 
(V7.2, Medis, Leiden, The Netherlands) by two experienced observers, blinded to the clinical details. 
 
Figure 2-3 Myocardial wall contouring 
 
 
Figure 2-4 Aortic valve flow quantification 
 
A ROI is contoured around the aorta using the modulus image through each of the phases 
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2.3.6 Sample Size and Statistical Analysis 
 
Based on published data (Bellenger et al., 2000), 20 patients per group were required to detect a 10ml 
change in LVEDV or 10g difference in LV mass regression between the two treatments (90% power 
and an alpha error of 0.05); 30 per group would be sufficient to detect a clinically meaningful 10% 
absolute difference in aortic peak forward flow velocity or regurgitant fraction (85% power and an 
alpha error of 0.05). Data are presented as mean ± SD (continuous) or median ± Interquartile range 
(IQR). Normality was determined by Shapiro-Wilks test. Frequencies are reported as number (%). 
The Student t-test and Wilcoxon signed rank test were used for continuous variables and chi-squared 
or Fisher’s exact test for categorical comparisons. Changes over time were assessed for differences 
between the treatment groups and clinical variables by 2-way repeated measures ANOVA. Predictors 
of functional change were calculated by a stepwise multiple linear regression model with baseline 
measurements entered as covariate factors. Variables with a univariate P<0.1 were entered into the 
multivariable analysis. Intraobserver reliability was calculated using a one-way two measures 
intraclass correlation co-efficient. All statistical analyses were performed using the PASW software 
package (version 17.0 SPSS, IBM, Chicago, Il, US) with a two-sided significance level of p<0.05 
considered statistically significant.  
2.4 Results 
 
Fifty patients (25 TAVI and 25 SAVR) completed both the pre-operative (TAVI group, median 1 day 
(IQR 1-1); SAVR group median 32 days (IQR 10-62)) and 6-month post-operative scans (TAVI 
group, median 182 days (IQR 176-184); SAVR group median 180 days (IQR 179-184)). Reasons for 
non-completion of the CMR protocol were varied and are depicted in Figure 2-5 Patient recruitment 
pathway. The procedural details of both SAVR and TAVI techniques are reported as Table 2-1. The 
baseline characteristics of the final study population are reported in Table 2-2 Patient and 
echocardiographic characteristics. The TAVI group were older but comparable in terms of gender and 
body mass index to the SAVR group. Co-morbidities were equally prevalent in the two groups, except 
for a greater frequency of atrial fibrillation, coronary and peripheral artery disease in the TAVI group. 
Procedural success was 100% for both TAVI and SAVR. There were no reported major adverse 
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cardiac events. Stroke occurred in 1 (4%) patient from each group. The SAVR group experienced a 
greater number of peri-operative complications (hemorrhage 1 (4%), transfusion 3 (12%), acute 
kidney injury 1 (4%) and significant pericardial effusion 1 (4%)) compared to no events in the TAVI 
group during the study period. 
The data presented in this thesis include the left and right ventricular function, aortic and mitral 
valvular function and the myocardial fibrosis results. The additional data acquired as part of the 
cardiac MRI protocol (tagging, aortic distensibility and pulse wave velocity) will not be reported as 
further data are being collected for future analysis and presentation.  
 
Figure 2-5 Patient recruitment pathway 
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Table 2-1 TAVI and SAVR procedural details 
                                       TAVI 
                                       (n=25) 
 SAVR 
(n=25) 
Valve type 
 
 CoreValve 
25 (100) 
 Bioprosthetic 
24 (96) 
Mechanical 
1 (4) 
Valve size (mm) 
18 
19 
20 
21 
23 
25 
26 
27 
29 
  
- 
- 
- 
- 
- 
- 
5 (20) 
- 
20 (80) 
  
1 (4) 
2 (8) 
1 (4) 
7 (28) 
10 (40) 
2 (8) 
1 (4) 
- 
- 
 
- 
- 
- 
- 
1 (4) 
- 
- 
- 
- 
Procedure time  (min) Catheterisation 72 ±37  Bypass 83 ±5 
 Fluoroscopy 24 ±8  Cross Clamp 61 ±17 
Revascularization* PCI 1 (4)  CABG 3 (12) 
 
Values are mean  SD or n (%). TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve 
replacement; PCI = percutaneous intervention; CABG = coronary artery bypass grafting. 
* Prior to or during valve replacement; no patient underwent subsequent revascularisation during the study 
period. 
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Table 2-2 Patient and echocardiographic characteristics 
 
Characteristics Total 
(n=50) 
TAVI (n=25) SAVR (n=25) P value*
 
Age 77±8 80±6 73±7 0.001 
Male gender, n (%) 31 (62) 14 (56) 17 (68) 0.56 
Body Mass Index (kg/m
2
) 27±4 27±3 27±5 0.77 
Body Surface Area (m
2
) 1.86±0.2 1.84±0.2 1.89±2 0.33 
Systolic Blood Pressure (SBP, mmHg) 139±24 136±28 142±20 0.48 
Diastolic Blood Pressure (DBP, mmHg) 73±11 67±10 77±9 0.002 
Valvuloarterial impedance (Zva) 4.0±1 3.98±1 4.01±1 0.94 
EuroSCORE (%) 16±15 22±14 7±3 <0.001 
CV History     
         NYHA Class 2.38±0.7 2.48±0.7 2.28±7 0.30 
         Coronary artery disease (%DS) 
< 50% 
50-70% 
>70% 
 
29 (58) 
8 (16) 
13 (26) 
 
9 (36) 
5 (20) 
11 (44) 
 
20 (80) 
3 (12) 
2 (8) 
0.004 
 
         Prior PCI, n (%) 5 (10) 4 (16) 1 (4) 0.17 
         Prior CABG, n (%) 9 (18) 8 (32) 1 (4) 0.01 
         Prior MI, n (%) 8 (16) 5 (20) 3 (12) 0.70 
Co-morbidities     
         Hypertension, n (%) 35 (70) 15 (60) 20 (80) 0.22 
         Hypercholesterolemia, n (%) 26 (52) 16 (64) 10 (40) 0.16 
         Diabetes, n (%) 13 (26) 7 (28) 6 (24) 0.75 
         CKD, n (%)  2 (4) 2 (8) 0 (0) 0.49 
         Atrial Fibrillation, n (%) 7 (14) 6 (24) 1 (4) 0.04 
         Previous Stroke, n (%) 6 (12) 4 (16) 2 (8) 0.39 
         Peripheral vascular disease, n (%) 7 (14) 6 (24) 1 (4) 0.04 
         COPD, n (%) 7 (14) 5 (20) 2 (8) 0.23 
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Echocardiographic data     
         AVA (cm
2
) 0.62±0.3 0.58±0.2 0.68±0.4 0.24 
         MPG (mmHg) 51 (41-61) 57±22 47±13 0.05 
         LV Ejection Fraction, n (%)  
Good (>50%) 
Fair (30-50%) 
Poor (<30%) 
 
34 (68) 
11 (22) 
5 (10) 
 
15 (60) 
7 (28) 
3 (12) 
 
19 (76) 
4 (16) 
2 (8) 
 
0.48 
 
Values are mean  SD or n (%).* P-value for comparison between procedure types. Zva = Valvuloarterial 
impedance (systolic arterial pressure + mean  transvalvular gradient / stroke volume index); NYHA = New York 
Heart Association; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft; MI = 
myocardial Infarct; CKD = Chronic kidney disease (eGFR<30); COPD = chronic obstructive pulmonary 
disease; AVA = aortic valve area; MPG = mean pressure gradient.   
 
2.4.1 Aortic and mitral valve haemodynamics  
 
The severity of pre-operative aortic valve stenosis was similar between the TAVI and SAVR groups. 
Post-operatively the trans-valvular pressure gradient at 6 months was significantly lower in both 
groups; compared to SAVR the TAVI group had a significantly greater reduction in their pressure 
gradient. The baseline AR fraction (%) was similar between the groups. Valve replacement resulted in 
an absolute 8% reduction of AR following both procedures, reaching statistical significance in the 
TAVI (p=0.003) but not in the SAVR group (p=0.09). ANOVA comparison of the two techniques 
showed no difference in the efficacy of the two procedures to reduce AR.  
Mitral regurgitation (MR) pre-operatively was greater in the TAVI (mild) compared to the SAVR 
(trivial) group. At follow-up, mitral regurgitant fraction (%) had significantly reduced post-TAVI and 
remained unaltered post-SAVR, Table 2-3. 
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Table 2-3 Reverse remodelling, valve haemodynamics and myocardial fibrosis. 
 TAVI  SAVR ANOVA 
 Baseline   6 Months  Baseline 6 Months P- value 
Left Ventricle       
LVEDVI (ml/m
2
) 94±18 90±20  92±19 74±12 
b
 0.04 
LVESVI (ml/m
2
) 46±18 41±17 
a
  44±22 32±6 
a
 0.19 
LVSVI (ml/m
2
) 48±10 50±10  49±8 42±7 
a
 0.14 
LVEF (%) 52±12 56±10
 a
  55±11 57±8 0.57 
LVM (g) 153±48 120±38
 c
  143±57 114±42 
c 
0.53 
LVMI (g/m
2
) 83±20 65±17
 b
  74±11 59±8
 b
 0.35 
LVM/LVEDV (g/ml) 0.88±0.2 0.73±0.2
 c
  0.80±0.1 0.81±0.2 0.001 
Right Ventricle       
RVEDVI (ml/m
2
) 77±19 74±13  78±14 76±17 0.60 
RVESVI (ml/m
2
) 38±13 35±10
 a
  31±7 34±10 0.80 
RVSVI (ml/m
2
) 39±9 39±9  47±11 41±14 0.37 
RVEF (%) 51±9 53±10  60±8 54±11
a
 0.63 
RVMI (g/m
2
) 19±4 16±3
 b
  18±4 17±4 0.17 
Aortic Valve       
Mean PG (mmHg) 58 (43-73) 21±8
 c
  51 (37-66) 35±13
 b
 0.017 
AR Fraction (%) 16±11 8±6 
a 
 18±7 10±11 0.46 
Mitral Valve       
MR Fraction (%) 20±16 14±23  2±8 2±6 0.007 
Late gadolinium enhancement       
Focal MF       
Mass (g) 14.1±8 8.6±5
 c
  5.9±3 5.1±3 0.005 
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Percentage myocardium (%) 10.9±6 8.5±5
 a
  4.2±2 4.1±2 0.02 
Myocardial infarction       
Mass (g) 20.6±12 13.8±11
 a
  22.7 18.0 0.80 
Percentage myocardium (%) 15.6±10 11.2±9  10.0 10.0 0.12 
 
Values are mean  SD or median (inter-quartile range). 
 ANOVA repeated measure overtime with procedure as covariate. Paired t-test vs. Baseline: 
 a
 P<0.05, 
b
 P<0.01, 
c
 P<0.001.  
LV = left ventricle; RV = right ventricle; EDVI = end diastolic volume indexed to body surface area; ESVI = 
end systolic volume indexed; SVI = stroke volume indexed; EF = ejection fraction; LVM = left ventricular 
mass; Mean PG = peak pressure gradient; AR = aortic regurgitation; MR = mitral regurgitation  
 
2.4.2 Left ventricular reverse remodelling 
 
Results of the baseline and follow-up CMR scans are shown in Table 2-3. No difference existed 
between the groups pre-operative indexed measurements of end-diastolic volume (EDVI), end-
systolic volume (ESVI), stroke volume (SVI), mass (LVMI), mass to volume ratio (LVM/LVEDV) 
and EF. Post-operatively, the TAVI group significantly decreased their ESVI, LVMI, LVM/LVEDV 
ratio and increased their EF. EDVI had reduced and SVI increased but did not reach statistical 
significance. The SAVR group experienced significant reductions in EDVI, ESVI and LVMI, post-
operative SVI decreased and no significant change occurred in EF or LVM/LVEDV ratio. ANOVA 
analysis showed the greater reduction in EDVI post-SAVR compared to post-TAVI was statistically 
significant, yet TAVI appeared superior at reversing the structural LV remodeling. Intraobserver 
variability for left ventricular measurements are reported in Table 2-4. The coefficient of variation 
was 0.28 ±0.1 (range 0.21-0.55). ESV had a lower ICC and greater variability but all measurements 
showed significant correlation.  
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Table 2-4 Intraobserver variability 
 
ICC = Intraclass correlation coefficient 
 
2.4.3 Left Ventricular wall geometry  
 
The study populations baseline LV wall measurements were typical of the concentric hypertrophy that 
occurs in AS. No difference existed between the TAVI and SAVR groups wall thickness, thickening 
or wall motion: EDWT (p=0.64), ESWT (p=0.82), wall thickening (p=0.13) and wall motion 
(p=0.75). Post-operative changes are represented on a segmental level in Figure 2-6 LV wall geometric 
changes post-TAVI and SAVR. EDWT reduced significantly (p<0.05) in 13/16 (81%) segments post-
TAVI and 5/16 (31%) segments post-SAVR group. ESWT reduced significantly in 9/16 (56%) 
segments post-TAVI compared to 5/16 (31%) post-SAVR. Wall thickening improved in 10/16 
segments (63%) post-TAVI but failed to improve significantly in any segment post-SAVR. Wall 
motion post-TAVI and SAVR significantly improved in only 2/16 (13%) and 4/16 (26%) segments 
respectively. Global EDWT and ESWT reduced significantly from baseline to 6 months post-TAVI 
(7.9±2 vs. 6.8±2mm, p<0.001 and 11.4±3 vs. 10.3±3 mm, p<0.001 respectively), but not post-SAVR 
(7.7±2 vs. 7.3±2 mm, p=0.05 and 11.1±3 vs. 10.7±3 mm, p=0.11 respectively). LV wall thickening 
  
Analysis 1 
Mean ± SD 
 
Analysis 2 
Mean ± 
SD 
 
Correlation 
coefficient 
 
Intraclass 
correlation 
coefficient 
 
Variability 
(1-ICC) 
 
p value 
 
EDV (ml) 
 
192 ± 40 
 
185 ± 45 
 
0.99 
 
0.96 
 
0.04 
 
<0.001 
 
ESV (ml) 
 
96 ± 32 
 
78 ± 43 
 
0.74 
 
0.65 
 
0.35 
 
0.005 
 
SV (ml) 
 
96 ± 27 
 
99 ± 26 
 
0.95 
 
0.91 
 
0.09 
 
<0.001 
 
EF (%) 
 
51 ± 12 
 
54 ± 11 
 
0.90 
 
0.86 
 
0.14 
 
<0.001 
 
LVM (g) 
 
171 ± 41 
 
161 ± 41 
 
0.96 
 
0.93 
 
0.07 
 
<0.001 
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also improved significantly post-TAVI (38.8±13 vs. 50.5±13%, p<0.001), but reduced post-SAVR 
(46±17 vs. 44±13, p=0.72). Wall motion did not change significantly in either group.  
MF was assessed for a relationship to LV wall geometry and post-operative change. The amount (%) 
of scar at baseline had no relationship to EDWT or ESWT but was inversely associated with the wall 
thickening (β -0.74, p=0.001) and wall motion (β -0.52, p=0.037) of each segment. Increased baseline 
MF by LGE predicted reduced post-operative improvement of EDWT (β -0.50, p=0.047), ESWT (β – 
0.34, p=<0.001) and wall motion (β -0.14, p=0.005). Wall thickening was not significantly affected (β 
-0.28, p=0.30). 
 
Figure 2-6 LV wall geometric changes post-TAVI and SAVR  
 
 
The p values represent the difference in global change, where individual segmental changes (AHA 16-segment 
model) are represented by lines. 
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2.4.4 Right ventricular reverse remodelling 
 
Baseline right ventricular (RV) volumes and mass were similar between the groups Table 2-3. Post-
operatively, TAVI resulted in a significant decrease in RV ESVI, RVM and a trend towards an 
increase in RVEF (p=0.07). SAVR resulted in non-significant reductions in EDVI, RVMI, an increase 
in ESVI (p=0.09), and an overall significant reduction in RVEF (p=0.04) at 6 months.  
2.4.5 Myocardial fibrosis and infarction 
 
MF was assessed by LGE in 47 patients (3 TAVI patients were not given contrast agent due to severe 
chronic kidney disease). Pre-operative MF was detected in 25 (53%) patients; 13 (59%) TAVI and 12 
(48%) SAVR (p=0.38). Fibrosis was predominantly distributed in the basal region and the septal 
segments for both groups, Figure 2-7 Distribution and frequency (%) of focal myocardial fibrosis 
(MF). The MF percentage of myocardial mass was greater in the TAVI group compared to the SAVR 
group (10.9±6 vs. 4.2±2%, p=0.003) at baseline. The severity of AS (aortic valve area and pressure 
gradient) had no relationship to the amount of MF, but increased Zva was associated with greater mass 
(g) of MF (β6.4, p=0.019). Post-operatively, MF decreased post-TAVI (10.9±6 % vs. 8.5±5%, 
p=0.03) but not post-SAVR (4.2±2% vs. 4.1±2%, p=0.98), Table 2-4.  
Sub-endocardial LGE consistent with previous MI (scar) was observed in 5 TAVI patients compared 
1 SAVR at baseline (p<0.001). Myocardial scar (g) appeared to reduce following TAVI, but the actual 
scar percentage did not decrease. Post-SAVR, scar mass (g) and percentage showed no difference 
from baseline, Table 2-3. New post-operative sub-endocardial infarction was evident in 6 individuals 
(1 TAVI and 5 SAVR, p=0.11). No variable (including procedure type, p=0.09) increased the risk of 
new post-operative myocardial infarction.  
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Figure 2-7 Distribution and frequency (%) of focal myocardial fibrosis (MF)  
 
Represented as a 16 segment AHA model. MF was greatest in the basal and septal regions and was significantly 
higher in the TAVI group. A typical example of MF (as highlighted by the white arrows) is shown on a single 
mid-ventricular LGE image. 
 
2.4.6 Predictors of left ventricular reverse remodeling 
 
Clinical variables including patient demographics, co-morbidities and pre-operative cardiac 
measurements were analysed to determine predictors of reverse remodeling, Table 2-5 Regression 
analysis for the prediction of left ventricular reverse remodelling. Worse individual baseline LV 
parameters (EDVI, ESVI, EF and LVMI) were independent predictors of reduced reverse remodeling 
following valve replacement. MF (mass and %) at baseline had no association to the degree of 
subsequent reverse remodeling, but increased myocardial scar (%) did, resulting in higher EDVI, 
ESVI and reduced EF post-operatively. TAVI procedure, aortic regurgitation, mean pressure gradient 
and peripheral vascular disease were also predictors of adverse reverse remodeling, Table 2-5 
Regression analysis for the prediction of left ventricular reverse remodelling.   
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Table 2-5 Regression analysis for the prediction of left ventricular reverse remodelling  
 
Variables 
 
Univariate analysis 
  
Multivariable analysis 
 B 
Coefficient 
±SD 
R 
2 95%  
CI 
P-
value 
 
B 
Coefficient 
±SD 
T 
95% 
CI 
P-
value 
EDVI (ml/m
2
)          
EDVI 
0.57±0.12 0.32 
0.33-
0.81 
<0.001  0.53±0.1 4.56 
0.29-
0.76 
<0.001 
TAVI procedure 15.5±3.8 0.50 7.9-23.1 <0.001  10.43±3.7 2.78 2.8-18 0.008 
CAD 
11.5±4.3 0.42 3.0-20.1 0.009  1.87±4.1 0.45 
-6.5-
10.2 
0.65 
Hypercholesterolaemia 
11.9±4.1 0.43 3.7-20.2 0.005  6.41±3.7 1.73 
-1.1-
13.9 
0.09 
PVD 
14.4±6.2 0.39 1.8-26.9 0.03  6.31±4.9 1.28 
-3.6-
16.3 
0.20 
AR (%) 
0.34±0.19 0.38 
0.39-
0.71 
0.08  0.3±0.1 2.18 
0.02-
0.57 
0.04 
Scar (%) 
2.01±0.34 0.68 
1.31-
2.70 
<0.001  1.25±0.3 3.79 
0.58-
1.91 
0.001 
ESVI (ml/m
2
)          
ESVI 
0.44±0.08 0.63 
0.28-
0.59 
<0.001  0.21±0.06 3.20 
0.07-
0.34 
0.003 
TAVI procedure 8.12±2.8 0.49 2.4-13.8 0.006  3.50±2.5 1.37 -1.6-8.6 0.17 
CAD 
5.23±3.1 0.44 
-0.97-
11.4 
0.09  1.66±2.6 0.65 -3.5-6.8 0.52 
AF 
8.97±4.3 0.45 
0.25-
17.7 
0.04  5.29±3.3 1.59 
-1.4-
11.9 
0.12 
PVD 
10.6±4.2 0.47 2.1-19.2 0.02  7.05±3.3 2.12 
0.35-
13.7 
0.04 
Scar (%) 
1.61±0.3 0.71 1.0-2.20 <0.001  1.30±0.2 5.43 
0.81-
1.78 
<0.001 
EF (%)          
EF 
0.49±0.8 0.66 
0.33-
0.65 
<0.001  0.51±0.08 6.78 
0.36-
0.66 
<0.001 
MPG 
0.14±0.05 0.53 
0.05-
0.23 
0.005  0.14±0.05 2.98 
0.05-
0.23 
0.005 
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LVMI (g/m
2
) 
LVMI 
0.64±0.07 0.67 
0.51-
0.77 
<0.001  0.69±0.07 9.88 
0.55-
0.83 
<0.001 
NYHA 
4.66±2.5 0.74 
0.48-
9.81 
0.07  4.3±2.5 1.74 
-0.73-
9.34 
0.09 
CVA 
3.77±2.2 0.69 
-0.71-
8.24 
0.09  3.66±2.2 1.69 
-0.72-
8.05 
0.1 
 
 
a 
Individual variables with a significance level of P<0.1 were entered in to the multivariable model. Each 
parameter of change had a separate multiple regression analysis performed.  
EDVI = end diastolic volume indexed to body surface area; ESVI = end systolic volume indexed; SVI = stroke 
volume indexed; EF = ejection fraction; LVM = left ventricular mass; LVEF = left ventricular ejection fraction; 
MPG = mean pressure gradient; CAD = coronary artery disease; CVA = cerebrovascular accident; PVD = 
peripheral vascular disease; AR = aortic regurgitation; MF = myocardial fibrosis; NYHA = New York Health 
Association;  
 
2.5 Discussion 
 
This study is the first using the reference standard of CMR to show that in an older, higher risk AS 
population, TAVI when compared to SAVR resulted in similar levels of overall LV reverse 
remodeling by 6 months post-procedure. This was associated with a greater post-operative reduction 
in trans-aortic pressure gradient and myocardial fibrosis in the TAVI group and an equivalent 
reduction in AR compared to SAVR.  
 
Our study population demonstrated baseline concentric and eccentric structural LV remodeling 
processes consistent with severe AS (Gaasch and Zile, 2011). No significant difference existed 
between the two treatment groups’ baseline LV parameters, aortic valve haemodynamics or the 
majority of co-morbidities. An ‘afterload mismatch’ process is known to alter ventricular geometry, 
raise LVM and progress to diastolic and systolic dysfunction. These factors are recognized adverse 
prognostic markers pre and post-SAVR (Lund, 2003, Gaudino, 2004, Lund et al., 1997).  Removing 
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the valvular impedance allows the ventricle to ‘reverse remodel’ and thus improve patient symptoms 
and prognosis (Biederman et al., 2005). This study used CMR with its greater accuracy and 
reproducibility to assess these factors in a TAVI population. Whilst comparisons of reverse 
remodeling between TAVI and SAVR have been previously conducted using echocardiography 
(Clavel et al., 2010, Forsberg et al., 2011) the limitations of this technique in remodeled ventricles 
restricts their conclusions.   
 
Improved valvular haemodynamics are markers of procedural success and influence ventricular 
remodeling. The superior reduction of trans-valvular pressure gradient post-TAVI has been previously 
noted at 6 months using echocardiography. This can be partially explained by a lower incidence of 
patient prosthesis mismatch compared to SAVR and may reflect smaller valve sizes inserted at 
surgery compared to those implanted during TAVI (Clavel et al., 2009).  
AR is an important complication following TAVI and has been identified as an independent predictor 
of mortality (Tamburino et al., 2011). Quantifying valvular and paravalvular regurgitation is however 
difficult using echocardiography. CMR assesses total (paravalvular and valvular) regurgitation with 
high levels of accuracy. In this study TAVI actually improved ‘total’ AR from baseline and was 
comparable to SAVR at 6 months. As may be expected in a pressure overloaded ventricle, mitral 
regurgitation decreased post-TAVI, although any comparison to SAVR remains difficult due to 
differences in the severity of baseline regurgitation.   
 
The reverse remodeling changes observed following TAVI are consistent with the current surgical 
aortic valve replacement literature (Sandstede et al., 2002, Biederman et al., 2011) and include new 
important observations. Similar levels of LV reverse remodeling occurred between transcatheter and 
surgical procedures except for small differences in EDV and EF. The smaller reduction in EDV post-
TAVI could be secondary to the greater burden of coronary artery disease and myocardial infarction 
in this sub-group, as both were predictors of reduced EDV reverse remodeling. The significant 
increase in EF following TAVI but not SAVR may be attributed to the greater reduction in aortic 
valvular impedance and wall stress post-TAVI (Clavel et al., 2009). This greater reduction in 
ventricular workload could also explain the differing structural pattern of reverse remodeling 
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(mass/volume) which only reduced post-TAVI. However, the smaller EDVI reduction in the TAVI 
group (secondary to greater myocardial infarction and coronary disease) is a more probable 
explanation for this observation. Therefore structural  remodeling which is an important predictor of 
stroke, myocardial infarction, heart failure and all cause mortality (Gaasch and Zile, 2011)  is unlikely 
to differ between the procedures. Global ventricular work is not just dependent upon valvular but also 
vascular load. Zva has been shown to adversely effect outcomes in AS patients. Our groups had 
similar levels of baseline Zva indicating that this was not a confounding factor in influencing reverse 
remodeling between the groups. 
LV wall geometric measurements provide supplementary information about the function of the LV, 
particularly when the EF appears normal. Wall thickening is a clinical indictor of wall stress, 
representing the circumferential twist and longitudinal shortening of the LV. In thick hypertrophied 
ventricles with a normal EF it is a more sensitive marker of myocardial function and strain (Dumesnil 
and Shoucri, 1991).  When compared to an AS population studied by Sandstede et al,(Sandstede et al., 
2000) the baseline wall thickness of our study group is similar but wall thickening was significantly 
lower, suggesting our patients had markedly impaired LV function despite only a mild reduction in 
EF. The TAVI group when compared to SAVR had a greater improvement in wall thickness and 
thickening on a segmental and global level. TAVI appears to result in a superior post-operative 
reduction in LV wall stress and improved strain and twist when compared to SAVR. This procedural 
difference could be the result of the greater reduction in trans-aortic valve impedance and wall stress 
following TAVI, as well as its earlier haemodynamic changes and less invasive nature (Clavel et al., 
2009, Dumesnil and Shoucri, 1991). These findings will need to be confirmed by a technique more 
sensitive to changes in LV strain and torsion, such as speckle tracking (echocardiography) or 
myocardial tagging (CMR).   
 
Right ventricular reverse remodeling appeared more favourable post-TAVI, as volumes and mass 
reduced and function improved compared to an actual decline in RV function following SAVR. This 
may reflect a post-bypass phenomenon but does require further research to establish if there is a 
specific role for TAVI in individuals with significant right heart disease. The high pacemaker 
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implantation rate post-TAVI meant some of our TAVI cohort could not undergo follow up scans. As a 
consequence the impact of pacing on left and right ventricular reverse remodeling could not be 
established.  
 
Focal MF secondary to AS has been reported in a similar frequency and distribution to the MF in our 
study (Rudolph et al., 2009, Weidemann et al., 2009b, Nigri et al., 2009). MF is an adverse prognostic 
indicator and is associated with reduced reverse remodeling post-SAVR (Azevedo et al., 2010, Dweck 
et al., 2011). In this study it was the quantity of baseline myocardial infarction, not focal MF that was 
associated with worse post-operative ventricular volumes and function. Following multivariate 
analysis the baseline LV parameters also remained significant predictors of reverse remodeling. This 
observation supports the theory that MF does not predict reduced reverse remodeling (Krayenbuehl et 
al., 1989), but is associated with poor baseline volumes and function, which are the true independent 
predictors of adverse reverse remodeling.  Fibrosis has been found not to regress substantially post-
AVR using histological (Krayenbuehl et al., 1989) and diffuse equilibrium measurements (Flett et al., 
2012). Our study using a less specific but well validated technique of LGE found similar results post-
SAVR but evidence of regression post-TAVI. This finding needs to be validated using a more 
sensitive technique such as T1 mapping, as it may reflect greater reverse remodeling post-TAVI at the 
cellular level rather than a true reduction in fibrosis.  
 
Post-procedural subendocardial myocardial infarction occurred more frequently in the SAVR group 
compared to the TAVI group. This has not been previously described and its clinical significance is 
limited by the small patient numbers involved. However, concerns related to covering the coronary 
ostia with the CoreValve
TM
 device and crushing the calcified native aortic valve leaflets do not seem 
to result in myocardial infarction as detectable on CMR. Equally it may suggest that peri-operative 
myocardial protection in severely hypertrophied ventricles is suboptimal in surgically treated patients.  
2.6 Limitations 
 
Although this was a small study population, comparisons between the two groups using the highly 
reproducible technique of CMR meant it was appropriately powered. Patients in the two treatment 
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groups had similar risk factor profiles, but due to the nature of current guidelines for TAVI patient 
selection, they could not be matched for age or EuroSCORE. Despite the positive selection of higher 
risk SAVR candidates this hampers our direct comparison of SAVR versus TAVI. Finally, 
quantification of fibrosis on LGE images was analysed using a semi-automatic, signal intensity 
threshold method rather than the newer T1 mapping techniques, as the latter were not widely 
employed at the time of patient recruitment. However, as of yet there is no consensus as to which of 
the multitude of T1 mapping techniques should be employed in myocardial interstitial disease. 
 
2.7 Conclusions 
 
This study provides evidence of significant reverse remodeling post-TAVI in a high-risk AS 
population with multiple adverse prognostic factors such as old age, high LVM, reduced LV systolic 
function and substantial MF. TAVI was comparable to SAVR in terms of global LV reverse 
remodeling. Baseline LV measurements and myocardial scar (infarction) were the dominant factors 
predicting change in reverse remodeling for both TAVI and SAVR. TAVI significantly reduced the 
trans-aortic pressure gradient and aortic regurgitation at 6 months, and when compared to SAVR 
produced a greater reduction in focal MF.  
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3 Diffusion-Weighted Magnetic Resonance Imaging Determined Cerebral 
Embolic Infarction Following Transcatheter Aortic Valve Implantation: 
Assessment of Predictive Risk Factors and the Relationship to 
Subsequent Health Status  
 
3.1 Abstract 
 
Background: ‘Silent’ cerebral infarction and stroke are complications of TAVI. The occurrence of 
cerebral infarction was assessed to identify predictive risk factors and assess the impact upon patient 
health related quality of life (HRQOL). 
Methods: Cerebral Diffusion Weighted-Magnetic Resonance Imaging (DW-MRI) of 31 AS patients 
undergoing MCV TAVI. HRQOL assessed at baseline and 30 days by SF-12v2 and EQ5D 
questionnaires. 
Results: New cerebral infarcts occurred in 24 of 31 patients (77%) and Stroke in 2 (6%). Stroke was 
associated with a greater number and volume of cerebral infarcts. Age (r=0.37, p=0.042), severity of 
atheroma (arch and descending aorta; r=0.91, p<0.001, r=0.69, p=0.001 respectively) and 
catheterisation time (r=0.45, p=0.02) were predictors of the number of new cerebral infarcts. HRQOL 
improved overall: SF-12v2 Physical Component Summary increased significantly (32.4±6.2 vs. 
36.5±7.2; p=0.03) with no significant change in Mental Component Summary (43.5±11.7 vs. 
43.1±14.3; p=0.85). The EQ5D score and Visual Analogue Scale showed no significant change 
(0.56±0.26 vs. 0.59±0.31; p=0.70, and 54.2±19 vs. 58.2±24; p=0.43).   
Conclusions: Multiple small cerebral infarcts occurred in 77% of TAVI patients. The majority of 
infarcts were ‘silent’ with clinical stroke being associated with a both higher infarct number and 
volume. Increased age and the severity of aortic arch atheroma were independent risk factors for the 
development of new cerebral infarcts. Overall HRQOL improved and there was no association 
between the number of new cerebral infarcts and altered health status. 
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3.2 Introduction 
 
TAVI has rapidly developed as an effective treatment for patients with severe symptomatic AS who 
are not suitable for SAVR. With over 50,000 patients treated worldwide using the MCV,
 
it reflects the 
increasing prevalence of AS in an ageing population and observations that 30% of individuals with 
severe AS are not offered surgery (Iung et al., 2005b). TAVI outcome data have demonstrated 
superior clinical outcomes to standard medical therapy, 97% procedural success, 6.4-8% 30 day and 
22-31% 1 year all cause mortality (Piazza et al., 2008, Rodes-Cabau et al., Leon et al.). Stroke 
however is an important complication that occurs in 0.6-5% of TAVI patients compared to 1.1% of 
patients treated with standard medical therapy (Zajarias and Cribier, 2009, Leon et al.). Stroke is 
believed to be secondary to ischaemic embolic events, either from aortic atheroma during the passage 
of a delivery catheter or degenerative valvular material released during the valvuloplasty and valve 
deployment. Procedural cerebral infarction can occur more frequently than is clinically apparent 
(Busing et al., 2005, Lund et al., 2005, Omran et al., 2003). These ‘silent’ ischaemic events have been 
documented post-cardiac surgery (Restrepo et al., 2002b, Stolz et al., 2004b) and are associated with 
neurological dysfunction and future cognitive decline (Goto et al., 2001). They may have a substantial 
effect upon an individual’s quality of life, potentially affecting patient selection and treatment 
recommendations, particularly if TAVI is expanded to a larger, younger, lower risk patient group.  
Computed tomography (CT) and T2w MRI are conventionally used to diagnose stroke and distinguish 
haemorrhagic from ischaemic stroke. Cerebral imaging also helps identify the location and size of a 
stroke aiding in its classification. However, during acute stroke CT and T2w MRI have false-negative 
rates of between 30-60% in the first 24 hours, thus limiting their usefulness. Cerebral ischaemia 
causes damage to the cellular N⁺ /K⁺  ATP pump, cytotoxic oedema and a reduction in the diffusion 
capacity of protons (water) in the brain (Schaefer et al., 2000).  This reduction in water diffusion can 
be detected by diffusion weighted magnetic resonance imaging (DW-MRI) within 5 minutes of 
symptom onset (Reith et al., 1995). DWI has the advantage of being able to differentiate ischaemic 
from nonischaemic and acute from chronic lesions with greater sensitivity (false negative rate of 5%) 
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compared to conventional T2w, Fluid attenuated inversion recovery (FLAIR) and proton density MRI 
(Lutsep et al., 1997, van Everdingen et al., 1998).   
The aim of this study was to determine the incidence of new cerebral infarction on DW-MRI after 
TAVI, identify demographic and procedural risk factors for clinically apparent and silent cerebral 
infarction and to assess the impact upon patients’ subsequent health status.  
 
3.3 Methods 
 
Between May 2008 and August 2010, 85 patients underwent TAVI at our institution. Each individual 
was assessed by a multidisciplinary team (cardiothoracic surgeon, cardiologist, cardiac anaesthetist) in 
accordance with international guidelines (Vahanian et al., 2008a). Severe AS was defined as an aortic 
valve area of less than 0.8cm² or a peak velocity of >4m/s on echocardiography. All patients were ≥65 
years of age, and had a logistic EuroSCORE >20, or co-morbidities that precluded cardiac surgery. 
Exclusion criteria for the study were MRI incompatible factors including pacemaker, claustrophobia 
or an inability to lie flat. The study complied with the declaration of Helsinki, was approved by the 
local research ethics committee and all patients provided written informed consent. 
3.3.1 Transcatheter Aortic Valve Implantation 
 
Patients were screened using echocardiography, invasive coronary angiography and aortography. Data 
collected included patient demographics, co-morbidity and potential risk factors for cerebrovascular 
accident (CVA). EF, LV End-Diastolic Dimensions (LVEDD) and aortic valve pressure gradient were 
recorded by transthoracic echocardiography (TTE). Aortic atheroma was assessed in the ascending, 
descending and arch of aorta by transoesophageal echocardiography (TOE) then graded for severity 
(1-5) by an experienced reader according to previously published criteria (Hartman et al., 1996). 
Aortic valve calcification was assessed by a combination of TTE and TOE and graded for severity: I-
No calcification; II-mild calcification; III-moderate calcification; IV-severe calcification (Rosenhek et 
al., 2000). TAVI was performed in all patients using the third-generation 18-Fr MCV RevalvingTM 
system. A standard technique was employed for implantation of the CorevalveTM prosthesis as 
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previously described (Piazza et al., 2008). All procedures were performed under general anaesthesia 
with TOE guidance and aortic balloon valvuloplasty prior to valve deployment. Patients received dual 
antiplatelet therapy with aspirin 75mg and clopidogrel 75mg daily, continued for a minimum of 6 
months post-operatively. Heparin was administered during the procedure to maintain an activated 
clotting time (ACT) >200 seconds.  
3.3.2 Cerebral MRI 
 
3.3.2.1 MR protocol 
Cerebral-MRI was performed using a 1.5Tesla system (Intera, Phillips Healthcare, Best, Netherlands 
or Avanto, Siemens Medical Systems, Erlangen, Germany). Baseline and post procedural scans were 
performed on the same scanner using an identical imaging protocol.  
1. T2 weighted Turbo Spin Echo sequence (repetition time [TR] 5016 msec, echo time [TE] 120 
msec, flip angle 90°,  20 axial slices, 7mm slice thickness, 0.7mm interslice gap, 1.2 minute 
acquisition time, FOV 350, RFOV 100).   
2.  T2 weighted Fast Field Echo sequence (repetition time [TR] 701 msec, echotime [TE] 23 
msec, flip angle 18°,  22 axial slices, 5mm slice thickness, 1mm interslice gap, FOV 350, 
RFOV 100).  
3. Diffusion weighted spin echo sequence (repetition time [TR] 4348 msec, echotime [TE] 89 
msec, flip angle 90°,   22 axial slices, 5mm slice thickness, 1mm interslice gap, FOV 350, 
RFOV 100). The apparent diffusion coefficients (ADC) were calculated for each pixel and 
displayed as an ADC map.  
 
The patients’ heads were supported in a head coil with wedges to reduce movement artefact. Ten 
minutes was required to complete the head protocol with 5 minutes allocated to the DWI.   
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Figure 3-1 Cerebral MRI protocol 
 
3.3.2.2 Image analysis 
Two experienced neuroradiologists (A.G and S.C) blinded to the clinical and procedural details 
independently reported the scans. A consensus reading was agreed upon if any conflicts in reporting 
occurred. Ischaemic lesions appear as areas of abnormal hyperintensity on the ADC maps.  These 
hyperintense (white) areas were contoured by direct planimetry on each slice using the post-
processing software (Qmass, v7.0, Medis, The Netherlands). The area was then multiplied by the slice 
thickness and interslice gap to give volume (ml) of cerebral ischaemia. Total cerebral infarct volume 
was calculated by the summation of all individual lesions volume to determine clinical significance. 
Finally, the location (hemisphere and cerebral arterial territory) and size (< or ≥ 5mm) of lesions were 
recorded.   
 
3.3.3 Neurological and Health Status Assessment   
  
Clinical examination of patients post TAVI (day 1 and 2) was performed by an experienced medical 
physician to assess for neurological signs according to the National Institutes of Health Stroke Scale 
(NIHSS). Symptoms and signs of <24 hours duration were defined as a Transient Ischaemic Attack 
(TIA) and if they persisted over 24 hours they were classified as a stroke. 
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No disease specific questionnaire exists for patients with AS, therefore health status was assessed 
using two well validated, generic Health Related Quality of Life (HRQOL) Questionnaires: SF-12v2 
and EQ5D. Each questionnaire was administered by a trained nurse or doctor with the patient pre-
procedurally (baseline) and at 30 days post-procedure by postal or telephone survey. The SF-12v2 
health outcomes questionnaire (©QualityMetric, Lincoln, RI, USA) assesses HRQOL using 8 
dimensions each with a score of 0-100. It is a shorter, simpler  version of the well validated SF-36 
(Ware et al., 1996a) and is thus more suited to an elderly population. This produces 1) a physical 
component summary (PCS) of: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BDP) 
and General Health (GH). 2) A mental component summary (MCS) score of Vitality (VT), Social 
Functioning (SF), Role Emotional (RE) and Mental Health (MH). EQ5D (©EuroQOL) uses 5 
dimensions to measure HRQOL: mobility, self care, usual activities, pain/discomfort and 
anxiety/depression. Scoring is from 0 (death) to 1 (full health). The second component of the EQ5D is 
a Visual Analogue Scale (VAS) of 0-100 (worst imaginable health to best possible health). 
 
3.3.4 Statistical analysis 
 
Statistical analysis was performed using the PASW software package (version 17.0 SPSS, Chicago, 
Ill, US). Continuous data are presented as mean ± SD, categorical data as frequencies and 
percentages. Test for normality was assessed using the Shapiro-Wilks goodness-of-fit test and Q-Q 
plots. Continuous variables were compared using the paired t-test. Categorical variables were 
compared using the Mann-Whitney or Fishers exact tests.  Linear regression analysis was used to 
identify the relationship between patient and procedural factors and the number of new cerebral 
infarctions following TAVI. Univariate analysis was used to identify individual predictors. Variables 
with a univariate significance of p<0.1 were entered into a multiple stepwise regression analysis to 
determine the independence of these predictors. Multivariate analysis was also performed using 
number of new infarcts and stroke as two dependent variables and the univariate predictors as factors 
and covariates. A two-sided significance level of p<0.05 was considered statistically significant. 
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3.4 Results 
 
3.4.1 Patient population 
 
Forty of the eighty five patients consented for recruitment into the study and underwent baseline pre-
procedure DW-MRI in order to identify any pre-existing lesions, Figure 3-2. Of these, 31 (78%) 
completed paired head scans pre- (median 1 day, IQR 1-2) and post-TAVI (median 5 days, IQR 4-6). 
Of the remaining 9 patients, TAVI was not performed on 4 individuals, and 5 individuals underwent 
TAVI but could not complete the MRI study due to: 3 patients requiring permanent pacemakers post-
valve implantation, 1 claustrophobic patient and 1 unable to lie flat in the scanner. The demographic 
and echocardiographic details of the 31 patients (mean age 81±5.9yrs; female 65%, Table 3-1) are 
representative of a typical unselected TAVI population.  
 
Figure 3-2 Patient Recruitment.  
 
 
Table 3-1 Baseline Patient Characteristics of the Study Population 
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Study population (n= 31) 
Age  81 (±5.9) 
Female Gender, n (%) 20 (65) 
BMI (kg/m²)  27 (±4.3) 
Logistic EuroSCORE (%)  23.9 (±16.4) 
AV Pressure Gradient (mmHg)  62.2 (±23.9) 
AV EOA (cm²)  0.55 (±0.13) 
LV Ejection Fraction, n (%)            
Good 
Moderate 
Poor 
 
18 (58) 
12 (39) 
1 (3) 
LV EDD (mm)  47 (±7.3) 
Creatinine (μmol/L)  114 (IQR 90-178) 
Hypertension, n (%)  14 (45) 
Hypercholesterolaemia, n (%)  20 (65) 
Diabetes, n (%)  9 (29) 
Atrial Fibrillation, n (%)  7 (23) 
Cerebrovascular disease, n (%)  3 (10) 
Peripheral Vascular Disease, n (%)  7 (23) 
Porcelain Aorta, n (%)  9 (29) 
 
BMI - Body Mass Index, AV- Aortic Valve, EOA- Estimated Orifice Area, 
LV - Left ventricle, EDD- end-diastolic dimension 
 
 
 
 
 
3.4.2 Procedural data 
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A 26mm MCV was deployed in 11 (35%) cases and a 29mm in 20 (65%), via either the femoral 26 
(84%) or subclavian 5 (16%) artery. Procedural success was 98%, with an average catheterisation 
time of 68±26 minutes, fluoroscopy time of 22±6 minutes and 150±47ml of contrast given. Valve 
dislocation and retrieval occurred in only 2 (7%) individuals. Despite this low occurrence, this 
resulted in a significantly longer catheterisation and fluoroscopy time (64±22 vs. 106±48, p=0.02 and 
21±5 vs. 35±9, p=0.05 minutes respectively). Post-dilatation of the self expanding valve was required 
in 11 (35%) cases, with no significant increase in either catheterisation or fluoroscopy times compared 
to those without post-dilatation (61±15 vs. 77±37, p=0.18 and 22±5 vs. 23±8, p=0.77 minutes 
respectively). TOE identified aortic valve calcification in all individuals, 20 (64%) patients had severe 
aortic valve calcification, 7 (23%) moderate and 4 (13%) mild. Aortic atheroma classification and 
grading are reported in Figure 3-2. Increased age was significantly related to the severity of aortic 
atheroma (p=0.016).  
Figure 3-3 Aortic atheroma  
 
Classified as ascending, arch or descending aorta then graded:  1- Normal to mild intimal thickening; 2 -severe 
intimal thickening; 3 - atheroma <5mm; 4 - atheroma ≥5mm; 5 - mobile atheroma of any size. 
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3.4.3 Cerebral Infarction on Diffusion-Weighted Imaging 
 
New cerebral infarction occurred in 24 (77%) patients. A total of 131 new infarcts occurred, 
distributed equally between the cerebral hemispheres (left 53%, right 47%), in multiple territories but 
predominantly in the regions of the following cerebral arteries: Anterior 7%, Middle 59%, Posterior 
14% and Vertebrobasilar 20%. The number of infarcts per patient was a mean of 4.2±6.5 and median 
of 2 (IQR 1-5), with an average infarcted tissue volume of 2.05±3.5ml. These were mostly of a small 
size (<5mm, n=19, 79%). The number of new lesions significantly correlated to the overall volume of 
infarct (r=0.82, p<0.001), but interestingly not to the size of the individual infarcts (p=0.61). An 
example of new cerebral infarction using DW-MRI is shown in Figure 3-4. 
Figure 3-4 Cerebral DW-MRI images  
 
Trans-axial slices of the entire cerebrum including cerebellum at: A- Baseline. B- post-TAVI procedure. This 
patient had multiple new cerebral infarcts (highlighted by the red arrows). 
 
New neurological signs were observed in 2 patients (6%). The first presented with an expressive 
dysphasia and scored 4 on the NIHSS, whilst the second developed gait ataxia and scored 2. DWI 
confirmed 26 new lesions in each of these individuals, distributed over several territories. These 
neurological deficits were diagnosed post-operatively on day 1, persisted at day 2 (>24 hours) and 
were therefore classified as a stroke. When compared to those patients without neurological signs, 
individuals with new neurological signs demonstrated a significantly higher number (26±0 vs. 2.7±3, 
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p=0.004) and volume (11.9±6ml vs. 1.1±1.1ml, p=0.007) of new cerebral infarcts, although patient 
numbers are small.   
 
3.4.4 Demographic and Procedural Risk Factor Assessment 
 
Risk factors were assessed for a relationship to the number of new infarcts, as reported in Table 3-2. 
Increased age was significantly related to a higher number of new infarcts (r=0.37, p=0.042). There 
were no associations between the co-morbidities of hypertension, hypercholesterolaemia, diabetes 
mellitus, atrial fibrillation, cerebrovascular disease, peripheral vascular disease and a porcelain 
(heavily calcified) aorta, to the number of new infarcts or the development of a clinical stroke. Risk 
calculation using logistic EuroSCORE had no predictive relationship to the number of new cerebral 
infarcts (r=-0.08, p=0.69) or clinical stroke. Atheroma burden in the arch and descending thoracic 
aorta (but not in the ascending aorta, r=0.4, p=0.35), was significantly associated with the number of 
new cerebral infarcts (r=0.91, p<0.001; r=0.69, p=0.001). The severity of aortic valve calcification 
was not related to the number of new cerebral infarcts (p=0.33).  
Procedural risk factor analysis revealed that increased catheterisation time was associated with the 
number of new infarcts (r=0.45, p=0.02) whereas increased fluoroscopy time did not reach statistical 
significance (r=0.36, p=0.05). All other procedural variables including the size of Corevalve
TM
 (26 or 
29mm, p=0.19) had no relationship to the number of infarcts or presence of clinical stroke. Corevalve 
post-dilatation or dislocation and retrieval did not effect the number of new infarcts observed (p=0.22 
and p=0.93 respectively). 
The univariate variables (age, fluoroscopy time, catheterisation time, arch and descending aortic 
atheroma) were then entered into a multiple regression model, where age and aortic arch atheroma 
remained independent predictors of new cerebral infarcts (p=0.036 and p=0.023 respectively), Table 
3-3. Multivariate analysis was used to determine if the univariate variables could predict the 
occurrence of stroke as well as the number of new infarcts. Aortic arch atheroma was the only 
variable to significantly predict both (F=7.16, p=0.008).  
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Table 3-2 Predictors of new cerebral infarcts.  
Risk Factor Univariate analysis 
       R               P value 
Age 0.37 0.042 
BMI (kg/m
2
) 0.01 0.974 
EuroSCORE (Logistic) -0.075 0.69 
AV Pressure Gradient (mmHg) 0.11 0.57 
AV EOA (cm
2
) -0.26 0.17 
Ejection Fraction (%) 0.12 0.52 
LV EDD (mm) -0.28 0.14 
Creatinine (μmol/L) -0.02 0.90 
Hypertension 0.19 0.30 
Hypercholesterolaemia 0.11 0.55 
Diabetes 0.1 0.59 
Atrial Fibrillation  0 0.93 
Cerebrovascular disease  0.2 0.28 
Peripheral Vascular Disease  0.06 0.73 
Porcelain Aorta  0.25 0.17 
Aortic  atheroma                                   Ascending 0.40 0.352 
                                            Arch  0.91 < 0.001 
Descending 0.69 0.001 
Aortic Calcification 0.28 0.327 
Fluroscopy time (min)  0.36 0.05 
Catheterisation time (min)  0.45 0.02 
Contrast dose (ml)  -0.12 0.53 
Heparin dose (u)  0.24 0.19 
BMI- Body mass index, AV EOA- Aortic Valve Estimated Orifice Area, 
LV - Left ventricle, EF- ejection fraction, EDD- end-diastolic dimension 
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Table 3-3 Multiple regression analysis 
Univariate predictor Multivariable analysis* 
 B         t       p value 
Age 0.50 2.2 0.035 
Fluroscopy time (min) 0.23 1.1 0.27 
Catheterisation time (min) 0.10 0.5 0.61 
Aortic arch atheroma 3.97 2.4 0.02 
Descending aortic atheroma 0.33 1.7 0.11 
 
* Univariate variables with a p value <0.1 were included in the model 
 
3.4.5 Health Status 
 
The HRQOL scores should be interpreted in comparison to the average score for a UK population 
matched for age and gender. These relevant scores were; PCS (36-38), MCS (50-51), EQ5D (0.69-
0.71) and VAS (70-75) (Hanmer et al., 2006). 
The SF-12v2 individual components that showed a significant increase from baseline were; physical 
functioning, bodily pain and general health (p=0.003, p=0.03 and p=0.003 respectively), Figure 3-5. A 
comparison of the summary scores revealed that the PCS increased significantly from baseline 
32.4±6.2 to 30 days 36.5±7.2, (p=0.03) with no significant change in MCS from 43.5±11.8 to 
43.1±14.3 (p=0.85), Figure 3-6. The PCS and MCS scores at 30 days showed no relationship to the 
number of new infarcts (r=0.19, p=0.33; r=-0.08, p=0.69 respectively), and were not significantly 
different between the stroke and non-stroke groups (PCS, p=0.39 and MCS, p=0.98).  
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Figure 3-5 Health Related Quality of Life- SF12 
 
Population mean scores (and standard error) at baseline (dark grey) and 30 days (light grey). 
Physical health: Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH). Mental 
Health: Vitality (VT), Social Functioning (SF), Role Emotional (RE), Mental Health (MH).  
* P <0.05  
 
Figure 3-6 Physical and Mental component summary scores 
 
PCS= physical component summary; MCS= mental component summary. * p = 0.03 
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The mean EQ5D score showed a non-significant increase from baseline to 30 days (0.56±0.26 to 
0.59±0.31, p=0.70). Similarly, there was a non-significant increase in the VAS component of the 
assessment at 30 days (54.2±19 to 58.2±24, p=0.43), Figure 3-7. The EQ5D and VAS scores at 30 
days showed no relationship to the number of new cerebral infarcts (r=0.11, p=0.95;        r= -0.085, 
p=0.65, respectively) and were not significantly different between the stroke and non-stroke groups 
(p=0.85 and p=0.44 respectively).  
Figure 3-7 EQ5D and VAS scores at baseline and 30 days.  
 
 
EQ5D is scored from 0-1 and VAS is a self -rated score of 0-100. 
 
 
3.5 Discussion 
 
Previous studies have described the incidence of cerebral infarcts post TAVI but have been unable to 
identify any significant risk factors (Ghanem et al., 2010, Kahlert et al., 2010).
 
This study is to our 
knowledge the first to demonstrate that increased age and aortic arch atheroma severity are 
independent predictors for the number of new cerebral infarcts following TAVI. In addition, this is the 
first study to assess the impact of these new cerebral infarcts on HRQOL.  
The small size, high number and distribution of new cerebral infarcts suggest an embolic source. It 
has been demonstrated in previous cardiac catheterisation studies that embolisation can occur through 
the contact of a catheter against aortic atheroma, (Segal et al., 2001) and that the risk of stroke 
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increases with the duration of procedure, fluoroscopy time and contrast dose (Busing et al., 2005, 
Lund et al., 2005). Our findings that prolonged catheterisation and fluoroscopy time are univariate 
predictors of infarct number support this as a mechanism of action in TAVI patients, reflecting the 
increased contact of a catheter or valve apparatus against the aortic wall and atheroma whilst moving 
around the aortic arch.  
An important finding is that the number of new cerebral infarcts is related to the severity of aortic 
atheroma. Evidence from non-TAVI populations have shown that atheroma plaques >4mm in the 
aortic arch are associated with an increased risk of stroke and death (Amarenco et al., 1994, Di Tullio 
et al., 2009). In this TAVI study the presence of atheroma ≥5mm thickness or mobile atheroma in the 
arch and descending thoracic aorta was significantly associated with greater infarct number and 
clinical stroke. The association of descending thoracic aortic atheroma to new cerebral infarcts likely 
reflects its relationship to the severity of arch atheroma rather than as an independent causative factor, 
as atheroma increases in thickness and complexity progressively from ascending to descending aorta 
(Meissner et al., 2004). The relationship of atheroma severity to infarct number could potentially be 
explained by an association with age as atherosclerotic plaques increase in thickness and complexity 
with advanced age. However in this study age and aortic arch atheroma remained independent 
predictors of infarct number following multivariate analysis.  
Our results did not identify any relationship to support the theory that embolisation occurs during 
balloon valvuloplasty or valve implantation. Conventional stroke risk factors such as atrial fibrillation 
or prior cerebrovascular disease and surgical risk (logistic EuroSCORE) were not significant 
predictors of new cerebral infarction or clinical stroke.  
New cerebral infarcts occurred in 77% of our cohort, yet only 6% developed clinical stroke. The 
multiple infarcts demonstrated on these two individuals were all small (<5mm) except for one lesion 
whose anatomical distribution would not have accounted for the neurological presentation. Recent 
literature has demonstrated similar rates of DWI-determined cerebral infarction and clinical symptoms 
(Kahlert et al., 2010, Ghanem et al., 2010). The clinical significance of ‘silent’ infarcts remains 
uncertain, as concern exists related to higher cognitive and neuropsychological changes such as 
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memory, mood and personality. New cerebral infarcts have been reported in 30% of individuals after 
CABG (Restrepo et al., 2002a) and 40% following SAVR; (Floyd et al., 2006, Stolz et al., 2004a) 
these were ‘silent’ in 67% of cases. These cerebral infarcts have been linked to post-operative 
cognitive decline (POCD), (Newman et al., 2001, Knipp et al., 2005) as well as possible dementia 
(Yoshitake et al., 1995).  
HRQOL is an important method of assessing patient outcomes and is particularly relevant for TAVI 
patients, as older age and multiple co-morbidities make long-term prognostic benefit less relevant 
(Gurvitch et al., 2011). The SF-12v2 MCS looks at mood, emotional well being and social 
functioning, all of which could be affected by POCD. Importantly overall health status improved and 
the reported mental health of our patients was not affected by the number of cerebral infarcts. Whilst 
an improvement in HRQOL post-TAVI has been reported previously at 30 days (Gotzmann et al., 
2010), 3 months (Krane et al., 2010) and 5 months (Ussia et al., 2009),  this is the first study to assess 
the impact of new cerebral infarction on HRQOL in a TAVI population.  
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3.6 Limitations 
 
This was a relatively small patient cohort with no direct surgical comparison group. It is however 
difficult to recruit comparable surgical patients, given that TAVI patients by their nature are older 
with greater co-morbidity and high surgical risk. No complex neurocognitive testing was undertaken 
and the health status follow up was only out to 30 days. Our institution uses only the Corevalve
TM
 for 
TAVI and thus did not assess the Edwards-Sapien valve or the transapical route. Interpretation of the 
findings related to stroke are limited by the small number of patients presenting with clinical signs. 
Larger studies are warranted in the future with appropriate cognitive assessment and long term follow 
up, to fully inform in a patient specific manner the associated risks of the TAVI procedure. 
3.7 Conclusion 
 
This study found that increased age and aortic arch atheroma independently predict the number of 
cerebral infarctions following TAVI, irrespective of patient co-morbidities or calculated surgical risk. 
The presentation of neurological signs was associated with an increased number and volume of 
cerebral infarcts. Aortic arch atheroma severity was the only predictor of both infarct number and 
stroke. Health status and quality of life improved at 30 days post TAVI with no functional mental 
decline. Although TAVI data demonstrates superiority to standard medical therapy, stroke remains a 
significant problem (Leon et al., 2010). The frequent and dispersed nature of cerebral infarcts 
following TAVI does suggest an embolic process, for which protection devices are already being 
trialled (Nietlispach et al., 2010). The identification of individuals at high risk of multiple cerebral 
emboli is important as it may help patient selection for the use of a protection device against stroke 
and POCD.  
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4 Serial change in health related quality of life over one year 
following Transcatheter Aortic Valve Implantation: Predictors of 
health outcomes.  
 
4.1 Abstract 
Background: Severe AS reduces the length and quality of a patient’s life. TAVI is superior to 
standard medical therapy and non-inferior to SAVR for 2-year mortality. HRQOL is an important 
outcome measure, for which there is limited evidence in TAVI populations.  
Methods: One hundred and two patients (age 80 ±0.6yrs, female 51%) attending for TAVI consented 
to participate. Two HRQOL questionnaires, the SF12v2 with physical and mental component 
summaries (PCS and MCS) and the EQ-5D (with Visual Analogue Scale; VAS) were completed at 
baseline, 30 days, 6 and 12 months as per the VARC recommendations. A SF-6D utility measure was 
calculated from the SF12 survey.  
Results: HRQOL significantly improved over 12 months (PCS, p=0.02; EQ-5D, p=0.02; VAS, 
p=0.01 and SF6D p=0.03) becoming similar to age adjusted US population norms. The greatest 
change occurred from baseline to 30 days (p<0.001) with further significant improvements to 6 
months (p<0.01). An insignificant decline occurred between 6-12 months (p>0.05), but a linear 
pattern of change remained for PCS, EQ5D and VAS (p<0.05). Male gender (SF6D, p=0.01) and 
increased operator experience (PCS, EQ5D and VAS, p<0.05) were independent predictors of a 
greater improvement in HRQOL. 
Conclusions: HRQOL significantly improves early following TAVI and is maintained out to one 
year. Patient factors, procedural complications and operator experience are predictors of health benefit 
at 1 year may help patients and physicians make a fully informed decision during the TAVI selection 
process.  
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4.2 Introduction 
 
Symptomatic AS reduces the quality and duration of an individual’s life. TAVI is indicated as a 
treatment for the large number of severe AS patients unsuitable for SAVR (Vahanian et al., 2008b).  
Clinical trial and registry data have demonstrated high procedural success, significantly improved 
survival compared to medical therapy, and non-inferiority in mortality to SAVR at two years (Zahn et 
al., 2011, Smith et al., 2011, Leon et al., 2010, Makkar et al., 2012b). HRQOL assessments are 
important clinical outcome measures of medical treatments. The VARC recommended that quality of 
life questionnaires be used as a TAVI clinical benefit end-point and that they should be conducted 
over four separate time-points (baseline, 30 days, 6 months and 12 months) (Leon et al., 2011). 
Quality of life is particularly relevant for TAVI patients, as in an elderly population with multiple co-
morbidities absolute survival benefit may be less substantial, increasing the importance of quality 
attained years. In addition the identification of particular risk factors and predictors of HRQOL would 
allow the ‘heart team’ to better inform patients of their likely individual benefits from this high-risk 
procedure.  
Health utility values are a measure of preferences for health states, which are essential for the 
calculation of quality-adjusted life years (QALYs) within the framework of cost-utility analyses. 
Cost-utility analyses are the preferred approach, with QALYs the preferred metric of organisations 
charged with evaluating the cost-effectiveness of medical technologies for the purpose of healthcare 
resource allocation and decision making. 
 
Quality of life data on TAVI populations are sparse (Gotzmann et al., 2010, Ussia et al., 2009), and at 
the time of writing only the PARTNER study has published HRQOL results over the range of 
recommended time-points (Reynolds et al., 2011), with no reports of health utility values for this 
patient group. Health utility values, especially multiple assessments over a long time period, are 
important to allow cost-effective analyses and decision analytical modelling to be undertaken.  
The aims of this study were to 1) assess serial changes in HRQOL and health utility at 30 days, 6 
months and 1 year after TAVI, 2) Identify the clinical variables that predict patient benefit.       
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4.3 Methods 
 
One hundred and two patients who underwent TAVI at our institution between May 2008 and May 
2010 provided informed written consent to the study, which was approved by the institutional ethics 
committee and performed in accordance with the declaration of Helsinki. Patient selection for TAVI 
was performed by a multi-disciplinary ‘heart team’ which included a cardiologist, cardiothoracic 
surgeon and cardiac anaesthetist. Severe AS was defined as a peak velocity >4m/s or a calculated 
aortic valve area <0.8cm
2 
by echocardiography. All individuals were symptomatic and deemed 
unsuitable for SAVR due to high calculated surgical risk (EuroSCORE >20) or in-operable co-
morbidities. Pre-operative assessments included invasive angiography of the coronary and iliac 
arteries and TOE. Patients were deemed unsuitable for TAVI if the aortic annulus was <20 or >27mm. 
Exclusion criteria were the inability to comprehend English language or impaired cognition.   
4.3.1 Transcatheter Aortic Valve Implantation 
TAVI was performed under general anaesthesia using the 18F MCV Revalving system (Medtronic, 
Minneapolis, Minnesota) as previously described (Piazza et al., 2008). A transfemoral approach was 
used where possible, with percutaneous access and closure.  A surgical subclavian approach was 
performed in patients without suitable femoral access (<6mm diameter). Aortic valvuloplasty under 
rapid pacing control was followed by CoreValve
TM
 implantation (26 or 29mm) with post-dilatation as 
required. The primary operator was identical for all procedures and the results reflect all cases 
sequentially performed following proctorship.  
4.3.2 Quality of Life Assessments 
HRQOL was assessed using two generic, validated questionnaires; SF-12v2 health outcomes 
questionnaire (©QualityMetric, Lincoln, RI, USA) and the EQ-5D questionnaire (©EuroQOL). Each 
patient completed a questionnaire at baseline, 30 days, 6 and 12 months. The initial survey was 
conducted by interview with a trained health care specialist and later time-points completed by postal 
or telephone survey. Exclusion criteria were the inability to comprehend English or impaired 
cognition. Patient characteristics, co-morbidities, NYHA class, procedural risk factors and variables 
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were collected prior to TAVI. Post-operative complications (e.g. vascular haemorrhage, permanent 
pacemaker implantation) and mortality were collected post-TAVI.  
The short form (SF) 36-item health survey was developed to enable the standardized practical 
assessment of general health as a medical outcome (Ware, 2000). It has been validated in chronic 
disease states in comparison to psychometric testing, clinical criteria and medical interviews (Ware et 
al., 1996b). The information attained is robust, unambiguous and an accurate representation of a 
patients’ medical and psychiatric health. The SF-12 health survey is based on the SF 36-item health 
survey but is shorter with fewer response categories, and is thus simpler to complete and more 
suitable to an elderly population (Brazier and Roberts, 2004). Evidence suggests that the results 
obtained by the SF-12 survey correlate highly with those from SF-36, providing an accurate estimate 
of health (Lundberg et al., 1999). However, the relative validity coefficient is approximately 10% 
lower. This greater variance may become important in smaller sample sizes but does not apply in 
larger samples (i.e. >100). The survey asks for single and ranked responses to questions pertaining to 
the individuals’ health over the preceding 4 weeks, Figure 4-1.  It uses 8 dimensions to assess physical 
and mental health; Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health 
(GH), Vitality (VT), Social Functioning (SF), Role Emotional (RE) and Mental Health (MH). The 
individual responses are then graded and scored from 0-100. These scores are normalised to a US or 
UK population (mean 50, SD 10), where a higher score reflects a better HRQOL.  Additionally, two 
separate component summary scores are reported, distinguishing between physical (PCS; physical 
component score) and mental (MCS; mental component score) health.  
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Figure 4-1 SF – 12 version 2 health survey 
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EQ-5D and SF-6D are two health-based utility measures (Brazier et al., 2004). Utility measures 
typically provide an index (quality of life weighting) between zero and one, where one reflects full 
health and zero, death. Utility values are combined in economic evaluation with survival data to 
calculate QALY gains from new treatments and technologies. The EQ-5D survey was developed by 
the EuroQol group (www.euroqol.org) as a standardised measure of health for clinical and economic 
evaluations (Rabin and de Charro, 2001). It is a straightforward questionnaire that is suitable for self-
completion via postal survey or via direct interview. The EQ-5D descriptive system uses 5 domains to 
assess health states; mobility, self care, usual activities, pain/discomfort and anxiety/depression. Each 
question has 3 potential responses: no problems, some problems, severe problems Figure 4-2. A single 
response is required for each domain, resulting in a scoring number (1, 2 or 3). This scoring system 
allows the identification of 245 health states (from no problems [11111], to dead or unconscious 
[33333]). The EQ-5D health state can be converted in to a single summary index by a formula that 
‘weighs’ each domains score. The appropriate values are derived from a ‘normal’ UK population 
sample to reflect local societal perspective.  The conversion is applied in a time-trade off valuation 
exercise: 1 – the index value (Dolan, 1997). Patients also completed an EQ Visual Analogue Score 
(VAS) of self-rated health, Figure 4-3 (Robinson et al., 1997). The scale is from worst imaginable (0) 
to best possible (100) health, and is used as a quantitative assessment of subjective health. Answers 
applied to the day of completing the questionnaire. SF-6D is a utility-based measure that is calculated 
using the SF-12 scores converted to SF-6D utility scores using a UK tariff (Brazier et al., 2002). This 
provides an additional domain (vitality) and different recall period (4 weeks) to the EQ-5D. 
Differences in the change of scores suggest that SF-6D has a higher sensitivity in severe disease 
processes (Quercioli et al., 2009, Brazier et al., 2004). 
In this TAVI population of generally poor health, the use of both EQ-5D and SF-12 surveys is 
complementary; EQ-5D is more suitable for a population with poor health as it demonstrates a ceiling 
effect in moderately severe health conditions, whereas SF-12 is reported to underestimate the severity 
of health status in poorer health groups but does not demonstrate a ceiling effect (Quercioli et al., 
2009).  
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Figure 4-2 EQ 5D survey 
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Figure 4-3 EQ visual analogue scale 
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4.3.3 Statistical Analysis 
Continuous data are presented as mean ±SD and categorical as frequency and percentage. Normality 
was determined by Shapiro-wilks test and Q-Q plots. Comparative statistics used were student t-test 
and Wilcoxon signed rank test as appropriate. All paired comparisons between baseline measurements 
and the various time-points were performed analysis by analysis, excluding un-paired results. Chi-
squared test was used for categorical comparisons. Repeated measures ANOVA general linear model 
was applied to detect changes over the four time-points and differences between subject factors. 
Predictors of the one year health scores were assessed by individual linear regression analysis with 
baseline scores entered as a covariate factor. Individual variables with a p value <0.1 were entered 
into the multivariate general linear model. All statistical analyses were performed using the PASW 
software package (version 17.0 SPSS, IBM, Chicago, Ill, US) with a two-sided significance level of 
p<0.05 considered statistically significant. 
 
4.4 Results 
 
All 102 patients completed baseline HRQOL questionnaires. Three patients had valvuloplasty instead 
of TAVI giving a 97% procedural success. The study population therefore consisted of 99 patients 
(age 80±6yrs, 49% male), whose clinical and procedural characteristics are reported in Table 4-1. All 
cause mortality was consistent with the published literature; 3 (3%) at 30 days, 7 (7%) at 6 months 
and 20 (20%) at one-year (Tamburino et al., 2011). Three patients (3%) were unable (due to cognitive 
decline) and 4 (4%) unwilling to complete all 4 time-point questionnaires. Incomplete questionnaires 
including those as a result of patient death, were excluded from subsequent time-point ANOVA 
analysis. Table 4-2 shows the health score results for each survey according to the VARC 
recommended time points, with the US population norms stratified for age (80-89yrs) to allow 
comparison to an equivalent age group of healthy individuals (Hanmer et al., 2006).  
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Table 4-1 Demographic, clinical and procedural characteristics of the TAVI population 
Variables  (n=99)  
Clinical characteristics   
Age  80 ±6  
Male  48 (49)  
EuroSCORE (logistic %)  20 ±13  
Smoker  
Never 
Ex-smoker 
Smoking 
 
34 (35)  
63 (64)  
2 (1)  
Diabetic  33 (33)  
Renal disease ¶  9 (9)  
MI  39 (39)  
AF  26 (26)  
COPD  23 (23)  
CVD  9 (9)  
PVD  15 (15)  
CABG  28 (28)  
Angina (CCS class)  
0 
1 
2 
3 
4 
 
62 (62)  
4 (4)  
12 (12)  
18 (19)  
3 (3)  
NYHA class  
1 
2 
3 
4 
 
0 (0)  
13 (13)  
60 (60)  
26 (27)  
Pulmonary Hypertension  15 (15)  
Porcelain aorta  15 (15)  
Procedural variables   
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Access 
Subclavian 
Femoral 
 
8 (8) 
91 (92)  
Valve  
26mm 
29mm 
 
26 (26)  
73 (74)  
Mortality (30 day)  3 (3)  
Peri-procedural MI  0 (0)  
Stroke 2 (2)  
Vascular haemorrhage  4 (4)  
Transfusion  26 (26)  
Acute Kidney Injury  1  (1)  
Permanent Pacemaker  20 (20)  
 
Values are mean ±SD or number (%). COPD = Chronic Obstructive Pulmonary Disease, CVD = 
Cerebrovascular disease, PVD = Peripheral Vascular Disease, CABG = Coronary Artery Bypass Graft, CCS = 
Canadian Classification Score of angina, NYHA = New York Heart Association, ¶ = eGFR <30 ml/min/1.73m
2 
 
Table 4-2 Health scores according to VARC time-points 
Paired comparisons               Time-point 
Health 
Survey  
 
US Norm† 
Baseline 
n=99 
30 Days 
n=90 
6 Months 
n=70 
12 Months 
n=65 
PCS   37.3 ±3 29.5 ±9 36.3 ±9*** 38.3 ±11** 34.4 ± 10* 
MCS   51 ±3 45.4 ±12 46.4 ±13 47.4 ±11 46.9 ±11 
EQ-5D   0.66 ±0.2 0.54 ±0.3 0.65 ±0.3** 0.68±0.3* 0.65 ±0.3* 
VAS   0.53 ±7 51.1 ±21 61.4 ±21*** 68.2 ±20** 61.5 ±21* 
SF-6D   0.72 ±0.1 0.60 ±0.1 0.66 ±0.1** 0.68 ±0.1** 0.63 ±0.1* 
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Values are mean ± SD. * p < 0.05, ** p < 0.01, p < 0.001. p values are reported for a change in health for each 
time point compared to baseline by paired t-test.  † US Norms are reported for a US population stratified by age 
(80-89 years).  
PCS = Physical Component Score, MCS = Mental Component Score, VAS = Visual Analogue Score .  
 
4.4.1 SF-12 Health scores 
The separate health component scores over the 4 different time-points are shown in Figure 4-4. 
Components that increased significantly from baseline to 30 days included: Physical functioning (PF, 
27.8 ±7 vs. 33.6 ±9, p<0.001), Role Physical (RP, 31.8 ±8 vs. 35.8 ±10, p=0.006), Bodily Pain (BP, 
38.9 ±14 vs. 45.9 ±12, p=0.001), General Health (GH, 33.4 ±10 vs. 40.3 ±11, p<0.001), Vitality (VT, 
36.8 ±9 vs. 41.2 ±10, p=0.006) and Mental Health (MH, 45.2 ±11 vs. 48.5 ±11, p=0.027). Social 
Functioning (SF, 37.4 ±14 vs. 39.7 ±13, p=0.22) and Role Emotional (RE, 39.2 ±12 vs. 40.8 ±15, 
p=0.75) improved but not significantly.  At 6 months there was a further increase from 30 days in PF 
(36.5 ±12, p<0.001), RP (39.3 ±10, p<0.001), VT (43 ±11, p=0.002), SF (42.8 ±15, p=0.06) and RE 
(42.6 ±13, p=0.67). BP and GH scores did not increase further but remained significantly higher than 
baseline (45.4 ±13, p=0.02 and 40.8 ±11, p=0.001). One year measurements revealed a non-
significant (p> 0.05) decrease in all components when compared to 6 month scores, with a sustained 
improvement compared to baseline scores in PF (34.9 ±10, p<0.001), RP (36.2 ±10, p=0.03), GH 
(38.8 ±11, p=0.003) and VT (40.2 ±10, p=0.03). Repeated measures ANOVA showed a significant 
improvement over the four time-points to one year for all physical component scores (PF, RP, BP, 
GH) but not for the mental component scores (VT, MH, SF, RE).  
 
 
 
 
 
  
114 
 
Figure 4-4 Changes in SF 12 health component scores following TAVI 
 
 
Time-points are represented by different coloured bars. P values by repeated measure ANOVA analysis are: *** 
= p<0.001, ** = p<0.01, * = p<0.05; NS = Not significant. PF = Physical Functioning, RP = Role Physical, BP 
= Bodily Pain, GH = General Health, VT = Vitality, SF = Social Functioning, RE = Role Emotional and MH = 
Mental Health.  
 
The summary score for physical health (PCS) increased from baseline (29.5 ±9) to 30 days (36.3 ±9, p 
<0.001) and 6 months (38.3 ±11, p<0.001). One year PCS whilst lower than the 6-month score was 
still significantly higher compared to baseline (34.4 ±10, p=0.02), Table 4-2. Repeated measures 
ANOVA in those patients that completed surveys at all 4 time points (n=65) demonstrated a 
significant linear (p=0.03) and quadratic (inverted U shaped curve, p<0.001) relationship over time,  
Table 4-3. Overall mental health (MCS) showed no significant change from baseline to any of the 
individual time-points (30 days, p= 0.47, 6 months, p=0.71 and 1 year, p=0.58; Table 4-2) which was 
confirmed on repeated measures ANOVA (p= 0.13,  
Table 4-3).   
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Table 4-3 Serial change in health scores 
  Time-point 
                                            
*p value  
Health 
Survey  
Baseline 
n=65 
30 Days 
n=65 
6 Months 
n=65 
12 Months 
n=65 
Quadratic Linear  
PCS  32.2 ±9 37.4 ±9 40.5 ±11 36.5 ± 11 < 0.001 0.03 
MCS  45.2 ±10 45.8 ±13 46.7 ±11 47.2 ±11 0.15 0.13 
EQ-5D  0.59 ±0.3 0.70 ±0.3 0.71 ±0.3 0.67 ±0.3 0.02 0.04 
VAS  52.8 ±19 64.6 ±20 64.8 ±21 63.3 ±21 0.002 0.02 
SF-6D  0.61 ±0.1 0.67 ±0.1 0.69 ±0.1 0.64 ±0.1 0.004 0.14 
 
Values are mean ± SD. * p values are reported for a change in health and were calculated by repeated measures 
ANOVA. Quadratic p values reflect a inverted U shaped curve, where linear p values represent a linear trend. 
PCS = Physical Component Score, MCS = Mental Component Score, VAS = Visual Analogue Score.  
 
4.4.2 Utility assessment scores 
EQ-5D and VAS scores increased significantly from baseline to 30 days (0.54 ±0.3 vs. 0.65 ±0.3, p< 
0.001 and 51.1 ±21 vs. 61.4 ±21, p<0.001 respectively). They improved further at 6 months (0.68 
±0.3, p=0.006 and 68.2 ±20, p=0.008) with a small insignificant decrease at 1 year (0.65 ±0.3, p=0.94 
and 61.5 ±21, p=0.70), Table 4-2. One year measures remained significantly higher than baseline for 
both EQ5D and VAS scores (p=0.02 and p=0.01 respectively). Repeated measures ANOVA 
demonstrated a significant linear and quadratic relationship over the four time-points for both EQ-5D 
(p=0.04 and p=0.02 respectively) and VAS (p=0.02 and p=0.002 respectively) scores,  
Table 4-3. SF-6D increased from baseline to 30 days (0.60 ±0.1 vs. 0.66 ±0.1, p=0.001) and was 
maintained at 6 months (0.68 ±0.1, p=0.001) and one year (0.63 ±0.1, p=0.03) (Table 4-2). Repeated 
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measures ANOVA once more showed a significant quadratic relationship over the 4 time-points 
(p=0.004),  
Table 4-3. 
 
4.4.3 HRQOL changes related to patient and procedural characteristics  
All variables were assessed for predictors of change in HRQOL from baseline to one year using a 
general linear model.  Age was considered as a linear variable as well as being categorised into groups 
of < or ≥80 years. Independent predictors of HRQOL change at one year are reported for the separate 
questionnaires in Table 4-4. MCS values have not been reported as there were no significant 
predictors of change.  
Male gender was an independent predictor of greater improvement in HRQOL at one year (SF-6D), 
Table 4-4. There was no gender difference in HRQOL scores at baseline, but at 1 year males had 
significantly higher HRQOL compared to females (SF-6D: 0.69 ±0.1 vs. 0.58 ±0.1, p=0.001),Figure 
4-5. Males had significantly worse baseline LVEF (p=0.004) and higher incidence of previous MI 
(p<0.001), with no difference between other characteristics (EuroSCORE, age, operation order). 
Health changes also differed between age groups, Figure 4-6. The younger age group (<80 years) 
compared to the older group (≥80 years) reported lower baseline health scores (EQ-5D 0.45 ±0.3 vs. 
0.58 ±0.3, p=0.04; VAS 43 ±25 vs. 54 ±20, p=0.02 and SF-6D 0.56 ±0.1 vs. 0.61 ±0.1, p=0.03) with 
no difference between their health scores at one year (EQ-5D 0.67 ±0.3 vs. 0.63 ±0.3, p=0.51; VAS 
58 ±21 vs. 64 ±20, p=0.29 and SF-6D 0.64 ±0.1 vs. 0.63 ±0.1, p=0.70).   
Other than prior CABG predicting a greater improvement in HRQOL, no other specific pre-existing 
co-morbidity predicted one year HRQOL. Those patients with higher baseline NYHA and angina 
class had a lower baseline HRQOL, but not significantly (p=0.55 and 0.48). Pre-operative NYHA 
class ΙΙΙ-ΙV patients did however experience a smaller increase in their HRQOL score compared to 
those individuals in class Ι-ΙΙ, Table 4-4.    
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Table 4-4 Predictors of one year Quality of Life    
 Univariate Analysis Mutivariate Analysis 
 B coefficient p value B coefficient p value 
PCS      
Age group 3.33 0.07 3.01 0.09 
Operation order 10.9 0.002 4.05 0.05 
CABG 4.56 0.04 3.47 0.07 
NYHA class 4.00 0.02 1.83 0.18 
EQ5D      
Operation order 12.6 <0.001 4.017 <0.001 
Male gender 3.06 0.09 0.69 0.41 
Vascular complication 5.94 0.02 9.68 0.03 
NYHA class 2.81 0.07 2.14 0.13 
VAS      
NYHA class 2.69 0.07 2.05 0.14 
Operation order 5.74 0.02 4.97 0.03 
SF6D      
Operation order 7.08 0.01 1.11 0.34 
Male gender 10.1 0.003 2.84 0.01 
NYHA Class 4.947 0.01 2.53 0.09 
 
P values represent the univariate and multivariate general linear regression model and the beta standard 
coefficients. Individual variables were entered in to a multivariable model if the p significance <0.1. CABG = 
Coronary Artery Bypass Grafting, NYHA = New York Heart Association  
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Figure 4-5 Gender 
 
Change over time for SF-12, EQ-5D, VAS and SF-6D by gender 
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Figure 4-6 Age group 
 
Change over time for SF-12, EQ-5D, VAS and SF-6D for individuals < or ≥ 80 years 
 
4.4.4 HRQOL changes related to operative variables 
Operator experience impacted on HRQOL, Table 4-4. Operative order was separated into two; the 
first 50 (group 1) and subsequent 49 (group 2) procedures. Patients in group 2 had a greater increase 
in all four health survey scores (PCS, EQ5D, VAS and SF6D) at 12 months. Group 2 patients had 
insignificantly higher baseline health scores compared to group 1, which increased further becoming 
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significantly different at 12 months (PCS, p=0.003; VAS, p=0.02; EQ-5D, p<0.001; and SF-6D, 
p=0.01), Figure 4-7. Vascular haemorrhage was an independent predictor of lower EQ5D at 12 
months, with no other specific procedural complication (transfusion or aortic regurgitation) resulting 
in a significant decline in HRQOL scores, Table 4-4.  
Figure 4-7 Operation order 
 
Change over time for SF-12, EQ-5D, VAS and SF-6D by operation order (Group 1 = first 50 cases, Group 2 = 
last 49 cases) 
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4.5 Discussion 
 
In a high-risk AS population, we have shown serial improvements in quality of life sustained over 12 
months following TAVI. Benefit was seen early at 30 days post-procedure and increased further at 6 
months. An insignificant drop in health status occurred between 6 months and one-year which 
appeared to be related to both patient and procedural factors. Male gender was an independent 
predictor of a greater increase in health score from baseline to one year. We have also shown for the 
first time that the ‘learning curve’ of operator experience impacted upon the health benefits for 
patients, independent of other procedural factors or complications.  
Quality of life is an important clinical outcome measure of TAVI as patients are elderly, often frail 
and have multiple co-morbidities. This study has demonstrated the change in HRQOL over time post-
TAVI, with the greatest change from baseline being observed at the 30-day time-point. This may be 
explained by certain early benefits from the less invasive nature of TAVI (compared to SAVR), such 
as shorter hospital stay, rapid haemodynamic response and reduced mortality (Smith et al., 2011, 
Clavel et al., 2009). Health scores increased further from 30 days to 6 months with an insignificant 
decline between 6 months and one year for all surveys. In separate studies, HRQOL post-TAVI has 
previously been shown to improve at the individual time points of 30 days, 5 months, or 12 months 
(Gotzmann et al., 2010, Gotzmann et al., 2011, Ussia et al., 2011) and over a series of time-points 
(Reynolds et al., 2011), but ours is the first study to show a pattern of health change over time as 
recommended by VARC for both health and utility measures. When compared to the age matched 
general US population norms, the baseline health of our TAVI population appears considerably 
worse. This improves up to 6 months where the average health is better than the general US norm for 
PCS, EQ-5D and VAS with similar scores in MCS and SF-6D. The small drop in reported health 
between 6 months and one year whilst statistically insignificant may reflect a decline in health that 
could become significant over a longer time period (e.g. 2 years). This observation is important in 
determining the health outcome post-TAVI and would suggest that future studies should involve long-
term (>1 year) follow-up.    
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An important finding of this study is that different subgroups within the TAVI population had 
different health responses. One of the major driving forces in the development of TAVI was to aid in 
the treatment of elderly patients with severe AS, who with high levels of morbidity and mortality were 
not receiving SAVR (Iung et al., 2005a). This observation was in spite of the evidence that SAVR 
improves relative survival (Kvidal et al., 2000, Krane et al., 2011) and quality of life in octogenarians 
(Sundt et al., 2000). Our study is concordant with that of Bekeredjian et al., showing that HRQOL 
improves post-TAVI in individuals ≥80 years (Bekeredjian et al., 2010). In addition, we have 
demonstrated that younger patients (<80yrs) actually have lower baseline health scores yet gain equal 
benefits from the procedure. This is important as in the future, TAVI may be performed on a younger 
population. Higher baseline health scores in the older age group may appear counterintuitive, but age 
itself does not affect HRQOL. It is the associated diseases and loneliness which prevail in the elderly 
that reduce HRQOL (Brazier et al., 2002).  Our age groups (<80, ≥80yrs) had similar baseline co-
morbidities and thus the elderly population may perceive their health to be relatively higher due to 
lower expectations.  
Females with AS have a decreased survival compared to males that is predominantly due to lower 
referral rates for SAVR, as once operated on they have similar mortality outcomes (Hartzell et al., 
2011).  TAVI data have not demonstrated any gender differences in clinical outcomes such as 
mortality or stroke, but no one has previously assessed this in relation to HRQOL as an outcome 
measure. Despite having a slightly higher rated baseline health, females improved less significantly 
than their male counterparts, with the difference becoming significant at 12 months. This was not 
related to any differences in baseline demographic characteristics or to the operative procedure. 
Although not formally assessed in this study it may reflect a greater prevalence of frailty in elderly 
females.     
Operator experience has been reported to adversely affect cardiovascular outcomes and 30-day 
survival following the TAVI procedure, as a result of a ‘learning curve’ and device developments 
(Gurvitch et al., 2010, Gurvitch et al., 2011). We describe for the first time the impact of this learning 
curve on HRQOL as a clinical outcome. Identical device technology was used in all subjects by a 
single primary operator, and although baseline characteristics differed, in 3 out of 4 health surveys 
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multivariate analysis showed operator experience to be independent of all other variables. This 
provides further evidence to support the training and performance of TAVI in high volume centres 
with experienced operators to maximise the improvement in patient outcomes.  
Patient selection remains one of the most challenging areas of TAVI practice. Our results provide 
evidence that a higher NYHA class predicts a less substantial improvement in health, whereas 
previous CABG patients gained a greater improvement in HRQOL. These factors may contribute 
towards the ‘heart teams’ TAVI patient selection criteria and aid the decision making process for the 
individual patient. 
The published TAVI data have demonstrated improvement in patient survival and symptoms, but it 
remains a costly procedure with a significant post-procedural risk of death, vascular haemorrhage and 
stroke. Cost-effectiveness and the calculation of QALY’s will therefore form an important part of 
health policy planning and outcome measurement in TAVI clinical practice. Until now no health 
utility measures have been reported in a TAVI population. In our study, a significant improvement 
occurred over 12 months for both utility measures which also showed a similar pattern of change. 
Further investigation is required to establish if the improvement in health of our study population, 
when combined with improved mortality rates will indicate a health economic benefit of TAVI.      
 
4.6 Limitations  
 
Although the study cohort was representative of a typical TAVI population, this was a single centre 
study in the UK and like all quality of life studies should be interpreted in the context of the local 
population. A surgical comparison group was not recruited given the difficulty in matching to a TAVI 
population for age, co-morbidities and risk factors, as a consequence of the current guidelines for 
TAVI patient selection. Incomplete questionnaires secondary to cognitive decline (3%) may indicate a 
reduced quality of life that has not been calculated. This study was not designed to perform a cost-
effectiveness analysis or calculate QALY’s from the health utility data. Ideally any future study 
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should combine both aspects in a multicentre, international registry to provide more comprehensive 
information to allow future health policy planning.  
 
4.7 Conclusions 
 
Quality of life improves early following TAVI and is maintained out to one year. Population sub-
groups respond differently to TAVI, as females have lower health improvements. Increased operator 
experience is a predictor of greater health response independent of other patient or procedural 
variables. Health utility measures showed a similar pattern of increased health out to one year, and 
could in the future be combined with mortality data to produce a comprehensive health benefit model 
for TAVI.  
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5 The Cost-Effectiveness of Transcatheter Aortic Valve Implantation 
versus Surgical Aortic Valve Replacement in Patients with Severe 
Aortic Stenosis at High Operative Risk 
 
5.1 Abstract 
 
Background: To determine the cost-effectiveness of TAVI compared to SAVR in a high-risk AS 
United Kingdom population. 
Methods: A cost-utility analysis employing the NICE reference case design for technology appraisals 
from the perspective of the UK National Health Service. TAVI and SAVR effectiveness was taken 
from the PARTNER A randomised controlled trial. Costs were modelled over a 10 year horizon using 
a Markov model. Incremental cost-effectiveness ratios (ICER) and cost-effectiveness acceptability 
curve (CEAC) were calculated with reference to the NICE willingness to pay per QALY gain 
threshold. Deterministic and probabilistic sensitivity analyses performed. 
 Results Despite greater procedural costs (£16,500 vs. £9,256), TAVI was cost-effective compared to 
SAVR over the 10 year model horizon (costs £52,593 vs. £53,943 and QALYs 2.81 vs 2.75), 
indicating that TAVI dominated SAVR. This appeared to be due to greater post-surgical costs, related 
to the length and cost of hospital stay. The results appeared robust to a number of deterministic 
sensitivity and probabilistic analyses. The CEAC indicated that at the NICE £20,000 willingness to 
pay threshold per QALY gained, TAVI had a 64.6% likelihood of being cost-effective, compared to 
35.4% for SAVR. 
Conclusions TAVI is likely to be a cost effective treatment for high-risk AS patients compared to the 
reference standard of SAVR. However, uncertainty surrounding the long-term outcomes for TAVI 
patients remains; this could have a substantive impact on estimates of cost-effectiveness.  
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5.2 Introduction 
 
AS is the most common valvular heart disease in the western world. As a predominantly degenerative 
process the disease prevalence increases with age, affecting 4% of individuals aged 85 years and older 
(Nkomo et al., 2006, Carabello and Paulus, 2009). The onset of symptoms predict a poor prognostic 
outlook and a reduced quality of life, with valve replacement the only successful treatment option 
(Pellikka, 2005, Kvidal et al., 2000). The European Heart Survey demonstrated that a third of suitable 
patients did not receive definitive surgical treatment due to factors such as age, left ventricular 
dysfunction and associated co-morbidities (Iung et al., 2005a). Transcatheter aortic valve implantation 
(TAVI) developed as an alternative procedure for those individuals deemed at high-risk or inoperable 
for conventional SAVR. TAVI improves survival, functional capacity and quality of life compared to 
standard medical therapy (Leon et al., 2010) and at 2 years is non-inferior to SAVR (Smith et al., 
2011, Kodali et al., 2012b). Despite its wide practice, there remains a question regarding the cost-
effectiveness of this intervention in an elderly high-risk population. To date, no economic evaluations 
have conducted a comparison of TAVI and SAVR in high-risk patients suitable for conventional 
surgery from the perspective of the UK health service.  
 
The aim of this study was to determine whether TAVI is a cost-effective alternative to SAVR in a 
high-risk group by developing a decision-analytic economic model using the available published 
evidence and values that reflect UK costs and clinical practice. We aim to provide an estimate of the 
average cost-effectiveness of TAVI across access site (Transfemoral (TF) or Transapical (TA)) and 
valve brands (Edwards-SAPIEN™ and Medtronic CoreValve™) with sensitivity analyses to cover 
differential performance according to these factors; this is to ensure model results reflect an overall 
viewpoint for the patient, clinician and purchaser in a health care system, where differential practice 
may occur. 
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5.3 Methods 
 
To determine the cost-effectiveness of interventions, health costs and outcomes relating to TAVI and 
SAVR were assessed by decision analytical modelling combining health related quality of life data 
from a UK AS population with data extracted from published randomised and registry studies.  
 
5.3.1 Analyses and model structure 
A cost-utility analysis was conducted with benefits expressed in terms of quality adjusted life years 
(QALYs) (Richardson and Manca, 2004), costs presented from the perspective of the UK health care 
provider and results expressed as incremental cost-effectiveness ratio (ICERs) (Reed et al., 2005). A 
decision tree was constructed to capture the costs and benefits of the interventions from baseline to 2 
years and a cohort Markov Model with annual cycles was used to propagate the costs and benefits 
over a 10 year time horizon, Figure 5-1. A Markov Model assumes that patients exist in one of several 
possible health states at any time and can move (or transition) between these health states over a time 
period or cycle. The probability of moving from one health state to another is calculated over several 
cycles, where the sum of each transition probability must equal 1. The Markov Model ends at a pre-
defined state (i.e. dead or time period). A supplementary analysis was based on life years provided by 
the interventions. Markov modelling requires that values are assigned to each health state in the form 
of costs and utilities. The costs and outcomes are summed at the end of each cycle according to the 
proportion of patients expected to be in each health state. Costs and benefits after year 1 were 
discounted at the National Institute of Clinical Excellence (NICE) preferred rate of 3.5%. Analyses 
were conducted in Microsoft Excel© (Microsoft Corporation, Redmond, WA, USA).  
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Figure 5-1  Structure of the decision model 
 
 
5.3.2 Outcomes and Utility 
Health benefits were based on NYHA class transitions with each class ascribed a mean EQ-5D 
(EuroQoL, 1990) health utility value generated from a UK study population previously described 
(Fairbairn et al., 2012). This population data did not include any NYHA category I patients, therefore 
EQ-5D values for this group were taken from UK population norms for the age group (Kind P, 1999). 
The utility value is multiplied by the unit of measure (life-years gained) in order to report the primary 
outcome measure (Quality Adjusted Life Years, QALY’s). As the only randomised study of TAVI 
versus SAVR in high-risk patients, PARTNER A was used as the basis of the patient outcomes data 
(Kodali et al., 2012b). The NYHA proportions from the trial publication were employed with the local 
NYHA mean EQ-5D values, to generate baseline to 2 year QALYs. As NYHA transition may not 
capture all the impact of complications additional utility decrements were calculated by subtracting 
mean utility values associated with complications in published literature from the mean EQ-5D scores 
for NYHA III. These were adjusted to 80% to reflect the proportion of patients with complications 
that would die. The NYHA proportions at 2 years were subject to the proportional changes observed 
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in NYHA classes by Kodali et al from 1 to 2 years. The changes from 1 to 2 years were employed as 
constant proportional changes (with half-cycle correction) in NYHA classes for the 10 year time 
horizon of the cohort, Table 5-1.  To illustrate, the population of NYHA category I was reduced by 
12% annually. Using this approach and considering the percentage reductions from the other NYHA 
categories, the annual mortality rate was set at 40%.  
 
Table 5-1 Utility scores and NYHA proportional changes 
 
5.3.3 Costs 
Costs were based on national UK values, Table 5-2. The TAVI procedure was charged at a standard 
NHS tariff payment-by-results fee. This fee covered the device costs, procedural costs (medical 
professionals, theatre time), post-operative recovery (coronary care unit) and 4 days general ward 
hospital stay. The TAVI care pathway incorporated 4 additional days general ward hospital stay, 
ambulatory monitoring, two echocardiograms, ECG’s, a vascular surgery consultation, and three 
follow-up visits as 1, 6 and 12 months. The SAVR clinical pathway was similar except that this group 
had 5 days in an intensive therapy unit bed, 7 days in a general ward bed. Long-term costs up to 2 
EQ5D utility scores Annual NYHA Changes 
from 2 years 
Utility decrements 
NYHA Reference % 
change 
Reference Complication Decrement Reference 
I 0.73 UK Norm  
(Kind-1999) 
-0.12 Kodali 
(2012) 
Major stroke 0.39 Solomon 
 (1994) 
II 0.63 Fairbairn  
(2012) 
 
-0.14 Kodali 
(2012) 
Vascular 
complication 
0.06 Morgan 
 (2006) 
III 0.56 Fairbairn 
 (2012) 
-0.06 Kodali (2012) Renal 
replacement 
therapy 
0.11 
 
Lee  
(2005) 
IV 0.46 Fairbairn 
 (2012) 
-0.08 Kodali (2012)    
Dead 0 N/A 40 Kodali (2012)  
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years included cost of the procedure, valve re-dos, length of hospital stay, complications and 
medication requirements. Future costs were calculated per NYHA category based on weekly care 
package and subsequent hospitalisation tariffs calculated using a previously published hospitalisation 
annual hazard per NYHA category (Caro et al., 2006).  
 
Table 5-2 Costs of TAVI and SAVR 
Unit Cost (source) 
 
TAVI SAVR 
  
Standard Procedure (NHS tariff) 
  
Procedure £16,500.00 £9,256.00 
Cardiology - Ambulatory Monitoring £25.65 £25.65 
Vascular Surgery  - Follow Up Attendance - 
Single Professional 
£120.00 NA 
CT Angio- aortic and peripheral £148.14 
 
NA 
Trans Thoracic Echo (Ultrasound) £27.64 £27.64 
Cardiology - Ultrasound Trans Oesophageal 
Echo 
£128.24 £128.24 
Cardiology – ECG £33.00 £33.00 
Chest physiotherapy £1,641.00 £1,641.00 
Cardiology follow-up attendance £113.00 £113.00 
General Ward bed day cost £280.00 £280.00 
Intensive Care Unit bed day cost £1,360.00 £1,360.00 
   
Complication unit costs (NHS Ref costs)   
Pacemaker Implant £2,886.00 £2,886.00 
TIA £1,252.00 £1,252.00 
Minor stroke £3,479.00 £3,479.00 
Major stroke £3,479.00 £3,479.00 
Myocardial Infarct £2,305.00 £2,305.00 
Vascular Complication £3,772.34 £3,772.34 
Major Bleed £3,772.00 £3,772.00 
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RR for Kidney fail £1,421.00 £1,421.00 
Endocarditis £5,261.00 £5,261.00 
Repeat Hospitalisation  £1,359.00* £1,359.00* 
   
Cost of care per NYHA category (PSSRU) 
β  
  
Dead £0.00 £0.00 
I £55.00 £55.00 
II £141.00 £141.00 
III £223.00 £223.00 
IV £626.00 £626.00 
Annual Medication costs (BNF )β    
Clopidogrel for stroke, TIA and MI £30.00 £30.00 
Secondary care anticoagulation services for 
AF 
£649.00 £649.00 
Beta Blockers for MI £19.66 £19.66 
Simvastatin £12.09 £12.09 
ACE Inhibitors for MI £14.75 £14.75 
 
*One night non-elective stay; β per person per annum  
PSSRU = personal social services research unit (Curtis, 2011) (excludes accommodation); 
BNF = British National Formulary (Britain.)  
 
5.3.4 Event probabilities 
The majority of event probabilities were taken from the PARTNER A study, Table 5-3. Due to 
variations in pacemaker implantation post-TAVI according to the valve type an average of 
probabilities was taken from previous studies to reflect mean event rates.  
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Table 5-3 Event probabilities and their reference source 
 TAVI 
 
SAVR 
 Probability Reference Probability Reference 
Procedural outcomes     
Conversion to 
SAVR/TAVI 
0.007  (Moat et al., 
2011) 
0.003 (Smith et al., 2011) 
Multiple valve (≥ 2 
implanted) 
0.02 (Smith et al., 
2011) 
0 N/A 
Intensive Care Unit bed 
days (n) 
 
0.5 LTHT 
Expert 
opinion* 
5 (Dimarakis et al., 2011, Smith et 
al., 2011) 
Coronary care bed days (n) 3 LTHT 
Expert 
opinion* 
0 LTHT 
Expert opinion* 
     
General ward bed days (n) 4 LTHT  
Expert 
opinion* 
7 (Dimarakis et al., 2011) 
LTHT 
Expert opinion*  
2 Year complications     
New Permanent 
Pacemaker 
0.15 Mean 
MCV/ESV 
0.05 (Smith et al., 2011) 
TIA 0.036 (Kodali et 
al., 2012b) 
0.020 (Kodali et al., 2012b) 
     
Stroke 0.077 (Kodali et 
al., 2012b) 
0.049 (Kodali et al., 2012b) 
Myocardial Infarction 0.004 (Kodali et 
al., 2012b) 
0.015 (Kodali et al., 2012b) 
Major Vascular 
Complication 
0.116 (Kodali et 
al., 2012b) 
0.038 (Kodali et al., 2012b) 
Major Bleed 0.19 (Kodali et 
al., 2012b) 
0.295 (Kodali et al., 2012b) 
RR for Kidney failure 0.062 (Kodali et 
al., 2012b) 
0.069 (Kodali et al., 2012b) 
Endocarditis 0.015 (Kodali et 
al., 2012b) 
0.01 (Kodali et al., 2012b) 
New Atrial Fibrillation 0.12 (Smith et al., 
2011) 
0.17 (Smith et al., 2011) 
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* LTHT = Leeds Teaching Hospitals NHS Trust; MCV = Medtronic CoreValve™; ESV = Edwards-SAPIEN™ 
 
Long-term data relating to the outcomes of TAVI patients or the longevity of the valve are not yet 
available, hence a number of assumptions were necessary: 1) The TAVI valve retains functionality for 
the lifetime of the patient. 2) Implanted pacemakers do not require replacement. 3) TAVI and SAVR 
patients are subject to the same NYHA proportional change rate after 2 years. In addition, it was also 
assumed that utility decrements associated with complications were experienced for the first 2 years 
only, as patients with serious complications are more likely to die early in the model. 
 
5.3.5 Sensitivity analyses 
Deterministic and probabilistic sensitivity analyses were conducted to evaluate the sensitivity of the 
results to the assumptions made and parameter values chosen (Maliwa et al., 2003) and to determine 
the level of uncertainty surrounding the base case estimates. Sensitivity analyses use the average 
estimates of utilities, cost and transition probabilities to test the robustness of the model. Variations in 
any of these variables can be performed in order to determine risk. Deterministic analyses utilise a set 
threshold to identify any effect upon results. Probabilistic analyses use the probability distribution of 
variables to (Monte Carlo simulations) to identify variations in results. Since the increased likelihood 
of early major stroke is a concern with the TAVI procedure, additional sensitivity analyses were run 
to explore the impact of this complication on the cost-effectiveness results.  
Hospitalisation hazard 
by NYHA 
    
I 0.26 (Caro et al., 
2006) 
  
II 0.42 (Caro et al., 
2006) 
  
III 0.79 (Caro et al., 
2006) 
  
IV 1.81 (Caro et al., 
2006) 
  
Dead 0 N/A   
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For the probabilistic sensitivity analyses (PSA), distributions for parameter values were specified and 
10,000 Monte Carlo simulations run using random draws for each parameter distribution and for each 
run incremental costs and benefits calculated, Table 5-4. The outcomes of the PARTNER A trial (the 
NYHA transitions from baseline to 2 years) were assumed to be fixed. The PSA allowed the NYHA 
lifetime changes to vary independently for TAVI and SAVR. The uncertainty surrounding the 
analyses were represented as incremental benefit and cost plots for each simulation run on a cost-
effectiveness plane. Net benefit was calculated and a cost-effectiveness acceptability curve (CEAC) 
(Fenwick et al., 2001) was generated to determine the probability that TAVI was cost-effective versus 
SAVR given a range of values of willingness to pay for an additional QALY.  
 
Table 5-4 Sensitivity analyses parameter values 
Parameter Analysis Source 
 
Costs    
Procedural costs -/+ 25% N/A 
Complication costs -/+ 25% N/A 
Weekly care costs by NYHA -/+ 25% N/A 
TAVI Length of ICU stay 2 Zahn (2010) 
TAVI tariff price £25,000 N/A 
 
Utility 
  
Alternative Utility values by NYHA   
I 0.85 Maliwa (2003)  
II 0.71 Maliwa (2003) 
III 0.57 Maliwa (2003) 
IV 0.43 Maliwa (2003) 
Complication utility decrement  +25%  
 
TAVI Event probabilities 
  
UK Registry data  Moat et al (2011) 
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TAVI extreme values (‘worst case’ scenario): 
Multiple valve  0.036 Tamburino et al (2011) 
Permanent pacemaker  0.393 Zahn et al (2011) 
Major stroke  0.1 Buellesfeld et al (2010) 
Myocardial Infarction  0.086 Gurvitch et al (2010) 
Vascular complication  0.324 Leon et al (2011) 
Major bleed 0.032 Tamburino et al (2011) 
Renal replacement for kidney failure 0.017 Leon et al (2011) 
New Atrial Fibrillation 0.0 Leon et al (2011 
   
Hospitalisation hazard rate by NYHA -/+ 25%  
Discount rate 1%/6% N/A 
 
5.4 Results 
 
5.4.1 Base case analysis 
 The NYHA proportions and mortality for the two groups over the 10-year horizon are shown as 
Figure 5-2. As the NYHA proportional changes were assumed the same across TAVI and SAVR the 
differential in costs and effects remains relatively constant after year 1 and across the model time 
horizon. TAVI ranges between £1,350 and £1,600 per patient cheaper than SAVR annually. After 
year 1 the annual QALY differences between interventions are negligible (around 0.003-0.005 in 
favour of TAVI). After Year 3 there was little difference between interventions in terms of mortality. 
By Year 10 in the simulations, 75% and 76% of the cohort were dead in the TAVI and SAVR groups, 
respectively. At 2 years TAVI was found to confer QALY gains of 0.956 compared to 0.925 provided 
by SAVR. After 10 years the average QALY gains per person were 2.81 and 2.75, respectively 
providing a modest incremental benefit for TAVI of 0.063 QALYs.  
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Figure 5-2 New York Health Association classification proportions over a 10 year horizon 
 
 
 
 
 
 
 
 
 
Procedural costs were estimated to be £19,368 for TAVI and £20,380 for SAVR. While the TAVI 
tariff was substantially more than the SAVR tariff, the surgical intervention incurred greater length of 
stay and time in intensive care which are significant drivers of cost, Figure 5-3. Complication costs 
were similar across the interventions though slightly higher in SAVR presumably due to the high 
costs associated with endocarditis and new atrial fibrillation (both more likely in SAVR). The long 
term care and hospitalisation costs over the 10 year time horizon were similar in TAVI and SAVR 
which is unsurprising as they were based on the NYHA proportions. The slightly lower long-term 
costs in SAVR may be due to the higher mortality in this group. Total 10 year per person costs, 
benefits (QALYs and life years) and the respective ICER are included in Table 5-5. The base case 
analysis figures indicate that TAVI dominates SAVR – i.e. is cheaper and more effective – over the 
time horizon.  
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Figure 5-3 Hospital and admission costs of TAVI and SAVR 
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Table 5-5 10 year deterministic and sensitivity analyses 
 Costs* QALYs ** ICER † 
 
 
Base case 
   
 
TAVI 
  
2.81 
 
Procedural and  re-do costs £19,368.32   
Complication costs (after 2 years) £2,125.14   
Annual medication costs (after 2 years) £82.63   
Long term care and re-hospitalisation costs £31,422.01   
TAVI total 10 year cost £52,593.02   
 
SAVR 
 
  
2.75 
 
Procedural and  re-do costs £20,380.03   
Complication costs £2,709.60   
Annual medication costs £113.62   
Long term care and re-hospitalisation costs £31,095.10   
 
SAVR total 10 year costs 
 
£53,943.40 
  
 
 
Incremental QALY 
 
 
 -£1,350.38 
 
 
0.063 
 
 
TAVI Dominates 
 
Life Years 4.42 4.30  
 
Incremental Life Years 
 
-£1,350.38 
 
0.13 
 
TAVI Dominates 
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Deterministic Sensitivity Analyses 
 
Incremental QALY 
 
Costs  
Incremental 
cost 
 
Incremental 
benefit 
ICER 
Procedural Costs +25% -£1,689.63 0.063 TAVI Dominates 
Procedural Costs -25% -£1,011.13 0.063 TAVI Dominates 
TAVI Tariff price £25,000 £7,294.12 0.063 £116,231.63 
TAVI Procedure costs +25% £3,393.00 0.063 £54,067.41 
TAVI Length of stay alternative values £689.62 0.063 £10,989.06 
Complication costs +25% -£1,497.51 0.063 TAVI Dominates 
Complication costs -25% -£1,203.25 0.063 TAVI Dominates 
Hospitalisation costs +25% -£1,336.36 0.063 TAVI Dominates  
Hospitalisation costs -25% -£1,364.40 0.063 TAVI Dominates  
Weekly care costs by NYHA +25% -£1,264.95 0.063 TAVI Dominates  
Weekly care costs by NYHA -25% -£1,435.81 0.063 TAVI Dominates  
    
Utility    
Alternative utility values -£1,350.38 0.066 TAVI Dominates  
Complication utility decrement +25% -£1,350.38 0.058 TAVI Dominates  
    
Event probabilities    
TAVI extreme (‘worst case’) scenario 
complication Probabilities 
£99.95 0.009 £11,307.18 
UK Registry TAVI complication Probabilities -£1,715.18 0.076 TAVI Dominates  
Hospitalisation rates by NYHA +25% -£1,336.36 0.063 TAVI Dominates  
Hospitalisation rates by NYHA -25% -£1,364.40 0.063 TAVI Dominates  
    
Other    
Time horizon = 5 years -£1,452.91 0.045 TAVI Dominates  
Discount rate 1% for costs and QALYs -£1,323.06 0.067 TAVI Dominates  
Discount rate 6% for costs and QALYs -£1,373.57 0.059 TAVI Dominates  
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TAVI = transcatheter aortic valve implantation; SAVR = surgical aortic valve implantation; NYHA = New 
York Heart Association classification. *All costs at 2011 prices;  ** Quality adjusted life years. †Incremental 
cost-effectiveness ratio 
 
  
Probabilistic sensitivity analysis – mean 
Monte Carlo simulation results 
 
 
TAVI 
 
£52,593.08 
 
2.82 
 
SAVR £54,004.89 2.75  
Incremental -£1,411.09 
 
0.066 
 
TAVI Dominates  
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5.4.2 Deterministic sensitivity and scenario analyses 
Deterministic and probabilistic sensitivity analyses are presented in Table 5-5. These suggest the base 
case results are robust to changes in input parameters, yielding similar ICERs. Only analyses where 
parameter values for one intervention changed (and the other held the same) appeared to have a 
substantive effect on the ICER value.  Thus using a worst case scenario 1 year complication 
probabilities for TAVI yielded an ICER of £11,307 – in this case TAVI is now more expensive but 
still offers incremental benefit. Increasing the TAVI procedural costs by 25% increased the ICER to 
just over £54,000. Allowing for 2 bed days in intensive care (Zahn et al., 2010) for TAVI patients 
increases the ICER to around £11,000- still below the NICE cost-effectiveness threshold. Including 3 
days of intensive care for TAVI yields an ICER of £32,660. The cost of the SAVR tariff would have 
to drop to £6,632 (ceteris paribus) or alternatively incur only around 3 intensive care bed days before 
the ICER exceeds the £20,000 threshold. TAVI tariff costs would have to be around £19,000 or 
£9,800 more expensive than the SAVR tariff, for the ICER to exceed £20,000. The alternative utility 
values did not significantly affect results, yielding slightly higher incremental benefits (0.066 vs. 
0.063) for TAVI. Reducing the time horizon to 5 years and alternating discount rates did not 
substantively affect results. 
 
TAVI remained dominant in the instance of increasing the probability of major stroke after TAVI 
(from 0.051 to 0.10) or increasing the utility decrement associated with stroke (from 0.39 to 0.70). 
Finally, if all values remain constant as per the base case, the cost of stroke would have to be 
increased to over £100,000 (from £3,479) before the ICER exceeded £20,000.  
5.4.3 Probabilistic sensitivity analyses 
Figure 5-4 is the cost-effectiveness plane plotting 10,000 incremental cost and benefit estimates from 
the Monte Carlo simulations. Most of the estimates are in the North-East and South-East quadrants 
indicating TAVI is more costly and more effective or cheaper and more effective.  
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Figure 5-4 Cost effectiveness plane TAVI versus SAVR 
 
 
 
 
 
Figure 5-5 is the cost effectiveness acceptability curve (CEAC), indicating TAVI is cost-effective 
regardless of the incremental QALY willingness to pay threshold. At the NICE threshold of £20,000 
TAVI has a 64.6% likelihood of being cost-effective, compared to 35.4% for SAVR. The mean 
incremental costs and benefits from the Monte Carlo simulations were very similar to the base case 
estimate, Table 5-5.    
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Figure 5-5 Cost-effectiveness Acceptability Curve 
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5.5 Discussion 
 
The economic analysis in this study suggests that from the UK healthcare provider perspective, TAVI 
is a cost-effective option in high-risk but operable elderly patients when compared to SAVR. Over a 
10 year horizon, the model yielded both incremental cost and QALY benefits for TAVI over SAVR. 
These results appear robust to numerous sensitivity analyses including those targeting major stroke. 
TAVI conferred only marginal quality of life benefits over SAVR with similar costs for both 
interventions. Therefore, results were sensitive to changes in costs and benefits when they occurred in 
either intervention arm in isolation. The additional device costs for TAVI appears outweighed by the 
greater length of stay cost (and intensive care stay) in the SAVR group. The probabilistic sensitivity 
analyses and CEAC suggest that TAVI is probably cost-effective regardless of the QALY willingness 
to pay threshold. 
 
The cost-effectiveness of TAVI versus medical therapy has been previously assessed in a UK 
population ineligible for surgery (Watt et al., 2012), but this analysis is the first UK study to compare 
the costs and benefits of TAVI and SAVR in a high-risk but operable AS group. The recently 
published PARTNER study cost-effectiveness analysis report a significant cost benefit at one year 
towards TF-TAVI with similarly higher procedural but lower hospitalisation costs compared to SAVR 
(Reynolds et al., 2012a). Procedural costs are likely to differ between studies (US versus UK costs) 
but health benefits (QALY’s) should remain universal. The one year incremental QALYs in both 
analyses are 0.027 supporting our model design, but this study reports lower QALY gains with TAVI. 
This may be a consequence of our combined TF and TA assessment as TA-TAVI resulted in lower 
quality adjusted life expectancy and was deemed economically unattractive in the PARTNER study. 
Another cost-analysis by Neyt et al (Neyt et al., 2012) concluded that TAVI was cost-effective in 
inoperable patients but not in high-risk operable patients. However, their conclusions are limited by a 
lack of health utility data. Doble et al (Doble et al., 2012) performed a comprehensive analysis of 
TAVI versus medical and surgical therapy concluding that TAVI may not be cost-effective compared 
to SAVR over a 20 year horizon. This observation was determined predominantly by the higher 
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procedural costs of TAVI. However, their SAVR costs were estimated using a lower risk, 70 year-old 
population rather than the older, higher risk population in this study and that of PARTNER. In 
addition there is no mention of the length or cost of hospital stay, a major driver in our own cost 
analysis. This study has shown that despite a greater procedural cost, TAVI remained cost-effective 
compared to SAVR due to lower post-procedural costs (length and cost of hospital stay). Our TAVI 
group had a mean ICU stay of 0.5 days and 3 further days in a coronary care unit. In the PARTNER A 
study there was a median ICU stay of 3 days reflective of US practice. If outcomes are in part a 
function of the intensity of care received, it is possible we overestimated outcomes or underestimated 
the costs for TAVI depending upon individual practice and national guidance. However, including 2.4 
days of intensive care for TAVI patients in this analysis still yields an ICER below £20,000. 
Additionally, the ICU stay post-SAVR in PARTNER A may be considered longer than is ‘normal’ for 
a standard SAVR post-operative recovery. The nature of high-risk cardiothoracic surgery in this older 
age group with a number of associated co-morbidities, results in a longer ICU and over-all hospital 
stay, thus driving up costs (Dimarakis et al., 2011). This study used the UK TAVI tariff as an average 
national procedural cost with sensitivity analysis to allow for variations which may occur locally. 
Transcatheter device costs are of particular concern as a driver of high procedural costs. Our results 
suggest that TAVI is no longer cost-effective when device costs rise above £19,000 (when the QALY 
gain willingness to pay threshold is £20,000).   
 
Post-TAVI we predicted no valve re-do’s after 12 months and that the integrity of valves were 
maintained for the model time horizon. Thus our results would be sensitive to any future evidence 
suggesting differential rates of valve failure and re-do procedures between SAVR and TAVI. Due to 
the uncertainties of long-term data, our model time horizon was performed at a conservative 10 years 
rather than a lifetime model. In their lifetime comparison of TAVI vs. standard medical therapy, 
Reynolds et al (Reynolds et al., 2012b) found significant cost benefits of TAVI within the first year, 
which were subsequently lost over long term follow-up due to the burden of incurred costs over an 
extended life time in an elderly population. This issue may not apply in a younger population with 
less co-morbidity, as studies have demonstrated that most long-term deaths post-TAVI are non-
cardiac in origin (Buellesfeld et al., 2011, Tamburino et al., 2011, Zahn et al., 2011). However, the 
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shorter timeframe of the model and uncertainty in terms of outcomes, device longevity and need for 
future valve replacements post-TAVI, mean that extrapolation of our findings to a younger-lower risk 
age group remains difficult. Stroke is a significant clinical concern post-TAVI (Smith et al., 2011). As 
a major contributor to hospital and social care costs, (Luengo-Fernandez et al., 2009) stroke could 
additionally impact upon the cost-effectiveness of the TAVI procedure. However, our analysis 
suggests that TAVI still dominates SAVR in cost-effectiveness even in the presence of a doubling of 
the stroke rate. This finding is reassuring, particularly when considering the latest evidence from 
PARTNER which suggests that the 2 year stroke rate is not significantly different between TAVI and 
SAVR. 
 
Our findings offer a perspective based on UK clinical practice, costs and local health utility values. 
The results provide useful information to local health care commissioning agencies and national 
policy makers regarding the relative cost-effectiveness of TAVI and SAVR in elderly high-risk 
patients. The clinical effectiveness of TAVI has been demonstrated in the PARTNER A trial; our 
study provides additional evidence that compared to SAVR, TAVI is likely to be a cost-effective 
approach in an elderly high-risk AS population.  
There is a clear requirement for longer term outcome data in TAVI patients. Such data will become 
available as the TAVI procedure becomes more common in clinical practice and large data registries 
are published. Avenues for future research in health economics include the employment of the value 
of information framework and the calculation of total decision uncertainty (expected value of perfect 
information) (Brennan et al., 2007) for parameters and samples. This information will help identify 
the parameters that are driving economic decision uncertainty and guide future research and trial 
planning.  
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5.6 Limitations 
 
As TAVI is a relatively new procedure there are limited data available to populate the decision model. 
Hence a number of assumptions were necessary which increase the level of uncertainty in the results. 
However, sensitivity analyses suggest our results are relatively unaffected by changes in parameter 
values.  
Whilst we have based costs on the UK care pathway for this population we have based the benefits on 
US data (PARTNER A). The PARTNER A trial employed both transapical and transfemoral 
implantation approaches but only the Edward Sapien device was used. Reliance on the PARTNER A 
study efficacy data may limit extrapolation of our findings outside of the studies recruitment criteria, 
in particular related to the Medtronic CoreValve system. In addition the PARTNER A cost-
effectiveness study report a 0.068 QALY gain with TF-TAVI, but 0.070 loss with TA-TAVI. This 
suggests a potential weakness in our methodology of reporting an average cost-effectiveness despite 
the use of deterministic and probabilistic sensitivity analyses. Future research should explore the 
differential cost-effectiveness of transapical and transfemoral approaches in the UK. 
 
5.7 Conclusions 
 
With any new treatment, the medical community must ask first if it is safe and clinically effective and 
secondly if it is cost-effective. In comparison to the accepted reference standard treatment SAVR, 
TAVI appears likely to be cost-effective in a high-risk elderly population. TAVI was cheaper and 
more effective than SAVR according to the base case analysis. Sensitivity analysis using the NICE 
threshold of £20,000 showed TAVI to have a 64.6% likelihood of being cost-effective, compared to 
35.4% for SAVR. Whilst the findings cannot be extended to other populations of different age or 
surgical risk, the evidence provided should help clinicians and commissioning groups in future 
decision making policies and resource allocation. 
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6 Final Discussion 
 
 
In the near future the United Kindgom is set to experience an AS epidemic (Berry et al., 2013). 
Demographic changes in the population indicate that this disease is set to pose an increasing challenge 
to clinicians managing valvular heart disease and represent a greater burden on the health care system 
(Nkomo et al., 2006). SAVR remains an excellent operation, delivering good prognostic and quality 
of life benefits. However, the real world situation exposed by the European heart survey (Iung, 2005) 
highlighted the need for an alternative. Since its inception TAVI has rapidly become the alternative 
treatment of choice for the inoperable patient and those at high operative risk. It has been shown to be 
a procedural success and significantly improves the survival and quality of life of a patient. Its 
benefits over medical therapy are substantial, with comparable results compared to SAVR in high-risk 
patients. Despite significant progress, TAVI remains a new technology only recently practised. Due to 
the high-risk nature of the procedure, limited resources and substantial associated costs, TAVI is 
unlikely to be a suitable treatment for all high-risk patients. Additionally, the usefulness of TAVI in 
an intermediate risk population is yet to be proven. Evidence that can guide patient selection and thus 
clinical practice will be essential to fundamentally establish the role of TAVI in the treatment of 
severe symptomatic AS.   
This thesis advances the practice of TAVI by contributing original evidence of the clinical and cost-
effectiveness of the procedure from the perspective of the patient as well as the health care provider. It 
comprehensively assesses several of the key areas of research as recommended by the international 
VARC (Kappetein et al., 2012b). However, there remain areas of research that were not possible to 
explore during the time of this thesis, yet they are relevant to our conclusions and merit inclusion in 
the final discussion.        
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6.1 Haemodynamics 
 
6.1.1 Reverse remodelling 
The unique attributes of MRI allowed us to assess ventricular reverse remodelling in the context of 
changes in valvular function, myocardial infarct and fibrosis. Post TAVI we have demonstrated that 
significant reverse remodelling of the left ventricle occurs due to reduced ventricular wall stress 
following a significant decrease in valvular pressure gradient and valvulo-arterial impedance. Our 
data are consistent with the available published echocardiography data (Clavel et al., 2009, Ewe et al., 
2010, Hahn et al., 2013), but do not rely upon the geometric assumptions inherent with the technique 
of echocardiography. As an appropriately powered study using the ‘gold standard’ technique, our data 
provide the most robust evidence to date of the haemodynamic benefits of TAVI. One recently 
published manuscript also used the technique of CMR to examine the changes in LV mass and 
volumes, 6 months following TAVI (La Manna et al., 2013). They observed similar levels of LV mass 
reduction and geometric changes (reduced LV mass/volume ratio), but did not demonstrate any 
change in volumes or function. This finding is in contrast to our own observations and those of the 
echocardiography studies. It also represents a disparity to the reverse remodelling effects established 
in the SAVR literature (Sandstede et al., 2000). The authors conclude that this may represent a 
difference in reverse remodelling processes between the procedures, but accept the limitation of a lack 
of surgical comparator group. Their conclusions are further limited by a lack of valvular 
haemodynamic data, nor do they assess the effects of myocardial fibrosis and scar. Comparing our 
two studies reveals differences in the TAVI population baseline characteristics. Our patient group had 
greater pre-procedural volumes (EDVi 94±18 ml/m
2
 vs. 87±35 ml/m
2
; ESVi 46±18 ml/m
2
 vs. 
34±29ml/m
2
), poorer function (EF 52±12% vs. 64±15%) and thus in all likelihood a greater severity 
of AS. As demonstrated by the results of our linear regression analyses the potential for reverse 
remodelling is greater in the instances of more advanced remodelling, providing a possible 
explanation for any differences observed.    
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6.1.1.1 Early versus late reverse remodelling 
A potential drawback in the design of our valve haemodynamics and ventricular reverse remodelling 
study was the limitation of imaging time points to baseline and 6 months. Conclusions regarding early 
and late changes in valvular and ventricular function are therefore restricted. However, we do know 
from echocardiography studies that post TAVI there is an immediate reduction in valvular pressure 
gradient and wall thickness (< 1 week) (Clavel et al., 2009), with changes in ventricular volumes 
occurring later (6 months – 2 years) (Hahn et al., 2013). In comparison following surgery, cavity 
volumes and SV are immediately reduced with no change in EF and late changes in RWT (Hahn et 
al., 2013). These echocardiographic findings appear to substantiate our own observations and 
contribute towards any conclusions. The immediate improvement in transvalvular pressure gradient 
and a lower incidence of patient prosthesis mismatch post TAVI results in a rapid decline in wall 
stress and ventricular workload (Clavel et al., 2009, Hahn et al., 2013, Kodali et al., 2012b). As a 
consequence ventricular twist and torsion are expected to improve early. Speckle tracking 
echocardiography studies have confirmed this in a small number of patients (Schueler et al., 2012, 
Delgado et al., 2013) but no comparison has been made to SAVR. Our results suggest that the earlier 
pressure reduction and greater AVA post TAVI has subtle but sustained benefits on LV wall thickness 
and thickening and potentially in strain and torsion compared to SAVR at 6 months. The difference 
may not be sustained in the long term (≥2 years) as the early advantage of TAVI is lessened with 
time. This subject matter needs further research, using a more accurate method of analysis (speckle 
tracking echocardiography or myocardial tagging study) to compare the effects of TAVI against 
SAVR.  
6.1.1.2 Reduced Ejection Fraction 
A major factor in the refusal of patients for surgical AVR was found to be a reduced EF (Iung, 2003). 
This is an area of particular concern, given the higher percentage of TAVI patients with a reduced EF 
and the uncertain nature of reverse remodelling in the impaired ventricle. The evidence from our work 
suggests that reduced EF does not by itself imply reduced capacity to reverse remodel post surgical or 
transcatheter aortic valve replacement. Indeed the individuals with the greatest change from baseline 
were those with the lowest function. Rather it is the percentage of myocardial scar and reduced 
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viability which influence inferior reverse remodelling. Evidence is beginning to indicate a specific 
role for TAVI in the severe AS patient with a reduced EF, as the reverse remodelling outcomes appear 
superior when compared to SAVR (Clavel et al., 2010, Bauer et al., 2013). The improved outcomes 
post-TAVI in this group may be related to the associated co-morbidities and risk factors, as our 
evidence suggests either procedure is a viable option and that the important factor is the assessment of 
scar burden. As TAVI expands identifying who is not a suitable candidate may become a more 
relevant issue than who is fit for intervention. CMR could thus be useful in aiding future patient 
selection.       
6.1.2 Coronary Artery Disease 
Given the prevalence of CAD in severe AS (25-50%) (Kvidal et al., 2000) substantial interest has 
been generated concerning the clinical impact and significance of CAD post TAVI. This question 
remains unanswered by PARTNER as patients with significant non-revascularised CAD were 
excluded from the study. The importance of CAD in the SAVR population is better recognised. 
Whilst CABG increases the surgical and mortality risk in the short term, non-revascularised CAD 
detrimentally effects long-term outcomes (Lund et al., 1990). Non-randomised TAVI studies suggest 
there is no significant effect of CAD upon procedural outcomes or early death (Thomas et al., 2011, 
Rodes-Cabau et al., 2010). We identified the adverse effects of significant CAD (>50% degree 
stenosis) in the reverse remodelling process post TAVI and SAVR, independent of the drop in 
valvuloarterial impedance. This adverse relationship was related to the amount (g and %) of 
myocardial infarct and associated viability of the ventricle as the main determinant of reduced reverse 
remodelling. This evidence is supported by the inferior long-term outcomes of patients with CAD 
described post TAVI (Masson et al., 2010, Dewey et al., 2010). Individuals with concomitant CAD 
(>50%) suffer from increased cardiac mortality, and lower ventricular EF improvement 9 months 
following TAVI (Rodes-Cabau et al., 2011b).   
The incidence and consequences of new peri-procedural myocardial infarct is still uncertain, as 
markers of myocardial damage are frequently elevated with little consensus or uniformity amongst the 
studies (Goel et al., 2013). VARC have attempted to clarify this matter by recommending a 
standardised definition of MI post TAVI, but results are still pending (Kappetein et al., 2012b). In a 
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small population, using the technique of LGE we established that the incidence of peri-procedural 
infarct is small post-TAVI and SAVR and has no clinical significance on reverse remodelling.       
Managing TAVI patients with significant CAD therefore remains a conundrum. If the presence of 
CAD is a marker of worse outcomes it raises the question, ‘should these patients be revascularised’? 
As of yet no evidence exists to suggest revascularisation of significant CAD provides protection 
against peri-operative MI or improved clinical outcomes (Rodes-Cabau et al., 2010). The 
appropriateness of PCI, its timing and type of stent is therefore still an unanswered question. 
Nevertheless, staged PCI revascularisation is occurring, in particular in instances of proximal CAD 
with a suspected high ischaemic burden. This is believed to minimise the risk of infarct and instability 
during TAVI, whilst limiting the contrast dose. Randomised controlled trials (ACTIVATION, 
SURTAVI and PARTNER 2) will go some way towards answering these questions, but CMR could 
play a pivotal role in any future research surrounding this topic. Adenosine stress CMR can identify 
myocardial ischemia and viability as pre-operative adverse markers, assisting in the management of 
CAD pre-TAVI and aiding patient selection. In addition, it could be used to assess reverse 
remodelling as a clinical endpoint.   
 
6.1.3 Patient survival  
This thesis concentrated on assessing post-operative functional cardiac recovery as a clinical endpoint. 
We did not explore the impact of haemodynamic measurements on other clinical outcomes, in 
particular patient prognosis. Although mortality was not a primary outcome measure the available 
literature suggests our study findings have relevance to patient survival, specifically in relation to the 
severity of post-operative AR.  
6.1.3.1 Aortic Regurgitation 
 Several studies have identified post-TAVI AR as an important predictor of increased mortality 
(Kodali et al., 2012b, Gotzmann et al., 2012a, Toggweiler et al., 2013, Moat et al., 2011, Gilard et al., 
2012). A majority of patients appear to have some degree of AR post-TAVI compared to very little 
post SAVR (Abdel-Wahab et al., 2011). Trivial or mild AR has no significant consequence on either 
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reverse remodelling or survival. Moderate to severe regurgitation is however independently associated 
with a reduced patient survival (Tamburino et al., 2011). The paravalvular nature of regurgitation 
makes the accurate grading of total AR technically challenging but important in order to gage 
procedural success and predict patient outcomes. Angiographic (Sellers criteria) and haemodynamic 
(AR index) assessments are useful and have some predictive capacity (Sinning et al., 2012), but are 
subject to significant variability and dependent upon external factors such as the use of ionotropes or 
the presence of a catheter across the heart valve (Sinning et al., 2013). Echocardiography and in 
particular TOE are used most frequently to determine the severity of AR. However, conventional 
semi-quantitative methods of grading AR do not apply in paravalvular AR, as the jet is not central but 
annular and eccentric. Quantitative assessment of total AR may represent a more precise method of 
assessing AR and the associated risk. CMR phase contrast imaging allows the quantification of total 
AR (regurgitant %) with greater accuracy and reproducibility when compared to echocardiography. 
Our study and that of Sherif et al unequivocally prove that this technique can be applied in a TAVI 
population (Sherif et al., 2011, Fairbairn et al., 2013). Whether this can then be used to provide 
prognostic data still needs to be established. The implications of post-operative AR have heralded an 
increase in the pre-operative multi-modality assessment of the patients’ aortic root in order to 
minimise the risk of developing this complication. 
6.1.3.2 Aortic Root assessment 
The prevention of post operative AR is therefore vital to improve patient survival. The causes of 
paravalvular regurgitation are believed to be predominantly due to mal positioning, under 
deployment, or under sizing of the device (Takagi et al., 2011). Severe aortic valve calcification is 
also thought to be implicated. Non-invasive imaging techniques are being increasingly used to 
provide detailed information about the size of the aortic root and burden of calcification. 2D TOE has 
traditionally been the imaging technique used to assess the size of the aortic root and degree of 
paravalvular regurgitation. However, the aortic route is frequently oval shaped and TOE 
underestimates the annular size and quantity of AR. 3D TOE improves the accuracy of these 
measurements but is still limited by low volume rates (Jilaihawi et al., 2013). Multislice computed 
tomography has developed as the ‘gold standard’ technique for preoperative aortic root assessment. 
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The aortic root can be assessed at multiple planes and levels with substantial evidence supporting its 
utility in predicting and reducing AR (Jilaihawi et al., 2012, Willson et al., 2012).  The anatomic 
detail afforded by CT is excellent but the functional information is limited. In comparison, CMR has 
been shown to be as accurate as CT in the anatomic assessment of the aortic annulus using multislice, 
multiplanar SSFP imaging and has the additional benefit of providing functional detail, in particular 
total AR (Jabbour et al., 2011).  This is undoubtedly an issue that could and should be answered in 
any future TAVI CMR research.   
 
6.2 Stroke 
 
In our assessment of cerebral embolic infarcts following TAVI we established the incidence cerebral 
infarcts and identified age and aortic atheroma as independent risk factors. To date this remains the 
only published data in the literature to establish risk factors for the number and volume of cerebral 
infarcts and therefore stroke. Limitations of our study include; the inability to establish the timing of 
embolisation and the failure to include TAVI patients with transapical access. Nor did we have a 
surgical comparator group. Furthermore, cerebral protection devices were not available at the time 
and were thus not trialled. Finally, whilst examining the effects on quality of life no detailed cognitive 
assessment was made. These factors are important to consider given the 5% risk of stroke following 
TAVI and the significant co-morbidity and mortality associated with the condition.        
 
6.2.1 Transfemoral versus Transapical route 
The mechanism of cerebral emboli during TAVI is thought to be secondary to bulky catheter devices 
dislodging aortic atheroma whilst moving around the aorta and releasing calcific debris whilst 
crossing the aortic valve. This theory was developed from previously established evidence concerning 
conventional stroke risk factors (Di Tullio et al., 2009), (Russo et al., 2009) and studies involving 
cardiac catheterisation (Lund et al., 2005, Busing et al., 2005). The relationship of aortic atheroma 
severity to the number of cerebral infarcts identified in our research would support this mechanism of 
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action. The TA access route could therefore be expected to result in a lower rate of infarcts and hence 
stroke, given the reduction in the number of catheters moving around the aorta and avoidance of the 
retrograde crossing of the aortic valve (Himbert et al., 2009). Two studies have examined this subject 
and have discovered no difference in the number of new infarcts between TF and TA TAVI (Rodes-
Cabau et al., 2011a, Astarci et al., 2011). The explanation provided for this unexpected observation 
was that cerebral emboli are in fact a consequence of microbubbles developed during the exchange of 
cardiac catheters. The incidence of cerebral emboli would therefore not differ between the two 
approaches, particularly as the TA approach requires a large 24F sheath to be inserted into the LV and 
the exchange of multiple catheters. They support this statement by demonstrating no relationship of 
aortic atheroma or calcification to the number of infarcts, in contrast to the findings of our own study. 
Whilst air embolism may contribute to the mechanism of cerebral infarcts both studies failed to prove 
the timing of emboli corresponding with the exchange of catheters. They also do not acknowledge 
that during both procedures stiff wires, balloons and valvular devices are moved across the valve and 
into the ascending aorta and around the arch.  
 
6.2.2 Transcranial Doppler and the timing of embolisation 
The timing of embolisation is thus important to help identify the aetiology of cerebral infarcts, 
determine associated risk factors and aid preventative measures. Transcranial Doppler can detect the 
occurrence of cerebral high intensity transient signals (HITS) and is used in standard practice during 
carotid endarterectomy (Koennecke et al., 1998). Two studies have identified several stages of 
cerebral embolisation or HITS separated into: (1) Passage of the wire across the valve (antegrade or 
retrograde), (2) Passage of the super stiff wire into the LV apex (TF) or descending aorta (TA), (3) 
introduction of the balloon, (4) valvuloplasty, (5) introduction and positioning of the stent valve, (6) 
valve implantation. HITS were observed in all patients at all stages with no overall difference noticed 
between the procedural routes (TF and TA) or valve type (THV vs. MCV) (Kahlert et al., 2012, 
Erdoes et al., 2012). The greatest number of HITS was observed during valve positioning and 
deployment for both valves via both routes. These peak events corresponded with the longest phase of 
valve manipulation in the aorta and against the valve. The peak HITS with THV replacement occurred 
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during valve positioning, which is time consuming but once in place is quick to deploy. In contrast the 
MCV, which is quick to position but slow to deploy had the greatest number of HITS during valve 
deployment.  
 
6.2.3 Clinical outcomes 
Whilst it is not possible to define the nature of any microbubbles identified during HITS (solid 
material or air emboli), the collective evidence clearly suggests the predominant cause of cerebral 
emboli is the manipulation of bulky valves against the atheromatous and calcified valve and 
ascending aorta (Fairbairn et al., 2011, Kahlert et al., 2010, Kahlert et al., 2012, Ghanem et al., 2010, 
Rodes-Cabau et al., 2011a). This process is to a point unavoidable, therefore the information may be 
most useful in identifying risk factors to assist in patient selection and when to use new embolic 
protection devices (Onsea et al., 2012, Naber et al., 2012).  The advantages and clinical application of 
these embolic protection devices in a TAVI population still needs to be verified using DW-MRI in 
randomised controlled studies.  
If prevention is not possible then a clear understanding of the consequences of cerebral emboli needs 
to be developed. Our study and others have established that stroke whilst the main complication of 
these emboli, is still a relatively infrequent one. Clinically ‘silent’ emboli on the other hand occur in 
66-93% of TAVI patients. These markers of acute cerebral ischaemia have been shown to be 
associated with long-term neurocognitive decline and dementia in non-TAVI populations (Yoshitake 
et al., 1995) and post cardiac surgery (Knipp et al., 2005). Having determined the clinical impact of 
cerebral emboli on short-term HRQOL we were unable to assess the impact upon complex cognitive 
function. Subsequently, one study has investigated cognitive function after TA-TAVI (Knipp et al., 
2013). Using 5 cognitive domains (short term memory, working memory, delayed recognition, verbal 
learning and verbal fluency) they found no evidence of cognitive decline 3 months post TAVI. This 
single centre study is limited by a small study population (n=27) and the lack of long-term data, but it 
does suggest that cerebral emboli may not herald cognitive decline. Neurocognitive decline post-
TAVI is a topic that will become increasingly important and relevant as the procedure is used in a 
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lower risk and younger population. Future research in this subject field will need to concentrate on 
long-term follow up data and comparisons to a matched surgical population.  
 
6.3 Quality of Life 
 
Quality of life is a particularly important clinical outcome measure in an elderly, frail TAVI 
population where the quality rather than quantity of life attained becomes more relevant. Our research 
established the improvement in HRQOL post-TAVI, its time course and identified patient and 
procedural predictors of improvement. The discovery of age, gender and operator experience as 
predictors of improvement in HRQOL post-TAVI will be used to greater inform patients of 
procedural outcomes and guide clinicians in deciding which patients are likely to benefit from the 
procedure.  
A pattern of improvement sustained over one year observed in our study has been confirmed in 
several subsequent HRQOL studies (Reynolds et al., 2011, Grimaldi et al., 2012, Krane et al., 2012, 
Reynolds et al., 2012c). These studies also highlighted the temporal changes of early (30 days) benefit 
with a minor 6-month decline then further improvement to 1 year. One study has described quality of 
life maintained out to 2 years (Taramasso et al., 2012). Evidence with a longer follow up period is 
necessary in order to have a full understanding of the impact on HRQOL. This data is being collected 
and should be disclosed in time. The choice of generic SF-12 and EQ5D questionnaires has been 
endorsed by VARC as an appropriate assessment tool in an AS population (Kappetein et al., 2012b). 
Alternative quality of life questionnaires have been trialled (Kansas city cardiomyopathy 
questionnaire and the Minnesota living with heart failure questionnaire) with similar results observed 
(Arnold et al., 2013). However, these questionnaires are disadvantaged by an inability to provide 
health economic outcome data.  
Our study was limited by a lack of either a TA-TAVI group or a matched SAVR group. Recent 
evidence suggests that the TA-TAVI approach should be considered separately, as it is performed at a 
greater cost in terms of lower HRQOL benefit, increased complications and a greater length of 
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hospital stay (Reynolds et al., 2012c). This may reflect the higher risk nature of this sub-group as 
testified by their higher calculated risk scores (STS or logistic EuroSCORE) and increased frequency 
of vascular disease (PVD and CVA). Reynolds et al separated TA and TF-TAVI and evaluated them 
against SAVR. The early (30 day) HRQOL scores improved more substantially post TF-TAVI 
compared to either the TA route or SAVR. This finding corresponds with the earlier haemodynamic 
changes observed in TF-TAVI trials.  Impaired early LV reverse remodelling, greater post-operative 
pain and increased vascular complications post TA-TAVI and SAVR may in part explain the lower 
HRQOL improvement. This difference in ‘physical’ improvement is further supported by 6-minute 
walk test distance scores post TAVI compared to SAVR (Gotzmann et al., 2011). Regarding mental 
health there appears uniform agreement between the studies and investigators that TAVI (TF or TA) 
and SAVR have no significant impact upon mental health (depression or anxiety) at any time point 
over a 2 year period.  
HRQOL data is utilised to determine the cost-effectiveness of a medical intervention in health 
economic studies. The differences observed in quality of life following TAVI (TF and TA) and SAVR 
could imply altered cost-effectiveness of these procedures.     
 
6.4 Health economics 
 
6.4.1 Background 
Having established the procedural success and mortality advantages of TAVI over medical therapy 
the number of procedures performed grew rapidly, particularly in Europe. Whilst UK numbers were 
significantly fewer than other European countries such as Germany, an increase in the demand for 
TAVI was developing alongside an increase in the number of patients being referred for SAVR. This 
reflects the increasing prevalence of a disease in an ageing population but is also a consequence of 
more patients being identified as potentially treatable whom previously may not have been 
considered. TAVI has significant health benefits for the affected individual but places a substantial 
cost burden on national health economies and thus society at large. In the UK the procedure was 
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therefore restricted to a certain number of procedures per head of population in nominated ‘high 
volume’ centres. An urgent demand for health economic data supporting the cost-effectiveness of this 
new procedure was stated by the department of health, clinicians and NICE (NICE, 2012). Cost-
effectiveness analyses (CEA) determine to what degree a medical intervention improves clinical 
outcomes compared to the best alternative treatment available in the context of the relative costs of 
the interventions. Health outcomes are normally reported as QALY’s. The ICER is a cost-benefit 
ratio, where the difference in health benefit (QALY) between two treatments is divided by their cost 
differential. Unlike a cost-benefit assessment, CEA do not assign a specific monetary value to a health 
outcome. As such no clearly defined threshold exists where a procedure becomes not cost-effective. 
The willingness to pay (WTP) for a procedure is therefore somewhat dependent upon the healthcare 
system/provider and the perspective of society at large. WTP is frequently interpreted in comparison 
to commonly accepted medical interventions. The US uses a WTP threshold of <$50,000 per QALY 
based on the assumed costs of annual renal dialysis, as an intervention that is universally covered for 
by the US Medicare insurance system. The UK NICE set a cost-effectiveness threshold of £20,000 per 
QALY. This acts as a guide to national commissioning groups but is not an absolute benchmark, as 
variations in local policy do occur.  
 
6.4.2 Cost-effectiveness of TAVI versus medical therapy 
Initial CEA concentrated on evaluating TAVI compared to the previously used treatment for 
‘inoperable’ individuals, medical therapy (Watt et al., 2012, Reynolds et al., 2012b, Simons et al., 
2013). These studies established the greater early cost of TAVI, predominantly due to cost of devices 
and the length of hospital stay. However, TAVI resulted in significantly greater QALY gains versus 
medical therapy (0.7-1.56) over a 10-year period (Watt et al., 2012) and lifetime horizon (Reynolds et 
al., 2012b, Simons et al., 2013). The PARTNER cohort B CEA (Reynolds et al., 2012b) estimated 
added life years of 1.9 and improved quality of life by TAVI compared to medical therapy. The initial 
cost of the procedure was therefore partially offset by lower rates of subsequent hospitalization in the 
TAVI group. Interestingly however they also observed that due to the increase in life expectancy the 
lifetime costs of this elderly group were overall greater. This resulted in an ICER of $50,212 per life 
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year gained, with the authors concluding that TAVI was probably cost-effective and certainly within 
the accepted range for other cardiovascular therapies. The UK study by Watt et al (Watt et al., 2012) 
modelled their study on the PARTNER B data and similarly found TAVI to be a cost-effective 
alternative with an ICER of £16,200.  
Considerable concern persisted about the validity of these CEA projections, given the changing nature 
of the TAVI procedure, in particular the reduced early complications but uncertain long-term survival 
benefit. Simons et al designed a piecewise exponential markov model using a hypothetical AS 
population to look at how variations in patient, procedural and healthcare costs affected the cost-
effectiveness of TAVI versus medical management (Simons et al., 2013). The higher base case costs 
and lower health benefits modelled in their analysis are open to criticism (Reynolds and Cohen, 
2013), but their analysis did once more raise the issue of additional long-term healthcare costs in the 
TAVI group due to increased survival. They modelled several clinical instances where the CEA was 
prohibitive, concluding that the underlying health status and co-morbidities of the patient were more 
significant drivers of future cost-effectiveness compared to variations in procedural costs, or patient 
survival. TAVI was therefore less cost-effective in individuals with greater co-morbidties and 
healthcare dependency than for a healthier population, such as those patients deemed suitable for 
SAVR. 
 
6.4.3 Cost-effectiveness of TAVI versus SAVR 
Our research sought to answer the question of cost-effectiveness in a high-risk but operable group by 
comparing TAVI to the ‘gold-standard’ available treatment, SAVR. It remains the only UK study to 
report health economic data for this type of population, although other international studies have 
subsequently been published. The markov model design of our study is similar to that of Watt et al in 
their comparison to medical therapy, but was based predominantly on the health outcomes of the 
PARTNER A study. Uniquely, health benefit outcomes were modelled on UK quality of life data 
(chapter 4) and the costs were based on a UK national tariff. An ICER of £20,158 suggests with high 
probability that TAVI is a cost-effective alternative to SAVR in a high-risk but operable AS 
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population. The health benefit data of our study closely matches those reported by Reynolds et al in 
their PARTNER A CEA (Reynolds et al., 2012a). Remarkably, despite using different costing data to 
reflect variations in national practice the two studies report a similar pattern of costs distribution. The 
greater device cost of TAVI compared to the surgical valve was offset by a greater length and cost of 
hospital say following surgery, in particular the ICU cost. The health benefits (HRQOL) achieved in 
our study were similar between procedural groups as per the PARTNER A evidence. Long-term 
health care costs were also similar between the TAVI and SAVR groups, but were on average lower 
than was observed in the inflated US healthcare system. An accepted limitation of our study was the 
‘averaging’ of health outcomes for both TAVI devices and procedural routes (TF versus TA). We 
performed this type of analysis in order to present data that would closely reflect current UK clinical 
practice. The PARTNER study group by performing sub-group analysis demonstrated lower health 
benefits post TA-TAVI compared to TF-TAVI or SAVR. As the CEA was dependent upon small 
variations in either health outcomes or costs, it is likely that we have overestimated the cost-
effectiveness of TA-TAVI and underestimated that of TF-TAVI. 
 
6.4.4 Future economic analysis 
Health economic analyses can be as precarious as forecasting the weather or the national economy. 
Variations in the design of an economic model and input characteristics mean that a range of opinions 
and values are reported. The continued reappraisal of the cost-effectiveness of a technology such as 
TAVI is necessary, particularly as data are released concerning developments in device technology, 
improved health outcomes and long-term results. Any medical intervention that extends life is 
unlikely to be a truly ‘cost-effective’ option. However, TAVI represents a significant medical 
advance, which on the basis of evidence from several studies including our own does appear to be 
affordable. Whether this affordability is deemed acceptable or justified will be dependent upon the 
view of health care commissioners who are responsible for balancing the various needs of the local 
population and the societal WTP. TAVI will not be a cost-effective option in everyone. Identifying 
those individuals in whom TAVI is least beneficial or particularly advantageous, will in all probability 
allow the selection of the most cost-effective option. As the role of TAVI expands in to an 
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intermediate risk population the clinical effectiveness may improve (Piazza et al., 2013, Wenaweser et 
al., 2013), altering the cost-effectiveness of the procedure. Evidence towards improved outcomes, 
reduced complications and device longevity will reduce the overall cost of TAVI in this lower risk 
group. Yet the cost of the procedure would remain significant given the high price of the transcatheter 
device compared to surgical valves. It may prove to be a less favourable option compared to SAVR if 
the post surgical hospital stay is less protracted in this population (Osnabrugge et al., 2012).   
 
6.5 Conclusion 
 
This thesis provides original evidence supporting the clinical and cost effectiveness of TAVI. We 
have compared TAVI to the gold standard treatment for symptomatic severe AS, SAVR and found it 
to be equivalent. In establishing the haemodynamic changes that take place post-TAVI we identified 
the foundation of future clinical improvement, which was confirmed by the change in quality of life. 
TAVI significantly improves clinical outcomes for the majority of appropriately selected individuals, 
as demonstrated by this research and that of others. A theme of this research has been the 
identification of patient and procedural markers of superior clinical outcome and potential 
complications. This information should aid the clinician and patient in deciding whether TAVI is the 
most appropriate and favourable treatment option and help society assess its affordability.  
 
6.5.1 Future Direction 
  
Many questions remain unanswered concerning TAVI, Ongoing trials (including the UK TAVI trial) 
will address many of the issues, in particular the management of concomitant CAD and the role of 
TAVI in a younger, healthier, intermediate risk AS population.  
This thesis identified several areas of interest. Whilst successfully addressing all of these topics our 
results did highlight additional questions pertaining to the clinical benefits and costs of TAVI that 
were not possible to answer during the time of this thesis. Having assessed gross myocardial function 
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and reverse remodelling, we aim to measure subtle markers of myocardial function (strain and 
torsion) using the myocardial tagging (CSPAMM) data acquired during the cardiac MRI. A 
comparison of the effects of TAVI versus SAVR will be possible, to determine whether the greater 
reduction in valvuloarterial impedance post TAVI translates into a difference in myocardial strain and 
torsion following the procedures. This information may also help identify individuals at greater pre-
operative risk, who appear to have a normal functioning ventricle but actually have markedly 
abnormal torsion and strain. This has the potential to act as a more sensitive clinical outcome end 
point, as the absence of change in EF does not necessarily mean a lack of improved myocardial 
function. There is also the prospect of combining myocardial strain data in a risk stratification model 
of asymptomatic AS patients in order to aid clinicians in deciding the timing of any AVR.  
This study has highlighted the ability of cardiac MRI through its multi-parametric approach to 
identify markers of adverse outcome in AS (valvular function, LV remodelling and MF) and act as a 
measure of clinical outcomes. These factors are not just important in the high-risk TAVI sub-group 
but in all AS patients. Considerable difficulties exist for clinicians and patients in deciding when the 
right time to operate is. This is particularly relevant in the severe asymptomatic AS group where some 
patients ventricles decompensate despite the absence of symptoms (McCann et al., 2011). Standard 
tools of assessment including exercise testing, β-natriuretic peptide and echocardiography have 
proved ineffective at risk stratifying this group of individuals (Dal-Bianco et al., 2008, Das et al., 
2005, Vahanian et al., 2012). Our study was insufficiently big enough to address this issue and 
involved a high-risk AS sub-group. However, it did identify several areas of possible future research 
using CMR. In collaboration with other centres we aim to determine the ability of CMR to predict 
clinical outcomes in a symptomatic and asymptomatic AS population (~500 patients).    
The effects of removing valvular impedance on aortic arterial stiffness have yet to be determined. 
Arterial stiffness is known to increase with age as well as in several cardiovascular (heart failure, 
stroke and diabetes) and non-cardiovascular (CKD and rheumatoid arthritis) disease (Rogers et al., 
2001). It is an important clinical outcome measure as an independent predictor of cardiovascular 
events as well as cardiovascular and all cause mortality (Vlachopoulos et al., 2010, Laurent, 2006). In 
addition, increased aortic stiffness has been shown to be associated with greater myocardial fibrosis in 
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a HCM population and reduced aortic compliance had a significant impact on LV after load and 
function in an AS population. Aortic stiffness or reduced elasticity can be measured using several 
different techniques and imaging modalities (Laurent et al., 2006). CMR has the ability to accurately 
determine arterial stiffness by measuring the aortic distensibility and pulse wave velocity (Grotenhuis 
et al., 2009, Dogui et al., 2011). Our study included the assessment of these variables in the cardiac 
MR protocol. Due to limitations in the number of patients studied and statistical power required it is 
not possible to report the data acquired in this thesis. However, the work is ongoing and we aim to 
present the changes in arterial stiffness following TAVI compared to SAVR, and their relationship to 
reverse remodelling and MF regression in the near future.  
CMR can measure the aortic root with greater precision to TTE or TOE and with similar accuracy to 
CT (Jabbour et al., 2011). The frequency and significance of post-TAVI paravalvular regurgitation is 
believed to be the consequence of inaccurate estimates of aortic root size and thus poor device 
selection/sizing (Takagi et al., 2011). We aim to address the issue of device sizing and aortic 
regurgitation by analysing the LVOT and aortic sagittal oblique cine images obtained in our cardiac 
MR protocol, comparing them to the TOE and TTE assessments and look for a correlation to post-
operative ‘total AR’ as measured by phase contrast MR imaging.  
Having identified the incidence and predictors of cerebral emboli post-TAVI, we aim to use cerebral 
DW MR imaging to compare a TAVI and SAVR population. This will include an assessment of the 
clinical utility of new embolic protection devices and a comparison of new TAVI valves. Further, 
having determined no short term effects of cerebral emboli on the health status of an individual we 
decided to assess the impact of cerebral emboli upon higher cognitive function post-TAVI. This study 
is presently being undertaken and is due to complete in 2014.   
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8.3 Patient Invitation 
 
We would like to invite you to participate in a research study, called MRI evaluation of Percutaneous 
and Surgical Aortic Valve Replacement.  
 
Please read the information sheet carefully and if you are interested in finding out more about the 
study before your planned admission to hospital then please phone us so that the research team can 
explain the study to you further and answer any questions you may have.  The numbers you can ring 
are 0113 392 5481 or 0113 392 5167, please ask for Dr Tim Fairbairn. Alternatively, once you are 
admitted to hospital for your valve replacement you will have a chance to discuss the study with one 
of the researchers. 
Please note that you are under no obligation to take part and it will not affect your treatment if you 
decide not to. However we would very much appreciate it if you would let us know. We will 
reimburse any travelling expenses you incur as part of this study.  
Thank you for considering this request. 
Yours sincerely 
 
Dr JP Greenwood 
Consultant Cardiologist 
Academic Unit of Cardiovascular Medicine 
G Floor Jubilee Wing 
Leeds General Infirmary 
Leeds 
LS1 3EX 
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8.4 Patient Information Sheet  
 
 
Division of Cardiovascular and Neuronal Remodelling Leeds Institute of Genetics, Health and 
Therapeutics  
Cardiovascular Research G Floor, 
 Jubilee Building Leeds General Infirmary Great George Street Leeds,  
LS1 3EX  
T 0113 392 5481 
 F 0113 392 8611 
 M 07922 512887  
 
 
MRI evaluation of Percutaneous and Surgical Aortic Valve Replacement 
Patient information Leaflet 
Version 1.1 April 2010 
Dear patient,  
You are being invited to take part in a research study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives and your GP if you wish. Ask us 
if there is anything that is not clear or if you would like more information. Take time to decide 
whether or not you wish to take part.  
WHY HAVE I BEEN CHOSEN?  
This study is looking at people like you, who are scheduled by their consultant for replacement of 
their aortic valve. We are looking at two groups of patients in this study: patients who are going to 
have a surgical valve replacement (done by a heart surgeon), and patients who are going to have a 
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percutaneous valve replacement, a procedure which replaces the valve without the need for surgery 
(done by a cardiologist). This second technique is newer and we still need to find out more about the 
long term results for patients.  
How your valve is going to be replaced has been decided by your doctor and is based purely on your 
health and symptoms. This study is completely separate from the decision of how your valve is going 
to be replaced.  
WHAT IS THE PURPOSE OF THE STUDY?  
Patients have their aortic valve replaced because their own valve does not work properly, which 
causes problems with the function of the heart and with the circulation. After the valve has been 
replaced the heart function and the circulation will normally improve. In this study we want to 
compare that improvement in the two groups of patients.  
We also like to study the blood vessels in the head. As your doctor will have told you one of the risks 
of valve replacement is small clots travelling from the heart to the head. It is important for us to find 
out how often this happens with surgery and with non-surgical replacement, and compare the results.  
We want to use Magnetic Resonance Imaging (MRI) in this study to look at the head and the heart. 
MRI does not involve radiation and is therefore very safe. It gives us very good images of the blood 
vessels and can tell how well the heart is pumping.  
DO I HAVE TO TAKE PART?  
It is up to you to decide whether or not to take part. You do not have to decide straightaway; once you 
come to hospital for your valve replacement you will be able to discuss the study further with a 
member of the research team. If you do decide to take part you will be given this information sheet to 
keep and be asked to sign a consent form. If you decide to take part you are still free to withdraw at 
any time and without giving a reason. This will not affect the standard of care you receive. 
Information collected up to the point of your withdrawal may still be used. In the unlikely event of 
you losing capacity (being unable to make decisions for yourself) you will be withdrawn from the 
study by us, but information already collected will be kept and used for the purposes of the study.  
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WHAT WILL HAPPEN TO ME IF I TAKE PART?  
All patients in this study will have MRI scans of their head and heart before and after the valve 
replacement procedure. Before the valve replacement we will scan your head and heart during one 
visit to the MRI department, whilst you are already an in-patient in the hospital. This scan will take 
approximately 60 minutes to complete. After the valve replacement, and before you go home, we will 
scan your head only, which takes about 10 minutes. Approximately 4-6 months later we will ask you 
to return to the MRI department so we can scan you heart, which takes about 50 minutes. The reason 
why we want to do this scan later is that your heart’s function may continue to improve for some time 
after the valve replacement.  
During each scan you lie in a short 'tunnel', which holds a large magnet. Short bursts of radio waves 
from the MRI scanner allow images to be created. You will hear periodical loud “banging” noises 
while we are acquiring the images. We will remain in communication with you throughout the scan. If 
you have normal kidney function then once during each heart scan, we will inject an MRI contrast 
medication into a vein in your arm. The needle used for this will feel like a sharp scratch. Usually 
people are not aware of the contrast dye injection. Should your kidneys be impaired then the injection 
will not be given  
During the actual valve replacement we will carry out an ultrasound scan of your head. This is a 
simple non-invasive study using ultrasound waves, with no known risk. You will wear a comfortable 
head band during the procedure which contains two small ultrasound probes. As you will be either 
sedated or fully anaesthetized you will not notice the scan.  
As part of the study we will ask you to fill out 2 questionnaires which will ask questions about how 
you feel the quality of your life is. A member of the research team can help you with this if you need 
assistance. We will ask you to complete these again after 1 month, 6 months, 1 year and 2 years. We 
will also do a short test (before and after the valve replacement) called the ‘mini-mental test’ which is 
a commonly used list of 10 questions which tests your memory.  
WHAT ARE THE RISKS AND DISCOMFORTS?  
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Magnetic Resonance Imaging (MRI) is safe and no X-rays or radiation are used for this scan. There 
are no known risks from this technique. Some patients may experience claustrophobia. The staff will 
provide every possible means to reduce this sensation. The scan will be stopped immediately if you do 
not wish to carry on with it. The contrast medication which we use is very safe but, as with any 
injection, reactions may occur. These include a warm sensation at the injection site, nausea or 
vomiting and transient skin rash. These effects usually only last for a few minutes. People with a 
history of allergy are more likely to suffer a more severe reaction, but this is rare (less than 1 in 3000). 
The department is equipped to cope with allergic reactions if they happen and medical staff will be on 
hand to deal with any unforeseen circumstances or problems.  
BENEFITS TO YOU  
There are no particular benefits to you from taking part in this study.  
EXPENSES  
We are able to meet reasonable expenses for costs of travel to and from the hospital for the scan after 
you have left hospital. Alternatively we can arrange transport by pre-paid taxi for you.  
WILL MY TAKING PART BE KEPT CONFIDENTIAL?  
All information, which is collected about you during the course of the research will be kept strictly 
confidential. This information will be securely stored at the Cardiac MRI Unit at Leeds General 
Infirmary on paper and electronically, under the provisions of the 1998 Data Protection Act. You will 
not be identified in any publication that may result from this research. All data will be anonymised so 
that your identity will not be revealed to anybody outside the Cardiac MRI Unit at Leeds General 
Infirmary.  
With your permission, we will inform your General Practitioner (GP) of your participation in this 
study as well as in the event of an unexpected abnormality on the scan.  
WHAT WILL HAPPEN TO THE RESULTS OF THE RESEARCH STUDY?  
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When the study is complete the results will be published in a medical journal, but no individual 
patients will be identified. If you would like a copy of the published results, please ask your doctor.  
INDEMNITY/COMPENSATION  
If you are harmed as a direct result of taking part in this study, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds to a legal 
action. Regardless of this, if you have any cause to complain about any aspect of the way you have 
been approached or treated during the course of this study, the normal National Health Service 
complaints mechanisms are available to you.  
If you have a private medical insurance please ensure that participation in the study does not affect 
your cover.  
WHO IS ORGANISING AND FUNDING THE STUDY?  
This is a research project of the Cardiac MRI department at Leeds General Infirmary.  
WHO HAS REVIEWED THE STUDY?  
The study has been reviewed and approved by the Leeds West Local Research Ethics Committee.  
For further information please contact:  
Dr Tim Fairbairn  
Cardiac MRI Department,  
B Floor, Clarendon Wing,  
Leeds General Infirmary,  
LS1 3EX  
Tel: 0113 39 25167  
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8.5 Consent Form 
 
Patient Study Number: ……………….. Date of Birth: …………………  
Hospital Number: ……………………. Initials: ………………………..  
CONSENT FORM – Version 1.1 April 2010  
MRI evaluation of Percutaneous and Surgical Aortic Valve Replacement 
Name of Researcher: Dr John Greenwood Please initial box  
 
1.  I confirm that I have read and understood the information sheet (version 1.1 
April 2010) for the above study and have had the opportunity to ask 
questions.  
 
2.  I understand that sections of any of my medical notes may be looked at by 
members of the research team and authorised personnel within the Leeds 
Teaching Hospitals NHS Trust and the University of Leeds, where it is 
relevant to the research or to assess that appropriate research standards are 
being maintained within the study. I give permission for these individuals to 
have access to my records. I understand that the information about me will be 
held in the strictest confidence and that my results will not be available to a 
third party.  
 
3.  I give my consent for my General Practitioner to be informed of my 
participation in the study.  
 
4.  I understand that images collected will be stored on a computer system, and, 
after my name and address have been removed, may be available to 
researchers at other institutions  
 
5.  I understand that my participation is voluntary; and that I am free to withdraw 
at anytime, without giving any reason, without my medical care or legal 
rights being affected.  
 
6.  I agree to take part in the study and that the general results of the study will 
be made available to medical community most likely through publication in a 
reputable medical journal  
 
7.  If I were to lose capacity, I understand that data already collected will be kept 
and used for the purposes of the study.  
 
 
